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In 2018 a total of 1,800,977 new cases of colorectal cancer (CRC) were diagnosed worldwide; 
1,006,019 in men and 794,958 in women. This makes it the third and second most common 
cancer in men and women, respectively.1 Although an increasing incidence is observed in non-
Western countries, the largest CRC burden is still present in developed countries. In Europe, 
500,000 new cases were reported in 2018, although incidence varied between countries.2 In 
the Netherlands, before the introduction of screening, yearly 13,000 individuals were newly 
diagnosed with CRC.3 Worldwide, the incidence of CRC is increasing due to ageing of the 
population, change in dietary habits and rise in risk factors like smoking, obesity, and lack of 
physical activity.4,5 It is expected that without interference the number of CRC cases in the 
Netherlands will increase from 13,000 to 17,000 persons per year by 2020.6 Life-time risk of 
developing CRC is 5% for men and 4% for women in the Netherlands.7 This is slightly lower 
than the observed life-time risk in the United Kingdom, estimating a life-time risk of 7% for 
men and 6% for women.8
In 2018, worldwide 861,663 persons died of CRC; 474,606 men and 387,057 women. 
Therewith, it is the fourth and third cancer-related cause of death worldwide in men and 
women, respectively.1 In Europe, 243,000 individuals died of CRC in 2018.2 There is a wide 
variation in CRC-related mortality rates, with higher mortality rates in less developed 
countries. Consequently, 5-year survival varies from 35% in Poland to 58% in Finland and 
60% in Sweden.9,10 This variation is probably the result of different cancer treatment or stage 
distribution at diagnosis. Recent numbers from the Netherlands showed a 5-year relative 
survival of 61%.7 The high incidence and mortality rates indicate that CRC is a major health 
problem.
Survival strongly depends on cancer stage at time of diagnosis.11,12 Staging of CRCs is done 
according to the 7th edition of the TNM classification.13 Stage 0 is considered carcinoma 
in situ. Stage I are tumours that were confined to the submucosa or had grown into the 
muscularis propria. Stage II are tumours that have invaded the serosa or penetrated to 
the peritoneal surface or other organs but without locoregional lymph node involvement. 
Stage III are tumours that also have metastasis in the locoregional lymph nodes. Stage IV are 
tumours that have distant metastases. In the Netherlands, 5-year survival is 94% for stage 
I compared to 12% for stage IV (Figure 1).7 This strong association between survival and 
stage distribution emphasises the importance to detect CRCs as early as possible, as this will 
improve survival after CRC diagnosis.
Progression of colorectal cancer
Development from a small polyp into CRC is characterised by a multistep process involving 
series of histological, morphological, and genetic changes over time. Currently, two CRC 
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pathways have been identified. The first, so-called traditional pathway, gives rise to 70-85% 
of all CRC.14 In this pathway, the normal colon epithelial cells change into aberrant crypt foci, 
and subsequently into small non-advanced adenomas (<1cm in size, with tubular histology). 
These adenomas can progress into advanced adenomas (AA) (adenomas with histology 
showing >=25% villous component or high-grade dysplasia or size >= 10 mm). From AA it 
can develop into early cancers and lastly advanced cancers with an accumulation of somatic 
mutations.15,16 Besides this conventional adenoma pathway, there is an alternative pathway, 
the so-called serrated neoplasia pathway. This pathway has another precursor lesion, the 
serrated polyp. It is estimated that 15-30% of the CRCs results from this pathway.17 Serrated 
lesions are divided in three subgroups: hyperplastic polyps, sessile serrated polyps and 
traditional serrated polyps. Of these subtypes, hyperplastic polyps are thought not to 
develop into CRCs.
As described above, CRC disease is characterised by a long pre-malignant stage. The 
dwell time is the time from the development of adenomas to symptom-detected CRCs in 
the absence of screening, which is estimated with microsimulations models to be 17-25 
years.18 The pre-cancerous stage polyps, either early adenomas or sessile serrated lesions, 
are asymptomatic. With advancing lesions, symptoms may become present but are often 
a-specific: abdominal pain, change in bowel habits, rectal blood loss, or weight loss.19 By 
the time the signs of CRC become evident, the disease has often already developed in an 
advanced stage with poor associated survival rates.




























Table 1 shows an overview of several risk factors and their impact on the development of 
CRC.20 These factors can be divided in two subgroups, modifiable and non-modifiable risk 
factors:
Modifiable risk factors
Different modifiable factors can lead to an increased risk for CRC. First, choice of diet can 
impact your risk for CRC. It has been shown that intake of processed meat or red meat 
increases the risk for CRC up to 17-18%.21 Note, large amounts of red meat have to be 
consumed (100 g/day). Second, obesity, low levels of physical activity, alcohol consumption 
Table 1: Overview of risk and preventive factors of colorectal cancer







Inflammatory bowel disease ↑↑
Diabetes ↑
Helicobacter pylori infection (↑)
Other infections (↑)
Colonoscopy ↓↓









High consumption of red and processed meat ↑
Fruit and vegetables (↓)
Cereal fibre and whole grain (↓)
Fish (↓)
Dairy products (↓)
↑↑↑=very strong risk increase. ↑↑=strong risk increase.↑=moderate risk increase.
↓↓=strong risk reduction. ↓=moderate risk reduction.
Parentheses show probable but not fully established associations.
11
GENERAL INTRODUCTION
and cigarette smoking are also be related with an increased risk for CRC.22,23 In contrast, 
intake of calcium, whole grains, fibre, and fruit and vegetables might decrease the risk for 
CRC up to 50%.24,25 It was estimated that 45% of all CRCs were attributable to an unhealthy 
lifestyle, irrespectively of a person’s genetic risk.26 Therefore, a healthy lifestyle with physical 
activity and healthy diet might lower the risk of CRC.
Non-modifiable risk factors
There are various non-modifiable factors that increase individuals CRC risk. Well-known 
non-modifiable risk factors are sex and age.1,27 Besides these two important risk factors, 
several diseases can lead to an increased CRC risk. Some examples are inflammatory bowel 
disease, type II diabetes and cystic fibrosis.28-31 Lastly, DNA plays an important role in the 
development of CRC. Genetic contribution to CRCs can be divided in a few subgroups: 
family history with nonhereditary CRC, hereditary CRC syndrome (such as Lynch syndrome 
and familial adenomatous polyposis (FAP)), and other genetic variation (known as single-
nucleotide polymorphisms (SNPs)).27,32,33
Modifiable and non-modifiable risk factors should be considered together to determine 
the overall risk for CRC. The combination of family history, environmental factors and 
genetics on top of age and gender will give the best prediction for an individual’s CRC risk.27 
It is unknown whether the impact of the above-mentioned risk factors is similar for the two 
precursors of CRC: conventional adenomas and serrated polyps. A recent study suggests that 
both precursors share most common risk factors, but the magnitude of the association might 
differ.34 Cigarette smoking, BMI, and alcohol consumption were more strongly associated 
with serrated polyps, whereas physical activity and dietary factors like folate, calcium, and 
Vitamin D had a stronger inverse association with conventional adenomas.
1.2 COLORECTAL CANCER PREVENTION
Reducing the burden of CRC could be established in three ways: primary prevention, 
secondary prevention and tertiary prevention. As the focus of the thesis is on screening, 
secondary prevention will be explained in more detail.
Primary prevention
It was estimated that almost half of all CRCs are attributable to an unhealthy lifestyle, such as 
smoking, alcohol consumption, diet, limited physical activity and body fatness.26 Therefore, 
it is of great importance that primary prevention will be focussed on these risk factors. 
Additional benefit of reducing these risk factors is the positive side effects on many other 
diseases such as diabetes and cardiovascular diseases.
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Besides a healthy lifestyle there is some evidence for a preventive effect of certain drugs 
(chemoprevention) on CRC. Best-known chemoprevention agents are aspirin and nonsteroidal 
anti-inflammatory drugs (NSAIDs).35 Although aspirin and NSAIDs have the potential to lower 
the CRC risk, they may also cause negative side effects, such as haemorrhagic strokes and 
gastrointestinal complications such as peptic ulcers and bleeding. Maybe it should only be 
considered for specific high-risk groups.20,36 However, there is no guideline yet on the usage 
of chemoprevention agent.
Secondary prevention
With screening, asymptomatic individuals are systematically tested to identify the disease 
or risk factors for the disease. Screening can prevent the disease or detect the disease 
in an earlier stage. CRC is a good candidate for screening as it is a slow growing cancer, 
characterised by a long pre-malignant disease stage. Premalignant lesions can be removed 
before they become cancer or otherwise CRCs can be detected in an early stage.11,12 
Adenomas with histology showing >=25% villous component or high-grade dysplasia (both 
considered as AA), are in generally larger in size and are more likely to conceal can cer cells. 
Also, the risk for adenomas to develop into CRC increases as the size of the polyp increases 
(>10mm, also considered as AA).37 Accordingly, AA is also considered as relevant finding of 
CRC screening. Both CRC and AA are therefore considered as true positives in CRC screening.
There are many different screening methods available for CRC screening. The most 
commonly used screening methods in Europe are stool-based occult blood test and 
endoscopy methods. Two types of stool-based occult blood test are used, the guaiac Faecal 
Occult Blood (gFOBT) and the faecal immunochemical test (FIT). Most important difference 
between those two tests is that FIT is a quantitative test, enabling to choose the preferred 
cut-off (µg Hb/g faeces) for referral for follow-op colonoscopy. This is important when 
considering a desired balance between true and false positive test results or encountering 
colonoscopy capacity problems. Two endoscopy methods are carried out, sigmoidoscopy 
and colonoscopy.38,39 Stool-based test and sigmoidoscopy also have to be followed by a 
colonoscopy for diagnosis and removal of lesions. Computed tomography colonography 
(CTC), so-called virtual colonoscopy, is another CRC screening method. This screening 
method is hardly offered within an organised programme. Newer screening methods are 
also available, like multitarget-stool DNA testing, SEPT9 biomarker assay or video capsule 
endoscopy.40-42 These newer screening methods are currently not offered in population-
based screening programmes in Europe.
There is robust evidence that both repeated gFOBT and once-only flexible sigmoidoscopy 
screening can reduce CRC-related mortality.43-49 No evidence is available from randomised 
controlled trials of the FIT on mortality reduction. gFOBT and FIT are similar tests, both 
stool-based tests; however performance of FIT is superior to gFOBT. Therefore, it is expected 
that the mortality reduction with FIT could even be larger than gFOBT. Additionally, there is 
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evidence on mortality reduction from observational studies.50-54 Therefore, it is assumed that 
FIT screening will also result in a reduction of CRC-related mortality. Currently randomised 
controlled trials of colonoscopy screening are executed. Estimates of long-term effect of 
colonoscopy screening on CRC-related mortality will soon be available.55-56 Colonoscopy is 
similar to sigmoidoscopy, but inspects the entire colon whereas sigmoidoscopy only inspects 
the lower part of the colon. As colonoscopy screening has a better test performance than 
sigmoidoscopy screening, combined with the evidence from observational studies, reduction 
of CRC-related mortality is also expected.57 Note, to observe a mortality reduction within 
the population, it is crucial that not only a proper screening test is used, but also that the 
screenings test is accepted within the population.
Another important aspect that should be considered before implementing CRC screening 
is the harm-benefit ratio. Benefits of screening have been discussed above, the potential 
of various screening methods to reduce CRC-related mortality. However, there are more 
noteworthy benefits like reduction in advanced disease stage and reduction of the CRC 
incidence. The harms of screening differ substantially between screening methods. Harms 
of stool-based test could be psychological distress after receiving a positive test result and 
fear of CRC diagnosis.58,59 The aversion of individuals to perform a stool test may also be 
considered as harm.60 An important harm is the number of false-positives undergoing an 
unnecessary follow-up with colonoscopy. Fear of receiving a positive test result and CRC 
diagnosis also apply for endoscopy screening. However, endoscopy screening can have 
more substantial harms than FOBT screening, namely endoscopy-related complications. 
Estimated risk for a major bleeding was estimated to be 8 per 10,000 colonoscopies and for 
a perforation 4 to 7 per 10,000 colonoscopies.59,61 Fatal complications after colonoscopy are 
very rare. Meta-analyses estimated the mortality rate ranging from 3 to 7 deaths per 100,000 
colonoscopies.62 Note, this rate includes fatal complications of colonoscopy with all indications 
and therefore not directly applicable on endoscopy screening. Another harm associated 
with screening, regardless of the screening method, is overdiagnosis. Overdiagnosis in CRC 
screening concerns detection of polyps or CRCs that, without screening, would not have been 
diagnosed in an individual’s lifetime. It is unknown which polyp’s progress or deteriorates. 
Therefore, it is uncertain which polyps would never develop into CRC and therefore will be 
removed unnecessarily. Thus, it is uncertain to what extent overdiagnosis is present in CRC 
screening. But inviting older individuals or individuals with comorbidities to participate in FIT 
screening, will most likely lead to overdiagnosis.63 However, quantification of the magnitude 
of overdiagnosis in CRC screening is currently lacking. It is very complicated to come up with 
a good estimation, as by the removal of precancerous polyps CRCs will also be prevented. 
To sum up, CRC screening is associated with harms, however serious harms like death as 
a result of endoscopy rarely occur. In generally, it is considered that the benefits of CRC 




Treatment of individuals with a CRC diagnosis to prevent further complications is considered 
as tertiary prevention, so-called survivorship. Tertiary prevention aims to prevent further 
health impact and improve quality of life after a diagnosis with CRC. Treatment of CRC 
is continuously changing with new innovations. A recent Dutch study presented an 
overview of the last 25 years of CRC treatment.64 This study showed an increase in the 
use of postoperative chemotherapy for individuals diagnosed with stage III colon cancer 
and an increase in preoperative radiotherapy for rectal cancer. Another increase was the 
more intensified care of stage IV CRC, resulting in improved outcomes.64 Other preventive 
strategies besides CRC treatment are similar to primary CRC prevention. But the target is on 
treatment-related side-effects or CRC-related morbidity. Strategies for tertiary prevention 
besides treatment options are an understudied topic. Known examples of strategies are; 
physical activity, healthy diet containing vitamin D, fibre, coffee, marine omega-3 fatty acid. 
Those strategies might improve survival and quality of life.25,65
1.3 MONITORING AND EVALUATION OF SCREENING PROGRAMMES
Screening programmes
Worldwide, many countries have implemented a CRC screening programme.38 Programmes 
are predominantly introduced in high income countries. Screening can be designed as 
opportunistic or organised programmes. In an organised screening programme, like in 
the Netherlands, the entire target population receives an invitation to participate. In an 
opportunistic screening programme, like in the US and Germany, screening is recommended 
and reimbursed but depends on individuals’ decision. They have to request the screening 
test themselves at the doctor or pharmacy.
Choosing the best screening strategy for the population is a complex process. When 
deciding on which test to use several aspects should be taken into account: test sensitivity, 
specificity, population preference, adherence, harms, capacity and costs. Colonoscopy has 
the highest sensitivity of all CRC screening methods; however it has downsides like severe 
complications, high costs, lack of adherence and straining colonoscopy capacity.66,67 All these 
downsides need also to be considered when offering screening to the total population. There 
is a growing recognition that an optimal screening method heavily depends on population 
preference and availability of resources.68,69 Besides the choice for the best test, starting age, 
stopping age and screening interval should be explored to design most effective screening 
programme for a population.
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The Dutch colorectal cancer screening programme
The Netherlands may serve as an excellent example weighing all these various aspect of 
screening in the decision for the optimal screening method for the Dutch population. In the 
Netherlands an extensive preparatory process has taken place before the implementation 
of the national population-based CRC screening programme.70 This process started with a 
report from the Dutch Health council in 2001 indicating the need for a national screening 
programme.
Pilot studies
In 2006 pilot studies were initiated to study the potential of a national CRC screening 
programme in the Netherlands.51,71-74 The aim of these Dutch pilot studies was to evaluate 
most important aspects (i.e. participation, diagnostic yield and cost-effectiveness) of most 
relevant screening methods: gFOBT, FIT (with FIT cut-offs ranging from 10-40 µg Hb/g faeces), 
colonoscopy, sigmoidoscopy and CTC. These trials were conducted in Rotterdam, Amsterdam 
and Nijmegen. FIT screening showed the highest participation rate up to 60-62% in the first 
round, compared to 47-50% for gFOBT, 32% for sigmoidoscopy, 34% for CTC and 22% for 
colonoscopy. FIT also showed the highest diagnostic yield, with the highest detection of CRC 
per 1,000 invitees over two screening rounds.75 Because of these favourable outcomes of 
FIT screening, the next step was to determine the optimal FIT cut-off. Outcomes of the pilot 
studies and subsequent modelling were used to inform policy makers to decide on the most 
optimal or feasible cut-off for referral to colonoscopy follow-up.70
Modelling studies
Microsimulation Screening Analysis (MISCAN)-Colon, a decision model that can be used 
to predict the benefits, harms and associated costs of different CRC screening strategies, 
was used to determine the optimal FIT cut-off. This model showed that a FIT cut-off of 10 
µg Hb/g faeces will result in highest sensitivity and will be most effective.76 With unlimited 
colonoscopy the optimal screening strategy for the Dutch population would be an annual 
FIT, with a cut-off of 10 µg Hb/g faeces for individuals aged 45-80 years.77 But in practice, 
colonoscopy capacity is not unlimited. The model demonstrated that with restricted 
colonoscopy capacity, the most effective strategy would be annual screening with a FIT cut-
off of 40 µg Hb/g faeces and smaller age range of individuals aged 50-75 years.77
Health Council
The Health Council plays an important role in designing and implementing a national 
screening programme in the Netherlands, advising the Minister of Health. They strongly 
advised on biennial screening with a FIT cut-off of 15 µg Hb/g faeces for individuals aged 55-
75 years old.78 This advice was based on the outcomes of the pilot studies and subsequent 
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modelling, but also on expert opinion and literature review. The final screening strategy in 
terms of FIT cut-off, interval and age range was based on the several considerations.
A FIT cut-off of 15 µg Hb/g faeces was advised by the Health council because it has a more 
favourable balance between true-positives and false-positives (higher positive predictive 
value (PPV)) and it results in a lower colonoscopy demand. Increasing the FIT cut-off from 
10 to 15 µg Hb/g faeces will have a minor impact on CRC detection, but more AA and non-
advanced adenoma will be missed.71
Annual gFOBT did show a higher CRC-related mortality reduction compared to biennial 
gFOBT screening (33% versus 20%).47 However, additional benefit of annual screening over 
biennial screening is debated.79 The Health Council concluded that the disadvantage of 
screening every year, as opposed to every second year, is that screening cost will almost be 
twice as high, while the desirable effects increase by smaller amounts. Therefore, biennial 
screening was considered as a more attractive option. The Health council therefore advised 
that the extra costs involved in annual screening do not outweigh the potential extra benefits.
The target age group was narrowed to individuals aged 55-75 years. This higher starting 
age was chosen because of the lower incidence of CRC in younger individuals at that 
time.78 The lower stopping age was decided to avoid the higher risk of colonoscopy-related 
complications in older individuals. This recommendation was based on the results of the 
modelling studies of our research group.
Design Dutch organised CRC screening programme
In accordance with the advice of the Health council, the minister of Health decided on 
May 25, 2011 to gradually implement a national population-based screening programme 
with biennial FIT with a cut-off of 15 µg Hb/g faeces for men and women aged 55 to 75 
years. The Dutch CRC screening programme was gradually implemented by age groups from 
2014 onwards. This phased implementation of five years allowed a timely increase of the 
colonoscopy capacity. Ultimately, in 2019 all individuals between 55-75 years old should 
have been invited at least once.
Relevance of monitoring and evaluation
The European guidelines for quality assurance in CRC screening state the relevance of 
monitoring and evaluation as follows: evaluation and interpretation of screening outcomes 
are essential to recognise whether a CRC screening programme is achieving the goals for 
which it has been established.80 Twenty important recommendations on CRC screening are 
given in this extensive guideline. Examples of relevant recommendations are: database with 
individual’s records, annual monitoring reports by age and gender, minimal FIT participation 
of 45%, minimal participation to follow-up colonoscopy of 90%, more favourable stage 
distribution for screen-detected CRCs than symptom-detected CRCs, and evaluation of 
17
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interval CRCs. If the above-mentioned recommendations are followed, it is expected that 
CRC screening will be effective in reducing CRC-related mortality.
In the Netherlands, as described above, an extensive preparatory process was followed 
before the implementation of a national CRC screening programme. Next, during a 
planning phase public tenders for test, laboratories and packaging were set out. In addition, 
quality assurance and accreditation programmes were set up for endoscopy, pathology 
and laboratories. Also, a large IT infrastructure was developed. This information system 
automatically structures the total screening process, integrates information from different 
sources and is continuously updated. This national information system (ScreenIT) enables 
real-time monitoring of the national CRC screening programme. Monitoring of a screening 
programme is crucial. Although the design of the Dutch CRC screening programme is 
evidence-based and well-planned, it is unknown if the performance on a national level will 
be in line with expectations. The Netherlands is indeed a good example that expectations 
and reality are not in line. In the first year in 2014 weekly monitoring was carried out to 
evaluate the performance of the national CRC screening programme. These weekly reports 
showed high positivity rates, low PPV and an increase in waiting period for colonoscopy. 
Consequently, the programme was adjusted after 6 months that will be described in more 
detail in Chapter 2.
1.4 AIM AND RESEARCH QUESTION
The general aim of this thesis is to evaluate the implementation phase of the national CRC 
screening programme in the Netherlands. After many years of extensive preparations, 
expectations on programme performance were high. To ensure that these expectations are 
met on a national level, monitoring and evaluation of the national screening programme in 
real setting c.q. national level is important. This led to the following research question of 
this thesis:
Is the performance of the Dutch colorectal cancer screening programme during the 
implementation phase satisfying and according to expectations?
The performance of the Dutch CRC screening programme was evaluated separately per 
performance indicator; participation FIT, FIT positivity, participation to follow-up colonoscopy, 
CRC and AA detection, stage distribution, location, interval cancers, socioeconomic 
differences and consistency of FIT performance. The outcomes of important performance 
indicators were also compared with surrounding countries using FIT screening.
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1.5 OUTLINE OF THIS THESIS
Chapter 2 to 7 addresses the Dutch national population-based CRC screening programme. In 
Chapter 2 the first year of the Dutch national population-based CRC screening programme 
was evaluated. It describes the relevance of real-time monitoring to optimise programme 
performance. We evaluated the participation rate, positivity rate, PPV and detection rates before 
and after needed adjustment of the FIT cut-off. Chapter 3 we compared the stage distribution 
of screen-detected and symptom-detected CRCs. In Chapter 4 the programme performance of 
the second screening round was evaluated. We also estimated the impact of the adjusted FIT 
cut-off on positivity rate, PPV and detection rates. In In Chapter 5 we estimated the interval CRC 
incidence and FIT sensitivity after the first screening round and the impact of the adjusted FIT 
cut-off. In Chapter 6 we evaluated social economic status (SES) differences in participation and 
yield of FIT screening. We used area SES and compared the performance indicators participation 
rate, positivity rate, PPV and detection rate. In Chapter 7 we evaluated the consistency of FIT in 
testing positive or detecting CRC or AA for different batches of specimen collection devices, lot 
reagents and laboratories. Chapter 8 compared important screening programme indicators of 
four organised CRC screening programmes using FIT; Basque country (Spain), France, Flanders 
(Belgium) and the Netherlands. In the general discussion in Chapter 9, the research question 
will be answered and discussed per element. Subsequently the methodological considerations 
of the analyses in this thesis will be explained and future perspectives will be touched on briefly. 
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After careful pilot studies and planning, the national screening programme for colorectal 
cancer (CRC), with biennial faecal immunochemical tests (FITs), was initiated in the 
Netherlands in 2014. A national information system for real-time monitoring was developed 
to allow for timely evaluation. Data were collected from the first year of this screening 
programme to determine the importance of planning and monitoring for optimal screening 
programme performance.
Methods
The national information system of the CRC screening programme kept track of the number 
of invitations sent in 2014, FIT kits returned, and colonoscopies performed. Age-adjusted 
rates of participation, the number of positive test results, and positive predictive values 
(PPVs) for advanced neoplasia were determined weekly, quarterly, and yearly.
Results
In 2014, there were 741,914 persons invited for FIT; of these, 529,056 (71.3%, 95%CI: 71.2-
71.4%) participated. A few months into the programme, real-time monitoring showed that 
rates of participation and positive test results (10.6%, 95%CI: 10.5-10.8%) were higher than 
predicted and the PPV was lower (42.1%, 95%CI: 41.3-42.9%) than predicted based on pilot 
studies. To reduce the burden of unnecessary colonoscopies and alleviate colonoscopy 
capacity, the cut-off level for a positive FIT result was increased from 15 to 47 µg Hb/g faeces 
halfway through 2014. This adjustment decreased the percentage of positive test results to 
6.7% (95%CI: 6.6-6.8%) and increased the PPV to 49.1% (95%CI: 48.3-49.9%). In total, the 
first year of the Dutch screening programme resulted in the detection of 2,483 cancers and 
12,030 advanced adenomas.
Conclusions
Close monitoring of the implementation of the Dutch national CRC screening programme 
allowed for instant adjustment of the FIT cut-off levels to optimise programme performance.
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INTRODUCTION
Colorectal cancer (CRC) is a major health problem.1 Fortunately, CRC is very suitable for 
screening and many countries have started CRC screening in the past decade. Choices for 
screening modality and strategy differ. Worldwide, many countries have implemented 
faecal occult blood testing (FOBT), in particular by means of faecal immunochemical testing 
(FIT).2-4 Various FIT-based initiatives arise based on the growing recognition that an optimal 
screening method depends on population preference and the availability of resources.5-9
In the Netherlands, the screening modality was determined after a period of careful 
piloting. These pilot studies and subsequent modelling showed that screening by FIT was 
most acceptable to the Dutch population with a participation rate of up to 60%-62% in the 
first round, compared to 47%-50% for guaiac-based FOBT (gFOBT), 32% for sigmoidoscopy, 
22% for colonoscopy and 34% for computed tomography colonography (CTC). As a result, FIT 
outperformed the other screening modalities in the detection of CRC per 1000 invitees.10-14 
FIT further allowed for adjustment of the cut-off level enabling a desired balance between 
true and false positive test results and colonoscopy referral rates to meet colonoscopy 
resource.11,15
Based on these findings, the Dutch government decided to gradually implement a national 
population-based screening programme based on biennial FIT from age 55 to 75 years at a 
cut-off level of 15 µg Hb/g faeces. During a 2-year planning period, a national information 
system was developed for real-time monitoring. Implementation of screening programmes 
requires careful planning, real-time monitoring and adjustment if needed to achieve the 
intended impact. Unfortunately, there is limited experience and literature on this process, 
which is relevant from a clinical as well as a public health perspective.
This article presents the outcomes of the first year of the Dutch CRC screening programme 
to illustrate the importance of planning and monitoring for optimal screening programme 
performance.
MATERIALS AND METHODS
The Dutch CRC screening programme
The Dutch CRC screening programme was implemented gradually by age group from 
2014 onward, with a projected roll-out period of 5 years, allowing for timely increase of 
the colonoscopy capacity to ultimately accommodate the target population of 2.2 million 
invitees annually (Appendix I). The target population for 2014 consisted of all individuals 
reaching the age of 63, 65, 67, or 75 years in 2014. The oldest age group was included in 
2014, because it was their only opportunity to be invited. The age groups around the median 
age of the programme were selected because these were expected to have the optimal 
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balance between CRC risk and remaining life-expectancy and experience the highest benefit 
from screening. Because the programme originally was supposed to start in 2013 and it had 
been publicly communicated that it would include screening for subjects born in 1938, these 
individuals also were invited despite having reached the age of 76 years in 2014. The target 
population received a pre-invitation letter by mail, followed 1 week later by an invitation 
letter by mail together with a single FIT test (FOB-Gold, Sentinel, Milan, Italy). After 42 days 
a reminder was sent automatically to nonresponders.
Each invitee was asked to perform a FIT and fill out a reply form including a sample date 
and return this in a prepaid envelope. Returning the FIT is considered informed consent, 
in accordance with the Dutch population screening act. The screening programme has been 
reviewed and approved by the Health Council as part of this act. Participants were informed 
about the FIT result by mail. If the FIT result equalled or exceeded the cut-off level, the family 
physician was informed and the participant was invited for a precolonoscopy intake interview 
in an accredited colonoscopy centre nearby. Participants whose sample was unreliable or not 
assessable were sent a new test. Individuals who actively deregistered from the programme 
were labelled as nonparticipants. Individuals who did not respond to the invitation were labelled 
as nonresponders.
Colonoscopy was the standard diagnostic follow-up test. All colonoscopies were performed 
by accredited endoscopists who perform at least 300 colonoscopies each year. All detected 
polyps were to be removed and sent for pathologic review.16 In case of advanced adenoma 
(AA) or CRC, the participant was referred for further treatment and surveillance.17
Monitoring System
A national information system (ScreenIT, Topicus, Deventer, the Netherlands) was developed 
to structure the screening process automatically, continuously integrate information from 
different sources such as endoscopy units and pathology laboratories, and facilitate real-
time monitoring (Figure 1). ScreenIT includes personal data from the municipal Personal 
Records database (personal details of every resident of the Netherlands), FIT results 
from the laboratories, available pre-colonoscopy intake slots, colonoscopy results from 
endoscopy centres, and pathology diagnoses from the Dutch national pathology registry 
(PALGA). Individuals had the right to object to data exchange for scientific research or quality 
assurance. Those who objected were labelled as nonresponders (n=24).
Screening outcomes from ScreenIT are reported weekly, quarterly, and yearly to the 5 
regional screening organisations that are responsible for the execution of the programme.
Programme performance
By using the outcomes of the Dutch pilot studies with FIT (OC Sensor; Eiken Chemical, Tokyo, 
Japan) as a reference, the programme was designed to accommodate a 60% participation 
rate with FIT, with a positivity rate of 6.4% at a cut-off level of 15 µg Hb/g faeces. At this cut-
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off level the expected positive predictive value (PPV) for CRC and AA combined was 51.6%, 
and detection rates of CRC were 4.5‰ and of AA were 23.8‰.
Outcomes and Analyses
Data were collected to assess FIT participation rate, positivity rate, participation rate of 
precolonoscopy intake and diagnostic colonoscopy, PPV for advanced neoplasia, detection 
rate and false positive rate. Data on the invitees of 2014 were collected until March 31 
2015. The FIT participation rate was defined as the number of individuals returning the stool 
sample divided by the number of individuals invited. The positivity rate was defined as the 
number of participants with a test result at or above the cut-off level divided by the number 
of participants with an assessable stool sample. The participation rate for precolonoscopy 
intake was defined as the number of participants who attended the pre-colonoscopy intake 
Figure 1: Graphical representation of the workflow in ScreenIT Information System*
Abbreviations: PALGA (pathology database), GP (general practitioner), MDL (gastroenterology), RCP-RCMDL 
(quality assurance system). Note: abbreviations are based on Dutch descriptions.
*The national information system ScreenIT automatically structures the screening process. It continuously 
integrates information from different sources, personal data from the municipal Personal Records database, 




divided by the number of persons with a positive FIT. The participation rate for colonoscopy 
was formulated as the number of persons who underwent a colonoscopy divided by the 
number of persons with a positive FIT. Advanced neoplasia (AN) was considered a relevant 
abnormality within a CRC screening programme.18 AN was defined as CRC or any adenoma 
with histology showing 25% or greater villous component or high-grade dysplasia or 
adenoma with size 10 mm or larger. The PPV was calculated as the number of persons with 
AN divided by the number of persons who underwent a colonoscopy. The detection rate 
was defined as the proportion of individuals with AN detected during colonoscopy per 1,000 
screened individuals with an assessable stool sample, also called the true positive rate. 
The false positive rate was defined as the number of persons without AN detected during 
colonoscopy divided by the number of screened persons with an assessable stool sample.
Proportions with 95% CIs were determined by descriptive analyses. Subgroup rates were 




The target population for 2014 consisted of 865,048 persons. By the end of the year, 
703,626 (81.3%) of those had been invited for screening. Weekly monitoring showed that 
in some screening regions the entire target population of 2014 had been invited before the 
end of the year. In these regions, an additional 38,288 persons aged 60 years were invited 
for screening, resulting in 741,914 invitees in total. Figure 2 shows the flow of individuals 
through the screening process. A total of 529,056 or 71.3% (95%CI: 71.2-71.4%) of the 
invitees returned the FIT to the laboratory. Of the 212,858 persons not returning a FIT, 32.1% 
were classified as nonparticipants and 67.9% were classified as nonresponders (including 
24 who objected to data exchange). Of the 529,056 participants, 524,095 (99.1%) had an 
assessable FIT with consent form. Overall, the test result was positive for 40,842 individuals 
or 7.8% (95%CI: 7.7-7.9%) however these rates were different for the first half of the year 
compared with the second half year, as will be discussed in the next section. Of all individuals 
who tested positive, 35,950 (88.0%) had a precolonoscopy intake interview. In total, 33,313 
(92.7%) individuals were advised to undergo colonoscopy. Colonoscopy and pathology data 
were available for 31,759 (95.3%) of the individuals who were recommended to undergo 
colonoscopy. Taken together, 77.8% of the participants with a positive FIT had undergone 
a colonoscopy. Excluding those for whom colonoscopy was not recommended (n=2,637), 
uptake of colonoscopy was 83.1%.
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Positivity rate, PPV, and detection rate in the first half of 2014
During the first months of the programme, real-time monitoring detected an age-adjusted 
positivity rate of 10.6% (95%CI: 10.5-10.8%) at a cut-off level of 15 µg Hb/g faeces. At this 
cut-off level, the PPV for CRC and AA was 42.1% (95%CI: 41.3-42.9%) and detection rates of 
CRC and AA were 5.8‰ (95%CI: 5.5-6.1‰) and 30.8‰ (95%CI: 30.1-31.5‰), respectively 
Figure 2: Flow of individuals through the screening process
Abbreviations: FIT (faecal immunochemical testing)
*As some screening areas had invited the entire target population already before the end of 2014, a number 
of individuals from the target population of 2015 were already invited in calendar year 2014.
† Including 24 individuals who objected to data exchange, who were also labelled as non-responders.
‡ Of all participants, 99.1% had an assessable FIT.
§ July 2014 the cut-off level for positivity was increased to 47 µg Hb/g faeces.
¶ Preceding the colonoscopy, a pre-colonoscopy intake interview takes places at an accredited screening 
colonoscopy centre. For 259 participants, no intake report was available in ScreenIT.













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Table 1). Both positivity (10.6% vs 6.4%) and detection rates of CRC (5.8‰ vs 4.5‰) and AA 
(30.8‰ vs 23.8‰) in the first half of the year were higher than the expected programme 
performance. However, the PPV for CRC and AA was lower than expected (42.1% vs 51.6%), 
with relatively more individuals having a false positive result. The false-positive rate was 
5.0% (95%CI: 4.9-5.1%), resulting in a higher burden of colonoscopy for both participating 
individuals and the programme. In addition, the participation rate also was higher than 
expected (71% vs 60%). Consequently, the demand for colonoscopies exceeded the capacity 
leading to a prolonged waiting period. There was no excess colonoscopy capacity in the 
Netherlands as a whole, so a further increase in colonoscopy capacity for the national 
programme was not possible in the short term. Because the programme was not performing 
according to the predefined quality indicators (i.e., positivity rate of 6.4; PPV of 51.6%; and 
follow-up colonoscopy within 3 weeks after a positive FIT), an immediate decision had to be 
made to improve the programme. A decision analysis was performed comparing 3 different 
methods to decrease colonoscopy demand in 2014: increase cut-off level, postpone 
screening in selected age groups, and forego screening in older age groups. This analysis 
showed that increasing the cut-off level not only resulted in the lowest decrease in CRC 
deaths prevented, but also resulted in a balance between harms and benefits of screening 
in accordance with the aims at programme start.19 In consultation with all stakeholders, the 
Dutch National Institute for Public Health the Environment (RIVM) decided to increase the 
cut-off level because this was the most efficient way to optimise programme performance. 
Therefore, the cut-off level for referral for colonoscopy was increased to 47 µg Hb/g faeces 
in July 2014.
Figure 3: Comparison of the balance between true and false positives by the two cut-off levels
Abbreviations: FIT (faecal immunochemical testing), Hb (haemoglobin)
† True positive rate was defined as the number of persons with CRC or AA detected during colonoscopy 
divided by the number of screened persons with assessable stool sample.
‡ True negative rate was defined as the number of persons without CRC or AA detected during colonoscopy 
divided by the number of screened persons with assessable stool sample.
§Rates are presented as age-adjusted rates, calculated with the exclusion of the 60-year-olds screened in the 
second half of 2014 (with the cut-off level 47 µg Hb/g faeces).
35
REAL-TIME MONITORING OF THE FIRST YEAR
Positivity rate, PPV, and detection rate in the second half of 2014
The adjustment of the programme resulted in an age-adjusted positivity rate of 6.7% (95%CI: 
6.6-6.8%) at a cut-off level of 47 µg Hb/g faeces. At this cut-off level the age-adjusted PPV 
for CRC and AA was 49.1% (95%CI: 48.3-49.9%). The age-adjusted detection rates at 47 µg 
Hb/g faeces of CRC and AA were 4.4‰ (95%CI: 4.2-4.7‰) and 20.6‰ (95%CI: 20.0-21.2‰), 
respectively. The false positive rate was 2.6% (95%CI: 2.6-2.7%). Increasing the cut-off level 
halfway through 2014 decreased the demand for colonoscopies by 37% and the number 
of false positive results by 48%, although CRC and AA detection rates decreased to a lesser 
extent by only 23% and 33%, respectively (Figure 3 and 4). If we would have applied a cut-off 
level of 47 µg Hb/g faeces during the first half year, 6433 (40.7%) fewer participants would 
have tested positive. This would have led to failure to detect 132 of 911 (14.5%) CRCs and 
1351 of 4319 (31.3%) AAs (Appendix 2).
DISCUSSION
These data show the additional value of real-time monitoring to successfully implement 
a national screening programme. A few months into the programme real-time monitoring 
showed a higher positivity rate and a lower PPV than expected. This resulted in a higher 
number of false positive test results, leading to unnecessary diagnostic colonoscopies with 
Figure 4: Comparison of age-adjusted† positivity rates‡, positive predictive value and detection rates§ by the 
two cut-off levels
Abbreviations: PPV (positive predictive value), AN (advanced neoplasia), Hb (haemoglobin)
* Comparing the two cut-off levels, the positivity rates, PPVs and detection rates were significantly different 
(p<0.05)
† All rates are presented as age-adjusted rates, with the exclusion of the 60-year-olds screened in the second 
half of 2014 (with the cut-off level 47 µg Hb/g faeces).
‡ Positivity rate was defined as the number of participants with an unfavourable test result (above the cut-off 
level) divided by the number of participants with assessable stool sample.
§ PPV was calculated as the number of persons with CRC or AA divided by the number of persons who 
underwent colonoscopy. 
¶ Detection rate was defined as the proportion of persons with CRC or AA detected during colonoscopy per 
1,000 screened persons with assessable stool sample.
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associated risks. In July 2014, the programme was adjusted resulting in a lower positivity 
rate and fewer false positive results, which was more in line with expectations. Despite this 
adjustment, the entire target population of 2014 could not be invited within that calendar 
year owing to high participation and high referral rates for colonoscopy in the first half of 
the year, together leading to higher colonoscopy demand than capacity. As a whole, the first 
year of the national CRC screening programme resulted in a high number of participants and 
the detection of 2483 cancers and 12,030 advanced adenomas.
The participation rate exceeded the level of 65%, put forward as the desirable level of 
participation in the European Union guidelines for quality assurance in CRC screening.18 It is 
remarkable that some countries with similar participation rates for population-based breast 
cancer screening programmes as the Netherlands, such as England and France, have lower 
participation rates for CRC screening.20-22 Potential explanations for the high participation rate 
are the choice of screening modality, the efficient organisational structure of the programme 
(e.g., invitation-based, pre-invitation letter, and enclosing the FIT within the invitation set), a 
detailed information leaflet, and the fact that the FIT is free of charge.23
The higher-than-expected positivity rate in the first year can be explained by several 
factors. First, the age distribution of the first half of the year was skewed toward older ages, 
and older age is related to a higher positivity rate.24 Second, the FIT (FOB-Gold) in the national 
programme was of a different brand than the FIT in the pilot studies (OC-Sensor). The choice 
of FIT in the programme was the result of a public tender required for all governmental 
purchases exceeding a certain monetary value. Previous studies have shown that FOB-Gold 
has higher positivity rates than OC-Sensor.25,26 However, these studies did not standardise a 
cut-off value for a positive test result in µg Hb/g faeces, which was performed in the Dutch 
programme. Equal performance of both tests later was assessed in a confirmative trial.27 
Counterintuitively, positivity rates for both tests were higher in this fourth round of screening 
than in the third round, indicating a change in test performance between the 2 study rounds. 
The explanation may be that the manufacturers recently adapted the composition of the 
buffer fluid in the collection device to improve sample stability. Nevertheless, because 
selecting a new screening test is always subject to public tender, in the future we might first 
pilot a newly chosen test.
Participation in diagnostic colonoscopy was short of the minimally acceptable level of 85% 
and was lower than in the pilot studies and other FOBT-based screening programmes.3,10,14,28,29 
One explanation may be that not all colonoscopy results were integrated in ScreenIT because 
some individuals may have had a colonoscopy in centres outside the screening programme. 
Another potential explanation is that colonoscopy costs are considered standard medical 
care and therefore are covered by health care insurance. Because all Dutch citizens have 
a yearly obligatory deductible excess of 360 Euro participants who did not have previous 
medical costs in the calendar year were obliged to pay part of the colonoscopy costs. One last 
explanation might be that individuals refrained from colonoscopy or that colonoscopy was 
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not considered appropriate because of comorbidities. This also was reflected in the higher 
participation rate when excluding those for whom colonoscopy was not recommended. This 
may have had a relatively large impact because older age groups were disproportionally 
present in the 2014 target population.
The success of the Dutch CRC screening programme can in large part be attributed to 
its coordinated preparation and implementation, including piloting and monitoring. The 
piloting phase allowed for an evidence-based choice of the screening test, cut-off level, 
interval, and age range for the Dutch setting.11-14 Real-time monitoring showed at an early 
stage that the programme performed differently than intended (e.g., higher positivity rate 
and a lower PPV) and therefore adjustments to the programme could be made immediately. 
Consequently, the programme now performs in line with expectations and recommendation 
of the Dutch Health Council.3,11-14 The decision to adjust the cut-off level of the test was 
based on a thorough decision analysis, which has shown that the adjustment will lead to 
similar long-term effectiveness as the intended programme; close monitoring of programme 
performance should be continued for 2 reasons.19 First, given the gradual implementation 
of the programme, the new cut-off level could be based on only a selected number of age 
groups. Second, results were all based on the first screening round. Data on participation 
rate, positivity rate, PPV, and the detection rate of subsequent rounds will be of interest 
to evaluate whether the chosen cut-off level will continue to provide the expected results. 
In the end, the interval cancer rate will be the most important performance parameter to 
monitor the adjustment of the programme.
One may argue that it is unethical to increase the cut-off level of a screening test after 
implementation of a screening programme, because an increase in the cut-off value would 
decrease detection of advanced neoplasia, and screening should not be implemented unless 
sufficient resources for follow-up evaluation and treatment have been secured.30 However, 
in our opinion this consideration is not applicable to the Dutch programme. The increase of 
the cut-off value has not been made in the consideration of colonoscopy capacity (alone), 
but rather because the chosen cut-off value did not result in the intended balance of harms 
and benefits of the screening programme as recommended by the Dutch Health Council.3 
The adjustments of the cut-off value halfway through the year was necessary to ensure that 
the programme again met this intended performance.
Three limitations of monitoring the Dutch CRC screening programme are noteworthy. First, 
at this point in time, there is a delay of reliable information on the stage and localisation 
distribution of the detected CRCs and the occurrence of adverse events because not all data 
sources have been completely linked to ScreenIT. It is expected that this will occur within the 
next 1-2 years. Second, only colonoscopies performed in accredited colonoscopy centres 
within the programme are reported in ScreenIT. A national colonoscopy database will be set 
up in 2016 and potential linkage with that database will ensure complete catchment of all 
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colonoscopies by using the unique personal identifier. Finally, as already mentioned, current 
results concern only individuals age 60 years or older.
Notwithstanding these limitations, the design of the Dutch CRC screening programme may 
serve as a best practice for many screening initiatives currently being organised worldwide.2 
The implementation of the Dutch programme illustrates that even in evidence-based, 
well-planned programmes, programme performance can deviate from planning. Therefore, 
real-time monitoring systems are indispensable in ensuring quality in all aspects of screening 
programmes. A considerable amount of literature has been published on reports of organised 
screening programmes.28,29 However, to our knowledge no other data on real-time short and 
long cycle monitoring of screening programmes is available. The results of the first year of the 
Dutch programme may serve as an example to show that real-time monitoring is different 
from a retrospective monitoring system. By using real-time monitoring, adjustments can be 
made instantaneously to obtain optimal programme performance and ensure a good balance 
between harms and benefits of the programme. The way monitoring is performed may differ 
throughout the world, to best fit specific conditions. But even in settings with opportunistic 
screening such as in the United States, monitoring systems can be put in place on local 
or institutional levels. The Kaiser Permanente Northern California organised CRC screening 
programme is an excellent example of setting up large organised programmes to document 
the entire screening process with the purpose of monitoring and quality assurance.31
At this phase of implementation, it was decided to stick to the original programme as much 
as possible and not experiment with alternative programme designs. Therefore, the cut-off 
level was increased the same way across the board, i.e. for all ages and screening rounds. It 
also was decided to stick to the re-screening interval of 2 years, even if the target population 
had not been completely invited yet. Once the programme has been fully implemented and 
established, future research should be performed to continually optimise the CRC screening 
programme. Looking at the impact of increasing the cut-off level, there are indications that 
the higher cut-off level has led to a greater reduction in screen-detected neoplasia in the 
older age groups compared with the younger age groups. Therefore, a differential cut-off 
level by age might lead to a more (cost-) effective screening programme. Decision analyses 
can be performed comparing such strategies to identify the optimal screening strategy for 
the current situation. Other examples of possible new strategies are applying different cut-
off levels for the first and subsequent screening rounds or allocating different intervals based 
on the haemoglobin level of the previous screening round.  
In conclusion, the Dutch national CRC screening programme was implemented successfully 
with high participation and yield. Real-time monitoring allowed for instant adjustment of 
the programme when it substantially differed from expected. Optimising the programme 
resulted in a programme that more closely meets expectations, with a better balance 
between true and false positive results.
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Table 1: Calculated positivity rate* and positive predictive value (PPV) † for biennial FIT screening in the first 
year of the Dutch CRC screening programme at a cut-off level of 47 µg Hb/g faeces
First half year 2014 Second half year 2014
Cut-off level original 15 µg 15 µg ->47 µg 47 µg
Positivity n % (95%CI) n % (95%CI) n % (95%CI)
All 15,802 12.2 (12.0-12.4) 9,369 7.2 (7.1-7.4) 25,040 6.3 (6.3-6.4)
age-adjusted§ 15,802 10.6 (10.5-10.8) 9,369 6.4 (6.3-6.4) 23,730 6.7 (6.6-6.8)
60 - - - - 1,310 5.0 (4.7-5.3)
63 207 7.7 (6.7-8.8) 125 4.6 (3.9-5.5) 4,635 5.4 (5.2-5.5)
65 2,598 9.1 (8.8-9.4) 1,533 5.4 (5.1-5.6) 5,308 6.1 (5.9-6.2)
67 1,753 10.5 (10.1-11.0) 1,056 6.3 (6.0-6.7) 7,840 6.3 (6.2-6.5)
75 3,454 13.2 (12.8-13.6) 2,066 7.9 (7.6-8.2) 4,335 8.3 (8.1-8.6)
76 7,790 14.1 (13.8-14.4) 4,589 8.3 (8.1-8.6) 1,612 8.4 (8.0-8.8)
PPV CRC n % (95%CI) n % (95%CI) n % (95%CI)
All 911 7.2 (6.8-7.7) 779 10.4 (9.7-11.1) 1,572 8.2 (7.8-8.6)
age-adjusted§ 911 6.8 (6.4-7.2) 779 9.7 (9.2-10.2) 1,534 8.7 (8.3-9.2)
60 - - - - 38 4.3 (3.2-5.9)
63 8 4.6 (2.3-8.9) 8 7.3 (3.7-14.0) 265 7.4 (6.6-8.3)
65 123 5.6 (4.7-6.6) 109 8.3 (6.9-9.9) 298 7.2 (6.5-8.0)
67 102 7.0 (5.8-8.5) 87 10.0 (8.2-12.2) 531 8.5 (7.8-9.2)
75 217 8.0 (7.1-9.1) 183 11.3 (9.8-12.9) 321 10.1 (9.1-11.2)
76 461 7.6 (6.9-8.3) 392 10.9 (10.0-12.0) 119 10.4 (8.7-12.3)
PPV AA n % (95%CI) n % (95%CI) n % (95%CI)
All 4,319 34.3 (33.4-35.1) 2,968 39.6 (38.5-40.7) 7,711 40.3 (39.6-41.0)
age-adjusted§ 4,319 35.3 (34.6-36.1) 2,968 40.9 (40.0-41.7) 7,379 40.3 (39.4-41.1)
60 - - - - 332 37.8 (34.6-41.0)
63 63 36.0 (29.2-43.4) 42 38.5 (29.9-48.0) 1,412 39.4 (37.8-41.0)
65 816 37.0 (35.0-39.0) 558 42.5 (39.8-45.2) 1,687 41.0 (39.5-42.5)
67 534 36.9 (34.5-39.4) 381 43.7 (40.5-47.1) 2,576 41.2 (40.0-42.4)
75 938 34.8 (33.0-36.6) 653 40.2 (37.8-42.6) 1,250 39.4 (37.7-41.1)
76 1,968 32.3 (31.2-33.5) 1,334 37.3 (35.7-38.8) 454 39.7 (36.9-42.5)
Abbreviations: FIT (faecal immunochemical testing), CRC (colorectal cancer), AA (advanced adenomas), PPV 
(positive predictive value)
* Positivity rate was defined as the number of participants with an unfavorable test result (above the cut-off 
level) divided by the number of participants with assessable stool sample. In this table, FITs was considered 
positive at a cut-off level of 47 µg Hb/g faeces.
† PPV was calculated as the number of persons with CRC or AA divided by the number of persons who 
underwent colonoscopy. Numbers of positive individuals attending colonoscopy are not shown.
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We read with interest the results of the pilot study in England, which was performed to 
establish the acceptability and diagnostic performance of screening with the Faecal 
Immunochemical Test (FIT) over the guaiac Faecal Occult Blood Test (gFOBT).1 When 
comparing gFOBT to FIT, the uptake increased from 59.4% to 66.4%, positivity rate increased 
from 1.7% to 7.8% (at a cut-off level of 20 µg Hb/g faeces) and colorectal cancer (CRC) 
detection doubled. Moreover, this report showed that also with FIT cut-off levels above 20 
µg Hb/g faeces, improved clinical outcomes can be achieved over gFOBT. However, for a 
screening programme to be effective it is a prerequisite to detect cancers in an early stage. 
Thus far, information on stage distribution of screen-detected CRCs in a population-based 
FIT screening programme is lacking. 
In our study, we collected data on all CRCs detected in patients aged 60 to 75 years in the 
Netherlands in 2015 through the Netherlands Cancer Registry. In total, 9,437 CRCs were 
diagnosed in 9,301 patients: 3,579 (38.5%) patients were diagnosed after a positive FIT in 
the CRC screening programme (screen-detected), 4,506 (48.4%) patients were diagnosed 
due to symptoms (symptom-detected) and 1,216 (13.1%) patients had another mode of 
detection. Among all patients, 2,679 (31.3%) CRCs were detected at stage I, 1,827 (21.2%) 





n (%) n (%) p value
Stage* I 1,697 (48.2%) 743 (16.7%)
II 652 (18.5%) 1,028 (23.1%)
III 957 (27.2%) 1,541 (34.6%)
IV 215 (6.1%) 1,143 (25.7%) <0.001
Location Right 944 (26.6%) 1,569 (35.4%)
Caecum 280 (7.8%) 588 (13.0%)
Ascending colon 268 (7.5%) 494 (11.0%)
Hepatic flexure of colon 112 (3.1%) 166 (3.7%)
Transverse colon 183 (5.1%) 203 (4.5%)
Splenic flexure 101 (2.8%) 118 (2.6%)
Left 1,628 (45.9%) 1,393 (31.4%)
Descending colon 176 (4.9%) 167 (3.7%)
Sigmoid 1,422 (39.7%) 1,213 (26.9%)
Rectosigmoid 30 (0.8%) 13 (0.3%)
Rectum 973 (27.4%) 1,476 (33.3%)
Rectum 973 (27.2%) 1,476 (32.8%) <0.001
Colon overlapping 11 (0.3%) 24 (0.5%)
Colon unspecified 23 (0.6%) 44 (1.0%)
* Stage distribution of screen-detected and symptom-detected CRCs was unknown of 109 patients.
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CRCs at stage II, 2,630 (30.6%) CRCs at stage III and 1,469 (17.1%) CRCs at stage IV. CRCs 
stage was unknown for 696 (7.5%) CRCs. Comparison of only screen-detected and symptom-
detected CRCs showed that 2,349 (66.7%) screen-detected CRCs were detected at an early 
stage (stages I and II), which was higher than the 1,771 (39.8%) symptom-detected CRCs (p 
<0.001, table 1). Screen-detected cancers were more often diagnosed in the left colon (45.9%) 
than symptom-detected cancers (31.4%, p <0.001). Figure 1 presents the comparison of 
screen-detected and symptom-detected CRCs by stage distribution for different subgroups 
(location, gender, age and social economic status). As shown in this Figure, in all subgroups 
the screen-detected CRCs had a more favourable stage distribution than the symptom-
detected CRCs. This indicates that there is no difference in impact of FIT-based screening on 
stage distribution among different subgroups.
The more favourable stage distribution of screen-detected CRCs may have two main 
explanations. The first is simply the earlier detection of cancers by FIT screening, which is 
the aim. However, it may also be due to overdiagnosis of indolent disease. In this case, 
screening would simply result in more detection of early-stage disease, without actually 
reducing the amount of advanced CRCs. Therefore, a more favourable stage distribution of 
screen-detected versus symptomatic CRCs in itself gives no definitive evidence for future 
mortality reduction.2,3 
On the other hand, stage distribution of the screen-detected CRCs is in line with that 
observed in randomized controlled trials, which eventually demonstrated a reduction in 
CRC mortality.4-6 It therefore is expected that the Dutch FIT-based screening programme 
may also decrease CRC mortality. The observed stage distribution is also in line with other 
FOBT programmes: the UK gFOBT-based screening programme and the FIT-based screening 
programme of the Basque country.7,8 In the British sigmoidoscopy trial, the proportion of 
CRCs detected at an early stage (74%) was slightly higher, but in line with our FIT programme.9 
In conclusion, screen-detected CRCs in a FIT-based screening programme are detected 
more often at an early disease stage than symptomatic cancers. As survival rates improve 
if cancers are detected at an early stage, the first prerequisite for mortality reduction as a 
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The Dutch colorectal cancer (CRC) screening programme started in 2014, inviting the target-
population biennially to perform a faecal immunochemical test (FIT). We aimed to present 
the results of the second round (2016) and evaluate the impact of increasing the FIT cut-off 
halfway the first round (2014) on outcomes in the second round.
Methods
Prospectively collected data were obtained from the national screening information system 
(ScreenIT). Participants were categorised based on first-round participation status and 
used FIT cut-off level: previously tested with 15 µg (FIT1st-15) or 47 µg (FIT1st-47) and previous 
non-participants (FIT1st-np). Second-round screening was done with a 47 µg Hb/g faeces FIT 
cut-off. Among others, outcomes included second-round participation and detection rate of 
advanced neoplasia (AN) and cumulative detection rate of AN over two rounds.
Results
348,891 (75.9%) out of 459,740 invitees participated in the second round. Participation 
rates were 93.4% among previous participants and 21.0% among previous non-participants. 
FIT1st-47 participants had a significantly higher detection rate of AN (15.3 vs. 10.4 per 1,000 
participants) compared to FIT1st-15 participants in the second round, while their cumulative 
detection rate of AN over two rounds was significantly lower (45.6 vs. 52.6 per 1,000 
participants).
Conclusions
Participation in the Dutch CRC screening programme was consistently high. Second-round 
detection rates depended on the first-round FIT cut-off. The cumulative detection over two 
rounds was higher among FIT1st-15 participants. These findings suggest that a substantial part, 
but not all, of the missed findings in the first round due to the increased FIT cut-off were 




Many countries have recently introduced colorectal cancer (CRC) screening with the aim to 
reduce CRC incidence and mortality. These programmes use different screening strategies.1 
Colonoscopy is the gold standard for detecting advanced neoplasia (AN) because of its high 
sensitivity. However, colonoscopy is an invasive procedure that demands extensive resources 
when used for primary screening on a population level. Many countries therefore prefer a 
non-invasive faecal test for primary screening, followed by colonoscopy when tested positive. 
Of the currently available faecal tests, faecal immunochemical testing (FIT) is associated 
with the highest participation and a high diagnostic performance.2-6 Besides its superior 
characteristics compared to other faecal testing screen modalities, FIT offers the advantage 
to adjust the cut-off level to match local resources.7 It allows for optimising the balance 
between the number of true- and false-positives, potentially impacting the detection rate.8,9 
Modelling studies based on real-life data reported that annual FIT at a low cut-off is equally 
effective in reducing CRC-related mortality as 10-yearly primary colonoscopy screening.10 
However, many organised programmes are currently forced to use a higher FIT cut-off and a 
longer screening interval, often due to a limited colonoscopy capacity.1,11-13
The Dutch FIT-based CRC screening programme started in 2014 after extensive piloting in 
previous years. During the first months after the start we observed a higher participation 
rate, a higher FIT positivity rate and a lower positive predictive value (PPV) compared 
to the results of the preceding pilot studies. Because the referral rate also exceeded the 
colonoscopy capacity, the FIT cut-off was increased halfway during the first year, resulting in 
a lower positivity rate and a higher PPV for advanced neoplasia.14 In this study we evaluated 
participation in the second round and estimated the impact of the adjusted FIT cut-off in the 
first round on screening outcomes in the second round. 
METHODS
The design of the Dutch CRC screening programme and its real-time monitoring system have 
previously been described.14 In summary, the target population consists of individuals aged 
55 to 75 years old, who are invited every two years to perform a FIT (FOB-Gold, Sentinel). 
Participants with a positive FIT (µg Hb/g faeces above the cut-off) are referred for a pre-
colonoscopy intake. Eligible individuals are then scheduled for colonoscopy. The target 
population was invited gradually by birth-cohort.
Study population
In 2014, at the start of the screening programme, individuals that reached the age of 63, 65, 
67, 75 and 76 years were invited for first-round screening. Persons aged 76 years were also 
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invited in 2014, due to a delayed implementation of the programme. For the second round, 
the same target group was re-invited in 2016, except for the invitees who tested positive in 
the first round, who had become older than 75 years, or who had deregistered permanently 
from the screening programme. In the first half year of 2014, a FIT cut-off of 15 µg Hb/g 
faeces was used. This was increased to 47 µg Hb/g faeces in the second half of 2014. In the 
second round, all FIT samples were analysed with FIT a cut-off of 47 µg Hb/g faeces.
Data collection
Of all invitees of the first round, data on participation status, FIT-result (µg Hb/g faeces), 
pre-colonoscopy intake and colonoscopy results in the first and/or second screening round 
were collected from the national screening information-system (ScreenIT).
Outcomes
Primary outcomes of this study were participation rate, FIT positivity rate, PPV for AN and 
detection rate of AN in the second screening round. An invitee was considered a participant when 
a FIT stool-sample was returned and a non-participant when there was no response or when the 
invitee deregistered. The participation rate was defined as the number of participants divided by 
the number of individuals invited. The positivity rate was defined as the number of participants 
with a FIT-result at or above the cut-off divided by the number of participants with an assessable 
FIT. The participation rate for pre-colonoscopy intake was defined as the number of persons who 
attended the pre-colonoscopy intake divided by the number of FIT-positives. The participation 
rate for colonoscopy was defined as the number of persons that underwent colonoscopy divided 
by the number of persons with a positive FIT. AN was considered a relevant finding within the CRC 
screening programme and was defined as CRC or advanced adenoma (AA).15 AA was defined as 
any adenoma with histology showing 25% or greater villous component or high-grade dysplasia 
or an adenoma with size of 10 mm or larger. The PPV for AN was calculated as the number of 
persons detected with AN divided by the number of persons who underwent a colonoscopy. 
The detection rate of AN was defined as the number of persons detected with AN of those who 
returned an assessable FIT. Secondary outcomes were cumulative positivity rate, cumulative 
detection rate of AN, number needed to scope (NNScope) to detect AN in one patient, and 
the association between concentration µg Hb/g faeces (FIT cut-off level) in the first round and 
screening-outcomes in the second round. Cumulative positivity rate was defined as the number 
of positive FIT results over both rounds divided by the number of participants that returned 
an assessable FIT in both rounds or tested positive in the first round. The cumulative detection 
rate was defined as the number of CRC or AN detected over both rounds in participants that 
returned an assessable FIT in both rounds or tested positive in the first round. The NNScope was 
defined as the number of performed colonoscopies divided by the number of detected CRC or 
AN, over both rounds. The FIT-level in the first round was tested on the association with positive 




All invitees to the second round were analysed for participation rate, positivity rate, 
participation rate of pre-colonoscopy intake and colonoscopy, PPV for AN and detection rate 
of AN. Primary outcomes were presented for three different subgroups: individuals that were 
tested with a FIT cut-off of 15 µg Hb/g faeces in the first round (FIT1st-15), individuals that were 
tested with a FIT cut-off of 47 µg Hb/g faeces in the first round (FIT1st-47) and individuals that 
did not participate in the first round (FIT1st-np). Secondary outcomes excluded participants of 
the first round of the oldest birth cohorts (1938 and 1939), since those participants were not 
part of the target population of 2016 and therefore not re-invited. The cumulative positivity 
rate, cumulative detection rate and NNScope over two screen-rounds were compared 
between FIT1st-15 and FIT1st-47 participants of both rounds. To assess the association between 
FIT-level in the first round and screening outcomes in the second round, the FIT-results of 
first round participants were categorised in 0 µg, 1-14 µg and 15-46 µg Hb/g faeces (the 
latter group was only applicable to FIT1st-47 participants).
Descriptive statistics were computed of the primary outcomes, including 95% confidence 
intervals (95%CI). Differences between groups were tested for statistical significance (p < 
0.05) using the Chi-square test or the Student’s t-test. Age-adjusted rates for the primary 
outcomes and secondary outcomes were calculated for groups with more than 50 invitees, 
therefore only age groups of 65, 67 and 69 years old were included. Because of substantially 
different age-distributions between subgroups, the chi-square was not applicable. Instead, 
differences between the age-adjusted rates were tested with the Standardised Rate Ratio 
(SRR).16,17 If the 95%CI of the SRR includes 1, no significant difference was observed between 
the age-adjusted rates. Multivariable logistic regression was performed to estimate the odds 
ratios (ORs) of the FIT-level in the first round on screening outcomes in the second round, 
adjusted for gender and age. As sensitivity analyses, we 1) tested the outcomes on significant 
differences between gender and 2) only included FIT1st-47 participants to rule out verification 
bias, since only FIT-positive participants are referred for colonoscopy (Appendix I & II).
RESULTS
In total, 459,740 individuals were invited for second-round screening. Of those, 348,891 
(75.9%) participated and 4.5% tested FIT-positive (Figure 1 & Table 1). Out of the 14,102 
(90.4%, 95%CI: 90.0-90.9%) individuals that attended the pre-colonoscopy intake, 93.3% 
(95%CI: 92.9-93.7%) were advised to undergo colonoscopy. Of all individuals that tested FIT-
positive, 12,864 (82.5%, 95%CI: 81.9-83.1%) participants underwent colonoscopy at which 
832 CRCs and 4,576 AAs were detected. This resulted in a detection rate of 15.5 (95%CI: 




Of all 348,071 second-round invitees who participated in the first round, 325,392 (93.5%) 
also participated in the second round (Table 2). Of all 111,669 second-round invitees who did 
not participate in the first round, a total of 23,499 (21.0%) participated in the second round.
Yield of screening
Among second-round invitees that had also participated in the first round, there were 39,257 
FIT1st-15 and 286,135 FIT1st-47 participants (Table 2). FIT1st-15 participants of the second round 
had a positivity rate of 3.3%, a PPV for AN of 36.9% (95%CI: 34.1-39.8%), and a detection rate 
of AN of 10.4 (95%CI: 9.4-11.4) per 1,000 participants. FIT1st-47 participants had in the second 
round a higher positivity rate of 4.3%, a higher PPV for AN of 41.2% (95%CI: 40.2-42.1%), 
and a higher detection rate of AN of 15.0 (95%CI: 14.6-15.5) per 1,000 participants. SRR 
presented a significantly higher age-adjusted positivity rate (SRR: 1.3, 95%CI: 1.1-1.5) and 











CT Colonography: 208 (1.5%)
Exclusion: 412 (2.9%)
Postponed: 278 (2.0%)
Prefers other screening centre: 41 
(0.3%)
























Abbreviations: FIT (faecal immunochemical testing)
* Off all participants, 348,726 (99.95%) individuals returned an assessable FIT
** Divided by the number of assessable FITs
†Divided by the number of participants with a positive FIT













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































age-adjusted detection rate of AN (SRR: 1.5, 95%CI: 1.2-1.9) in FIT1st-47 participants of the 
second round (Table 2). Differences in age-adjusted PPV between the used cut-offs were 
non-significant. The FIT1st-np participants of the second round showed a high positivity rate 
of 7.9%, PPV of 54.9% (95%CI: 52.2-57.6%) for AN and detection rate of AN of 30.1 (95%CI: 
27.9-32.3) per 1,000 participants (Table 2). All outcomes were significantly higher compared 
to second-round participants that had participated in the first round.
Cumulative rates and NNScope
Of FIT1st-15 participants, 13.1% (95%CI: 12.8-13.4%) tested positive in the first (10.1%) or second 
(3.0%) round (cumulative positivity rate). This cumulative positivity rate was higher compared 
to the FIT1st-47 participants, of which 10.4% (95%CI: 10.3-10.5%) tested positive in the first 
(6.3%) or second (4.1%) round. The age-adjusted cumulative positivity rate over two rounds 
was significantly higher in FIT1st-15 participants (SRR: 1.2, 95%CI: 1.2-1.3). Per 1,000 FIT1st-15 
participants, CRC was detected in 7.5 (95%CI: 6.7-8.3) participants in the first (6.0) or second 
(1.4) round and AN were detected in 52.6 (95%CI: 50.6-54.8) participants in the first (43.3) 
or second (9.3) round (cumulative detection rate) (Figure 2). A lower cumulative detection 
rate of CRC and AN was observed per 1,000 FIT1st-47 participants, in which 6.9 (95%CI: 6.6-7.2) 
participants were detected with CRC in the first (4.8) or second (2.1) round and 45.6 (95%CI: 
44.8-46.3) with AN in the first (31.5) or second (14.1) round. Age-adjusted rates showed a 
non-significant difference in the cumulative detection rate over two rounds for CRC (SRR: 1.1, 
95%CI: 0.8-1.4), yet significantly more FIT1st-15 participants were detected with AN (SRR: 1.2, 
95%CI: 1.1-1.3). Over two rounds, 14.9 (95%CI: 14.5-15.3) FIT1st-15 participants and 12.7 (95%CI: 






























Abbreviations: CRC (colorectal cancer), AN (advanced neoplasia)
61
SECOND SCREENING ROUND
12.6 – 12.9) FIT1st-47 participants needed to undergo colonoscopy (NNScope) to detect CRC in 
one participant, with a significant difference after age-adjustment (SRR: 1.2, 95%CI: 1.1-1.3). 
A similar pattern was observed for the NNScope to detect AN in one participant (Figure 3).
Figure 3: Number of participants that underwent colonoscopy (NNScope) over two rounds of screening to 






























Yield by previous FIT result
The positivity rate, PPV and detection rate in the second round was strongly related to 
the concentration of Hb detected in faeces in the first round. Participants with a FIT-level 
in the first round between 15 and 47 µg Hb/g faeces showed a positivity rate of 23.3%, 
a PPV for AN of 60.3% and a detection rate of AN of 120.3 per 1,000 participants in the 
second round (Table 3). The outcomes in these participants were significantly higher than 
in participants with a FIT-level below 15 µg in the first round. Compared to participants 
with no (0 µg) detectable Hb in their faeces sample, a participant with a FIT-level between 
15 and 47 µg was remarkably more likely to test FIT-positive (OR 11.9, 95%CI: 11.3-12.5) or 
have an AN detected during colonoscopy (OR 23.2, 95%CI: 21.5-25.1). While the sensitivity 
analyses ruled out verification bias, it pointed out significant differences between male and 
female participants (Appendix I & II). However, this did not change the conclusion, as both 





This study presents the results of the second round of the Dutch FIT-based CRC screening 
programme and evaluates the impact of increasing the FIT cut-off in the first round on the 
yield of the second round. We observed a consistently high participation as almost all first-
round participants also participated in the second round. The detection rate of AN in the 
second round was significantly higher in FIT1st-47 participants compared to FIT1st-15 participants. 
Nevertheless, the cumulative detection rate of AN over two rounds was significantly lower 
in FIT1st-47 participants. We found a strong correlation between the concentration µg Hb/g 
faeces in the first round and the detection of AN in the subsequent round.
The Dutch government was the first to change the FIT cut-off in a running national 
CRC screening programme. Therefore we are the only country yet in which evaluation of 
the programme can demonstrate the impact of adjusting the FIT cut-off on the yield at a 
population level. The main reason to increase the FIT cut-off during the first round was to 
reduce colonoscopy demand and the proportion of false-positive FIT-results. As previously 
reported, this indeed successfully decreased the positivity rate and increased the PPV in first 
round FIT1st-47 participants, at the cost of a lower detection rate (14). We demonstrated in the 
current study that, cumulatively, the detection rate over two rounds was still lower in FIT1st-47 
participants. However, we also observed that the difference in cumulative detection rate of 
AN between FIT1st-47 and FIT1st-15 participants decreased from 11.8 AN per 1,000 participants 
in the first round, to 7.0 AN per 1,000 participants in the second round. This means that a 
substantial part of the missed lesions in the first screening-round due to the increased FIT 
cut-off from 15 to 47 µg Hb/g faeces are detected at the subsequent round. If the difference 
Table 3: Yield of the second round relative to FIT results of the first round
First screening round FIT result (Hb/g faeces) 0 µg >0 µg and <15 µg ≥15 µg and <47 µg p value
Total 248,310 66,030 10,961
Positivity rate
n (%) 6,000 (2.4) 5,187 (7.9) 2,553 (23.3) < 0.001
OR (95% CI) - 3.4 (3.3 - 3.5)* 11.9 (11.3 - 12.5)*
PPV AN
n (%) 1,390 (27.9) 1,993 (45.7) 1,319 (60.3) < 0.001
OR (95% CI) - 2.2 (2.0 - 2.4) 3.9 (3.5 - 4.3)
Detection rate AN
n (per 1,000 participants) 1,390 (5.6) 1,993 (30.2) 1,319 (120.3) < 0.001
OR (95% CI) - 5.4 (5.0 - 5.8)* 23.2 (21.5 - 25.1)*
Abbreviations: OR (Odds Ratio), PPV (Positive Predictive Value); AN (Advanced Neoplasia)
* Significant interaction between male and female gender (see appendix)
OR are adjusted for age and gender
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in cumulative detection rate of AN between FIT1st-47 and FIT1st-15 participants keeps declining 
per subsequent screening, the impact of adjusting the FIT cut-off on yield of screening might 
become insignificant within one or two subsequent screening rounds.
The majority of undetected CRCs due to the increased FIT cut-off seem to be detected in 
the second round, as the cumulative detection rate of CRC over two rounds in FIT1st-47 and 
FIT1st-15 participants was almost similar. This suggests that increasing the FIT cut-off resulted 
in limited harms. However, it is unclear if the higher cut-off resulted in more interval cancers 
and if the detected CRCs in the second round were still diagnosed in an early stage, which is 
a prerequisite for screening to be effective. Therefore, interval cancers have to be analysed 
and data on stage distribution have to be evaluated. The effect of increasing the cut-off in 
the older birth cohorts, 1938 and 1939, which were not re-invited for a second round as 
they exceeded the target age, should be assessed separately. As the missed lesions in FIT1st-47 
participants of these birth cohorts will not be detected in a subsequent round, they might 
potentially progress to symptomatic CRC.
The reported participation rate (75.9%) in the Netherlands can be considered the highest 
in a subsequent round, even higher than observed in the Dutch CRC screening pilots.18-20 
However, this outcome is overestimated by approximately 2%, because the calculation of 
participation rate excluded invitees who deregistered permanently during the first round 
and were therefore not invited to the second round.
The strong correlation between the level of Hb concentration of a negative FIT result and the 
chance of detecting AN in the subsequent round, suggests an excellent opportunity for more 
personalised FIT screening based on Hb concentration. For example, the screening interval 
of participants with no detectable blood (0 µg Hb/g faeces) could potentially be prolonged. 
Similarly, it may be reasonable to re-invite participants that tested just negative (15 – 47 µg 
Hb/g faeces) already after one year to detect relevant findings in time. In concordance with 
our data, a similar association between FIT level and outcomes in the subsequent rounds has 
previously been presented by a Dutch, Spanish and Taiwanese study.21-23
Important strengths of our study are the nation-wide implementation of the screening 
programme, the large sample size and the well-developed registration, therefore providing 
accurate data. Nevertheless, two limitations are noteworthy. As mentioned before, data on 
stage distribution are lacking, which would provide important information on the potential 
consequences of missed lesions in the first round caused by the increased FIT cut-off. These 
data will be available in the near future. Second, not every birth cohort has been invited 
yet for the Dutch CRC screening programme; conclusions are therefore based on a few age 
groups.
Notwithstanding these limitations, we are the first to present on how using a different FIT 
cut-off in the first round impacts the outcomes of a subsequent round. Our findings are of 
value to other FIT-based CRC screening programmes considering an appropriate cut-off in 
their setting, in particular when the used FIT cut-off is within the same range.
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In conclusion, participation in the Dutch CRC screening programme was high and consistent. 
Our results showed that using a higher FIT cut-off in CRC screening has limited impact on the 
yield of screening because a substantial part of AN will be detected in subsequent rounds. To 
confirm whether these AN are still detected in an early stage, retrieving more information on 
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Table 1: FIT positivity rate and detection rate for advanced neoplasia in the second screening round relative 
to the first screening round FIT result by sex
First screening round FIT result (Hb/g faeces) 0 µg >0 µg and <15 µg ≥15 µg and <47 µg
Positivity rate (OR (95% CI))
Male - 3.2 (3.0 - 3.4) 11.3 (10.5 - 12.0)
Female - 3.6 (3.4 - 3.8) 12.8 (11.8 - 13.9)
Detection rate AN (OR (95% CI))
Male - 5.0 (4.6 - 5.4) 20.6 (18.6 - 22.7)
Female - 6.0 (5.4 - 6.7) 28.2 (24.8 - 31.9)
Note: other outcomes were not significantly different between male and female
Abbreviations: OR (Odds Ratio); AN (Advanced neoplasia)
APPENDIx II
Table 1: Yield of the second round relative to FIT results of the first round, including only participants tested 
in the first round with 47 μg Hb/g faeces
First screening round FIT result (Hb/g faeces) 0 µg >0 µg and <15 µg ≥15 µg and <47 µg p value
Total 217,435 57,662 10,948
Positivity rate
n (%) 5,334 (2.5) 4,553 (7.9) 2,550 (23.3) < 0.001
Odds-ratio (95% CI) - 3.4 (3.2 - 3.5)* 11.7 (11.1 - 12.3)*
PPV AN
n (%) 1,230 (27.8) 1,748 (45.7) 1,317 (60.3) < 0.001
Odds-ratio (95% CI) - 2.2 (2.0 - 2.4) 3.9 (3.5 - 4.3)
Detection rate AN
n (per 1,000 participants) 1,230 (5.7) 1,748 (30.3) 1,317 (120.3) < 0.001
Odds-ratio (95% CI) - 5.4 (5.0 - 5.8)* 22.9 (21.2 - 24.9)*
Outcomes are adjusted for age and sex
Abbreviations: PPV (Positive Predictive Value); AN (Advanced Neoplasia)
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This study evaluated the interval cancer incidence after the first screening round in 
an organised colorectal cancer (CRC) screening programme using the FOB-Gold faecal 
immunochemical test (FIT) in relation to FIT cut-off.
Methods
Screening participants with a negative FIT in the first screening round in national population-
based CRC screening programme in the Netherlands in 2014 were included in the study. 
Cumulative incidence of interval cancer after negative FIT and FIT sensitivity for CRC at a low 
(15 µg Hb/g faeces) and higher (47 µg Hb/g faeces) cut-off were estimated.
Results
Among the 485,112 participants with a negative FIT in 2014, 544 interval cancers were 
detected: 126 interval cancers among 111,800 FIT negatives at low cut-off and 418 interval 
cancers among 373,312 FIT negatives at higher cut-off. Mean age of individuals tested at 
the low cut-off was 72.0 years and at the higher cut-off was 66.7 years. The age-adjusted 
two-year cumulative incidences of interval cancer after negative FIT were 9.5 vs 13.8 per 
10,000 persons at respectively the low cut-off and higher cut-off, which were statistically 
different (p 0.005). Age-adjusted FIT sensitivities for CRC were statistically different with 
90.5% respectively 82.9% at the low and higher cut-off (p <0.0001). The overall FIT sensitivity 
for CRC was 87.4% among men and 82.6% among women (p <0.001).
Conclusions
The incidence of interval CRC after a negative FIT is low. Although FIT sensitivity for declined 




Many countries have introduced a screening programme for colorectal cancer (CRC) in recent 
years. Different screening modalities are suitable for that purpose. Opportunistic screening 
programmes most often use colonoscopy for primary screening, while organised population-
based programmes mostly prefer faecal immunochemical testing (FIT).1 Colonoscopy has 
better test characteristics compared to FIT when applied for one-time screening, yet is 
invasive, burdensome, and costly. FIT is non-invasive, non-burdensome, and less costly, but 
has lower test sensitivity.2-4 For optimal programme sensitivity and preventive effect, FIT 
should be repeated regularly.
FIT has been shown to be effective in detecting CRC at low cut-offs or short screening 
intervals.5,6 Modelling studies suggested that by repeating FIT annually, with an assumed test 
sensitivity of 73.8% for CRC, the long-term preventive effect would be similar to colonoscopy 
screening.5 The number of interval cancers in the Dutch CRC screening pilot study was recently 
evaluated, based on three biennial FIT screening rounds. This relatively small study showed 
an interval CRC incidence rate of 0.1% and a sensitivity of 77% over three screening rounds.6 
However, these interval CRCs were observed while using a very low FIT cut-off of 10 µg Hb/g 
faeces. In many regional or national population-based organised programmes a higher cut-
off for a positive FIT with referral to colonoscopy is chosen for a better balance between 
true and false positives.1 Six months after the start of the Dutch national programme, the 
FIT cut-off was increased from 15 to 47 µg Hb/g faeces, because of a higher than expected 
positivity rate with an associated lower positive predictive value and shortage in colonoscopy 
capacity.7 Consequently, we assumed that 12% of the CRCs would be missed.8
Evaluation of the number of interval CRCs within organised population-based screening 
programmes is important. The results of the Dutch CRC FIT-based screening programme 
enable us to evaluate the number of interval CRCs after the first screening and determine 
the impact of using a relatively high versus a low FIT cut-off on the cumulative incidence and 
sensitivity of FIT for CRC.
METHODS
Screening programme and population
In the Netherlands a national population-based CRC screening programme was implemented 
in 2014, with biennial FIT screening for persons aged 55 through 75 years. The programme 
was rolled-out in 5 years (2014-2018), with a phased-implementation by age groups (birth 
cohorts). In 2014 individuals aged 60, 63, 65, 67, 75, and 76 years old were invited. For 
once also persons aged 76 years were invited in 2014, because the start of the programme 
was delayed. Individuals received an invitation letter by postal mail including one single FIT 
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(FOB-gold, Sentinel, Italy). Participants with a positive FIT were referred for colonoscopy. 
Participants with a negative FIT were re-invited 24 months after the previous invitation date. 
Note, this is not 24 months after a negative FIT, therefore screening interval could be shorter 
than 2 years. At the start in 2014, the cut-off for a positive test was defined at 15 µg Hb/g 
faeces. As a result of a higher than expected participation and positivity rate and a lower 
than expected positive predictive value for CRC and advanced adenomas (AA), it was decided 
to increase the cut-off in June 2014 to 47 µg Hb/g faeces. A more extensive description of 
the Dutch national CRC screening programme and the decision analysis on increasing the 
cut-off was given in a previous publication.7 This current paper evaluated the interval CRCs of 
participants invited in the first year of the national Dutch CRC screening programme in 2014.
Outcomes
We estimated the cumulative incidence of interval cancers and test sensitivity. The cumulative 
incidence was calculated as the number of interval CRCs within two years after a negative 
FIT in the first screening round divided by the total number of individuals with a negative FIT 
in the first screening round. Number was presented per 10,000 individuals with a negative 
FIT. FIT sensitivity was approximated by the number of screen-detected CRCs after a positive 
FIT in the first screening round divided by the sum of screen-detected and interval CRCs in 
the first screening round. This is a commonly applied approximation in screening literature.
We defined FIT interval CRCs according to the internationally recommended nomenclature 
of the working group on interval CRC of the World Endoscopy Organization.9 They designated 
an interval CRC as a CRC after a negative FIT but before the invitation of subsequent screening 
round with FIT.
An interval CRC in this study population was defined as follows for two distinct subgroups:
1) Participants with a negative FIT in 2014 and eligible for screening in the subsequent 
round: CRCs that occur between date of FIT analyses with negative FIT and date of 
invitation of the subsequent screening round. 
2) Participants with a negative FIT in 2014 and not eligible for screening in the subsequent 
round because of the upper age limit: CRCs that occur between date of FIT analyses with 
negative FIT plus 24 months.
Screen-detected CRCs were defined as cancers detected within 6 months after a positive FIT 
in the first screening round.
Data collection
Data of participants with a negative FIT in 2014 were obtained from the national screening 
database ScreenIT; Hb concentration, gender, age, invitation date, and date of analyses. All 
individual records of these participants were sent to the Netherlands Cancer Registry (NCR). This 
registry contained information on cancers detected in the Netherlands including data on patients, 
tumour, and treatment characteristics, collected from medical records. Linkage of participants 
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with a negative FIT from the screening database and the cancer registry was established by 
matching on: initials, birth name, family name, gender, date of birth, postal code, place of birth, 
and date of death. If an individual with a negative FIT had a CRC registered in the NCR after the 
date of the FIT analyses in 2014 and before the invitation date of the second screening round, 
incidence date, and stage (TNM classification) were collected through the registry. To calculate 
the number of screen-detected CRCs, individuals with a positive FIT in 2014 were similarly linked 
with the NKR and equivalent data on screen-detected CRCs were collected. All CRCs detected 
within 6 months after a positive FIT were considered a screen-detected CRC. For staging of 
CRCs, the 7th edition of the TNM classification was used. Tis (carcinoma in situ) were excluded 
from the analyses, because these are not invasive cancers. If individuals had more than one CRC 
diagnosed, for example at two different locations, the CRC with most advanced disease stage 
was selected for the analyses. The International Classification of Disease for Oncology (ICD-O) 
was used for coding location and was defined as rectum, rectosigmoid, sigmoid, descending 
colon, splenic flexure, transverse colon, hepatic flexure, ascending colon, and cecum (C18-C20).4 
Left-sided colorectal cancers included locations from rectosigmoid until descending colon and 
right-sided colon cancers included locations from splenic flexure to cecum. Appendicael cancers 
were not considered a CRC in the Dutch CRC screening programme.
Analyses
In all analyses the cut-off of 15 µg Hb/g faeces was referred to as low cut-off, the cut-off of 
47 µg Hb/g faeces was referred to as higher cut-off. Proportions of cumulative incidence and 
sensitivity with 95% confidence intervals (95% CI) were determined by descriptive analyses. 
The different subgroups (age and sex) were compared using chi-squared test. Because of a 
substantially different age distribution between the two cut-off groups, we could not use the 
chi-square test to compare rates by cut-off. Instead, we used multivariable logistic regression 
analyses to test for statistically significant differences (p <0.05) between the two cut-offs, 
adjusting for gender and age.
To also facilitate estimates for countries considering different cut-offs than 15 or 47 µg 
Hb/g faeces, we performed an exploratory analysis to estimate the number of interval 
CRCs at alternative cut-offs. For every individual we used the absolute concentration of 
Haemoglobin (Hb) in the sample to determine the numbers of FIT positives and negatives 
at cut-offs of >0 µg, 10 µg, 20 µg, 40 µg, 60 µg, 80 µg, 100 µg, 120 µg, 140 µg, and 160 µg 
Hb/g faeces and subsequently we determined how many CRCs would have been missed at 
those alternative cut-offs. This analysis was based on assumption that all screen-detected 
CRCs would have become an interval cancer when a cut-off below the measured faecal Hb 
concentration was applied. Visa versa we assumed that interval CRC after a negative FIT 
of a certain faecal Hb concentration would have been detected by screening when that 
concentration was surpassed by the cut-off.




In the first screening round in 2014, a total of 525,916 individuals had an assessable stool 
sample, of which 40,942 (7.8%) had a positive FIT and 484,974 (92.2%) had a negative FIT. 
127,411 were assessed with the low cut-off; 15,611 (12.3%) had a positive FIT and 111,800 
(87.7%) had a negative FIT. 398,505 were assessed with the higher cut-off;25,331 (6.4%) had 
a positive FIT and 373,174 (93.6%) had a negative FIT. 33,298 (81.3%) of the FIT positives 
had a colonoscopy follow-up. Among those with a colonoscopy follow-up, 3,210 screen-
detected CRCs were diagnosed, 1,102 with a low cut-off and 2,108 with a high cut-off (Table 
1). Among those with a negative FIT, 544 interval CRCs were detected: 126 interval CRCs with 
the low cut-off and 418 interval CRCs with the higher cut-off. Mean age of individuals tested 
at the low cut-off was 72.0 years and at the higher cut-off was 66.7 years. Median follow-up 
time between negative FIT and end of interval (invitation subsequent screening round of 24 
months for those over 75 years of age) was 730 (IQR 726-730) days. Median follow-up time 
between negative FIT and date of interval CRC was 469 (IQR 283-618) days. Of all interval 
CRCs, 188 (34.6%) were detected in the first year after a negative FIT, and 356 (64.4%) were 
detected in the second year after a negative FIT.
Table 1: Characteristics of the study population by cut-offs (15 and 47 µg Hb/g faeces)
15 µg 47 µg Total
n (%) n (%) n (%)
Total tested 127,411 (100) 398,505 (100) 525,916 (100)
Gender
Men 60,936 (47.8) 194,537 (48.8) 255,473 (48.6)
Women
Age
66,475 52.2) 203,968 (51.2) 270,443 (51.4)
76 54,961 (43.1) 19,256 (4.8) 74,217 (14.1)
75 25,997 (20.4) 52,204 (13.1) 78,201 (14.9)
67 16,103 (12.6) 124,768 (31.1) 140,871 (26.8)
65 28,111 (22.1) 88,340 (22.2) 116,451 (22.1)
63 2,239 (1.8) 86,959 (21.8) 89,198 (17.0)
60 - 26,978 (6.8) 26,978 (5.1)
FIT Negative 111,800 (87.7) 373,174 (93.69) 484,974 (92.2)
FIT Positive* 15,611 (12.3) 25,331 (6.4) 40,942 (7.8)
Screen-detected CRCs 1,102 (0.9) 2,108 (0.5) 3,210 (0.6)
Interval CRCs 126 (0.1) 418 (0.1) 544 (0.1)
Abbreviations: CRC (colorectal cancer), FIT (faecal immunochemical testing)




The cumulative incidence of interval CRC after a negative FIT in the first screening round was 
11.2 (95%CI: 10.3-12.2) per 10,000 individuals. The cumulative incidence for men of 12.2 
(95%CI: 10.9-13.7) per 10,000 individuals was slightly higher than the cumulative incidence 
for women of 10.3 (95%CI: 9.2-11.6) per 10,000 individuals, but just not significantly different 
(p 0.06). Cumulative incidence significantly increased with age (Figure 1; p <0.001). Note, 
only selected age groups were invited. After adjusting for age differences, the cumulative 
incidence of interval CRCs was 9.5 per 10,000 individuals at the low cut-off vs 13.8 per 
10,000 individuals at the higher cut-off. Multivariable logistic regression analysis showed a 
significant difference between the two cut-offs, after adjusting for gender and age (p 0.0005).




















Abbreviations: FIT (faecal immunochemical testing)
*Cumulative incidence is the number of interval CRCs after a negative FIT per 10,000 individuals with a 
negative FIT.
Sensitivity
Average sensitivity for CRC over both cut-offs in the first screening round was 85.5% (95%CI: 
84.3-86.6%). The sensitivity of 87.4% (95%CI: 86.0-88.7%) among men was higher than the 
sensitivity of 82.6% (95%CI: 80.6-84.5%) among women (p <0.0001). Sensitivity was not 
significantly different by age (Figure 2; p 0.52). Age-adjusted sensitivity at the low cut-off was 
90.5% and 82.9% at the higher cut-off. Multivariable logistic regression analysis showed a 
significant difference between the two cut-offs, after adjusting for gender and age (p <0.0001).
Exploratory analysis across the full range of relevant cut-offs showed the expected inverse 
correlation between cut-off and interval CRC rate, with a marked increase in interval CRC 
rate at high cut-offs (Figure 3). Largest decrease (1.3-0.5%) in positivity rate was observed 
at low cut-offs (above 0 up to 80 µg Hb/g faeces). Above 80 µg Hb/g faeces approximately 
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Abbreviations: FIT (faecal immunochemical testing)
*Sensitivity is the number of screen-detected CRCs after a positive FIT divided by the total number of CRCs 
(screen-detected CRCs and interval CRCs).
0.3% decrease in positivity rate was observed per 10 µg Hb/g faeces increase of FIT cut-
off. Contrary, largest decrease in FIT sensitivity for CRC was observed at high cut-offs. FIT 
sensitivity drops below 70% with cut-offs higher than 90 µg Hb/g faeces, with a sensitivity of 
only 52.0% at the FIT cut-off 160 µg Hb/g faeces.
Stage distribution and location
A total of 93 (19.8%) stage I interval CRCs were detected, 82 (17.5%) stage II interval, 175 
(37.2%) stage III interval CRCs and 120 (25.5%) stage IV interval CRCs. Of 74 (15.7%) interval 
CRCs stage was unknown. There was no difference between the low cut-off with 75 (63.0%) 
interval CRCs and the high cut-off with 220 (62.7%) interval CRCs in a late stage (stage III and 
IV, p 0.84) 269 (52.5%) of the interval CRC were located right-sided, 106 (20.5%) left-sided 
and 141 (27.3%) at the rectum. At the low cut-off a larger proportion of the interval CRCs 






















































































































































































































































































































In the first screening round of a national FIT-based CRC screening programme, a low 
incidence of interval CRC in the two years after a negative FIT was observed, irrespective 
of cut-off. This supports the high FIT sensitivity for CRC. However, the cumulative incidence 
of interval CRC was higher and sensitivity was lower for individuals tested with the higher 
cut-off. Older age was associated with a higher interval CRC incidence and FIT sensitivity was 
lower for women than for men.
We observed a low cumulative incidence of interval CRCs because of a high FIT sensitivity 
for CRC. Our estimated risk of CRC diagnosis after a negative FIT is approximately 5-fold lower 
compared to the risk in a similar population before the introduction of CRC screening.10 The 
sensitivity in the first screening round for both cut-offs (90.5% and 82.9%) was higher than 
anticipated (77%), based on the Dutch pilot studies preceding the national programme.6 
There are three potential explanations for this. First, the stability of the buffer of the FIT has 
been improved. Consequently, higher FIT cut-offs result in similar sensitivity for CRC as lower 
FIT cut-offs in the past. Second, the median interval between screening rounds was longer 
in the pilot study (2.4 years) compared to our study (2.0 years).6 A longer interval could 
Table 2: Screen-detected and interval cancers, cumulative incidence and sensitivity using two cut-offs (15 and 
47 µg Hb/g faeces)
Cut-off







Total n n n
Per 10,000 
individuals
(95% CI) % (95% CI)
All 484,974 3,200 544 11.2 (10.3-12.2) 85.5 (84.3-86.6)
Men 231,138 1,964 282 12.2 (10.9-13.7) 87.4 (86.0-88.7)
Women 253,836 1,246 262 10.3 (9.2-11.6) 82.6 (80.6-84.5)
All 15 µg 111,800 1,102 126 11.3 (9.5-13.4) 89.7 (87.9-91.3)
Age adjusted 9.5 90.5
Men 52,025 656 73 14.0 (11.1-17.7) 90.0 (87.6-92.0)
Women 59,775 446 53 8.9 (6.8-11.6) 89.4 (86.4-91.8)
All 47 µg 373,174 2,108 418 11.2 (10.2-12.3) 83.5 (82.0-84.9)
Age adjusted 13.8 82.9
Men 179,113 1,308 209 11.7 (10.2-13.4) 86.2 (84.4-87.9)
Women 194,061 800 209 10.8 (9.4-12.3) 79.3 (76.7-81.7)
Abbreviations: CRC (colorectal cancer), FIT (faecal immunochemical testing)
*Cumulative incidence is the number of interval CRCs after a negative FIT per 10,000 individuals with a 
negative FIT.
†Sensitivity is the number of screen-detected CRCs after a positive FIT divided by the total number of CRCs 
(screen-detected CRCs and interval CRCs).
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result in more interval CRCs and therefore may have decreased the sensitivity. However, 
the third and most important explanation is that we estimated the sensitivity in the first 
screening round of the national programme, which is a prevalent screening round, while the 
sensitivity of the pilot study was derived from the total of three screening rounds. In the first 
screening round relatively more screen-detected CRCs will be detected than in subsequent 
screening rounds, but the interval CRCs will remain stable, therefore the sensitivity is likely 
to decrease in subsequent screening rounds. We approximated the FIT sensitivity using 
screen-detected and interval CRCs, because the real number of CRCs in the population at 
the moment of screening is unknown. This approximation has three biases. First, sensitivity 
may be overestimated, because not all missed CRCs will have developed into interval CRCs 
within two years. This hypothesis is in line with a recent systematic review with all individuals 
having a colonoscopy follow-up after one-time only FIT, showing a FIT sensitivity for CRC of 
71%.4 Second, some interval CRCs included in the definition of the sensitivity may not have 
been a missed screen-detected CRC, but still an AA at previous screening. This might lead to 
an underestimation of the sensitivity. Third, deaths before the end of the interval may have 
resulted in an overestimation of the sensitivity.
Our estimated FIT sensitivities are at the higher end of those observed in literature.11-14 
However, the Kaiser Permanente group also reported a sensitivity of 85% in the first 
screening round and then showed a decrease in sensitivity of 6-8% in subsequent screening 
rounds. Consequently, the sensitivity over four screening rounds was approximately 80%.11 It 
is therefore expected that our sensitivity will also decrease in subsequent screening rounds, 
and will not be that different from the 77% reported in the Dutch pilot studies.6
We observed differences between the age-adjusted cumulative incidence and sensitivity 
between the low and higher FIT cut-off. Despite this difference, the cumulative incidence 
with the higher cut-off was still low with 13.8 per 10,000 individuals and more than 4 out 
of 5 CRCs will be detected in the first screening round. Also, with our prior assumption that 
12% of the CRC would be missed, we would expect a decrease in sensitivity around 10%. 
However, the decrease of 7.6% in this study was smaller.8 The exploratory analysis across 
the full range of relevant cut-offs showed an increase in interval CRC rate at high FIT cut-offs, 
which is in line with our main finding. With high FIT cut-offs (>= 160 µg Hb/g faeces) half of 
the CRCs will probably be missed
The sensitivity for CRC with the higher cut-off was in line with findings of the aforementioned 
Dutch pilot studies using a cut-off of 10 µg Hb/g faeces and the Kaiser Permanente group 
using a cut-off of 20 µg Hb/g faeces.6,11 Again this confirms that the performance of FIT with 
the old buffer using a low cut-off is comparable to the FIT with the new buffer using a higher 
cut-off. In a recent systematic review, no difference in sensitivity was observed between 
different cut-offs, but most included studies used a relatively low cut-off (10-20 µg Hb/g 
faeces). Nevertheless, the high sensitivity for CRC with a higher cut-off in the current study is 
promising for many organised programmes using high FIT cut-offs.15 The results of this study 
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were based on FOB-Gold screening, but we do expect that they will be generalizable to other 
FIT brands as a recent study showed comparable performance of FOB-Gold and OC-Sensor.16 
Noteworthy is the difference between the results of the higher cut-offs with FIT in this study 
compared to sensitivity of guaiac Faecal Occult Blood Testing (gFOBT) of 67.1%.17
Our results confirm the higher FIT sensitivity for men than for women.6,13,14,18 This might 
raise the question whether different screening strategies for men and women should be 
applied. However, a decision analysis has shown that risk stratification by gender is currently 
not effective.19 We were unable to demonstrate that FIT sensitivity differed by age. This 
is contrary to other findings suggesting a different sensitivity by age, although the studies 
presented conflicting results. The increased cumulative incidence for an interval CRC by age 
can be explained by the higher risk of having a CRC or AA at older age.13,14,20,21 The stage 
distribution and location of the interval CRCs were similar for both cut-offs. Interestingly, 
the stage distribution of interval CRCs is comparable to the stage distribution of clinically 
detected CRCs, indicating that there probably is no false reassurance after receiving a 
negative FIT. In contrast, location of the interval CRC is substantially different from that 
of CRCs detected after symptoms, with many more right-sided interval CRCs, suggesting a 
lower FIT sensitivity for right-sided CRCs.22
The major strength of this study is the opportunity of comparing two FIT cut-offs, applied 
in the same population within an organised CRC screening programme. We obtained 
valuable information on the impact of using a higher cut-off. Another strength is the large 
sample size, using data of a national screening programme. A limitation of the study is that 
we could not estimate sensitivity for AA. AAs are mostly asymptomatic and therefore not 
picked up between screenings, and even then not registered at the cancer registry. A recent 
systematic review showed lower FIT sensitivity for AA than for CRC for one-time testing 
only.4,5 However, we expect that missed AA will be detected with repeated FIT in subsequent 
screening rounds, as AA or an early CRC. Another limitation is that the current conclusions 
can only be based on the results of selected age groups, due to a phased implementation by 
birth cohort. Now the full screening programme is implemented, we will assess interval CRCs 
of all age groups and interval CRCs of subsequent screening rounds.
In conclusion, the incidence of interval CRC after a negative FIT is low. Although FIT 




 1. Schreuders EH, Ruco A, Rabeneck L, et 
al. Colorectal cancer screening: a global 
overview of existing programmes. Gut 
2015;64:1637-49.
 2. Lee JK, Liles EG, Bent S, et al. Accuracy of 
faecal immunochemical tests for colorectal 
cancer: systematic review and meta-analysis. 
Ann Intern Med 2014;160:171.
 3. Quintero E, Castells A, Bujanda L, et al. 
Colonoscopy versus faecal immunochemical 
testing in colorectal-cancer screening. N Engl 
J Med 2012;366:697-706.
 4. Imperiale TF, Gruber RN, Stump TE, et 
al. Performance Characteristics of Faecal 
Immunochemical Tests for Colorectal Cancer 
and Advanced Adenomatous Polyps: A 
Systematic Review and Meta-analysis. Ann 
Intern Med 2019.
 5. Knudsen AB, Zauber AG, Rutter CM, et al. 
Estimation of Benefits, Burden, and Harms 
of Colorectal Cancer Screening Strategies: 
Modeling Study for the US Preventive 
Services Task Force. JAMA 2016;315:2595-
609.
 6. van der Vlugt M, Grobbee EJ, Bossuyt PMM, 
et al. Interval Colorectal Cancer Incidence 
Among Subjects Undergoing Multiple 
Rounds of Faecal Immunochemical Testing. 
Gastroenterology 2017;153:439-447 e2.
 7. Toes-Zoutendijk E, van Leerdam ME, Dekker 
E, et al. Real-Time Monitoring of Results 
During First Year of Dutch Colorectal Cancer 
Screening Program and Optimization by 
Altering Faecal Immunochemical Test Cut-Off 
Levels. Gastroenterology 2017;152:767-775 
e2.
 8. Aanpassing uitvoering bevolkingsonderzoek 






 9. Sanduleanu S, le Clercq CM, Dekker E, et al. 
Definition and taxonomy of interval colorectal 
cancers: a proposal for standardising 
nomenclature. Gut 2015;64:1257-67.
 10. Selby K, Jensen CD, Lee JK, et al. Influence of 
Varying Quantitative Faecal Immunochemical 
Test Positivity Thresholds on Colorectal 
Cancer Detection: A Community-Based 
Cohort Study. Ann Intern Med 2018;169:439-
447.
 11. Jensen CD, Corley DA, Quinn VP, et al. Faecal 
Immunochemical Test Program Performance 
Over 4 Rounds of Annual Screening: A 
Retrospective Cohort Study. Ann Intern Med 
2016;164:456-63.
 12. Portillo I, Arana-Arri E, Idigoras I, et al. 
Colorectal and interval cancers of the 
Colorectal Cancer Screening Program 
in the Basque Country (Spain). World J 
Gastroenterol 2017;23:2731-2742.
 13. Shin A, Choi KS, Jun JK, et al. Validity of 
faecal occult blood test in the national 
cancer screening program, Korea. PLoS One 
2013;8:e79292.
 14. Wieten E, Schreuders EH, Grobbee EJ, et al. 
Incidence of faecal occult blood test interval 
cancers in population-based colorectal 
cancer screening: a systematic review and 
meta-analysis. Gut 2018.
 15. Digby J, Fraser CG, Carey FA, et al. Can the 
performance of a quantitative FIT-based 
colorectal cancer screening programme be 
enhanced by lowering the threshold and 
increasing the interval? Gut 2018;67:993-
994.
 16. de Klerk CM, Wieten E, Lansdorp-Vogelaar 
I, et al. Performance of two faecal 
immunochemical tests for the detection of 
advanced neoplasia at different positivity 
thresholds: a cross-sectional study of the 
Dutch national colorectal cancer screening 




 17. Steele RJ, McClements PL, Libby G, et 
al. Results from the first three rounds 
of the Scottish demonstration pilot of 
FOBT screening for colorectal cancer. Gut 
2009;58:530-5.
 18. Giorgi Rossi P, Carretta E, Mangone L, et 
al. Incidence of interval cancers in faecal 
immunochemical test colorectal screening 
programmes in Italy. J Med Screen 
2018;25:32-39.
 19. Meulen MPV, Kapidzic A, Leerdam MEV, et 
al. Do Men and Women Need to Be Screened 
Differently with Faecal Immunochemical 
Testing? A Cost-Effectiveness Analysis. 
Cancer Epidemiol Biomarkers Prev 
2017;26:1328-1336.
 20. Brenner H, Hoffmeister M, Stegmaier C, et al. 
Risk of progression of advanced adenomas to 
colorectal cancer by age and sex: estimates 
based on 840,149 screening colonoscopies. 
Gut 2007;56:1585-9.
 21. Wieten E, Schreuders EH, Nieuwenburg SA, 
et al. Effects of Increasing Screening Age and 
Faecal Hemoglobin Cutoff Concentrations in 
a Colorectal Cancer Screening Program. Clin 
Gastroenterol Hepatol 2016;14:1771-1777.
 22. Toes-Zoutendijk E, Kooyker AI, Elferink MA, 
et al. Stage distribution of screen-detected 





SOCIOECONOMIC DIFFERENCES IN PARTICIPATION AND 
DIAGNOSTIC YIELD WITHIN THE DUTCH NATIONAL 
COLORECTAL CANCER SCREENING PROGRAMME WITH 
FAECAL IMMUNOCHEMICAL TESTING
Miriam P. van der Meulen, Esther Toes-Zoutendijk, Manon C.W. Spaander, Evelien 
Dekker, Johannes M.G. Bonfrer, Anneke J. van Vuuren, Ernst J. Kuipers, Folkert J. 
van Kemenade, Marie-Louise F. van Velthuysen, Maarten G.J. Thomeer, Harriët van 
Veldhuizen, Harry J. de Koning, Iris Lansdorp-Vogelaar, Monique E. van Leerdam, on 






CRC mortality rates are higher for individuals with a lower socioeconomic status (SES). 
Screening could influence health inequalities. We therefore aimed to investigate SES 
differences in participation and diagnostic yield of FIT screening.
Methods
All invitees in 2014 and 2015 in the Dutch national CRC screening programme were included 
in the analyses. We used area SES as a measure for SES and divided invitees into quintiles, 
with Quintile 1 being the least deprived. Logistic regression analysis was used to compare 
the participation rate, positivity rate, colonoscopy uptake, positive predictive value (PPV) 
and detection rate across the SES groups.
Results
Participation to FIT screening was significantly lower for Quintile 5 (67.0%) compared to 
the other Quintiles (73.0% to 75.1%; adjusted OR quintile 5 versus quintile 1: 0.73, 95%CI: 
0.72-0.74), as well as colonoscopy uptake after a positive FIT (adjusted OR 0.73, 95%CI: 
0.69-0.77). The detection rate per FIT participant for advanced neoplasia gradually increased 
from 3.3% in Quintile 1 to 4.0% in Quintile 5 (adjusted OR 1.20, 95CI: 1.16-1.24)). As a result 
of lower participation, the yield per invitee was similar for Quintile 5 (2.04%) and Quintile 1 
(2.00%), both being lower than Quintiles 2 to 4 (2.20%-2.28%).
Conclusions
Screening has the potential to reduce health inequalities in CRC mortality, because of a higher 
detection in more deprived participants. However, in the Dutch screening programme, this is 




Colorectal cancer (CRC) is the second most common cause of cancer-related mortality in 
the Western world.1 Screening can prevent part of these deaths by early detection and 
treatment of CRC and its precursor lesions. Therefore, various countries and local initiatives 
across the world have adopted population-based screening for CRC aiming for equal access 
to CRC screening for the entire population.2,3 In Europe, CRC mortality rates are consistently 
shown to be higher among individuals with a lower socioeconomic status (SES).4 Since 
screening can reduce CRC mortality and CRC incidence depending on screening methods 
and screening uptake, it has the potential to decrease these health inequalities.
However, if the participation to and performance of the screening programme differ across 
SES groups, screening may fail to reduce or even augment health inequalities. Indeed, several 
studies demonstrated that lower SES groups had lower participation rates in CRC screening 
with colonoscopy, guiac faecal occult blood test (gFOBT) and faecal immunochemical test 
(FIT).5-11 However, less is known about the participation to subsequent colonoscopy and the 
performance of a screening programme across SES groups in terms of positivity rate and 
diagnostic yield. A large study using gFOBT showed that the most deprived individuals had a 
higher positivity rate and no difference in positive predictive value (PPV).7 As far as we know, 
only one small study from the Basque country using FIT showed a similar PPV among SES 
groups and a higher detection rate in deprived men (but not in women).12 Because many 
organised screening programmes across the world have chosen to use FIT, it is important to 
get more insight into the potential impact of a FIT screening programme on inequalities in 
health.3
Data from the Dutch national CRC screening programme with FIT enabled us to investigate 
SES differences in participation and diagnostic yield with FIT screening.
METHODS
Dutch CRC screening programme
The Dutch national CRC screening programme using biennial FIT was introduced in 2014 with 
a gradual roll-out by age within a period of five years. The target population will eventually 
consist of individuals aged 55 to 75 years. The target population receives a pre-invitation 
letter by post, followed by an invitation letter by post together with a single FIT sampling 
device (FOB-Gold, Sentinel, Italy). As a result of the gradual roll-out, in 2014 only individuals 
aged 63, 65, 67, 75 and 76 years and in 2015 only individuals aged 61, 63, 65, 67, 69 and 75 
years were invited. The first half year of 2014, the cut-off level for referral to colonoscopy was 
15 µg Hb/g faeces, thereafter, the cut-off level was increased to 47 µg Hb/g faeces because of 
higher than expected participation rate, positivity rate, and a lower than expected PPV.13 We 
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present the data at a cut-off level of 47 µg Hb/g faeces, also for the individuals screened with 
the lower cut-off level. All data of the screening programme are continuously collected in a 
national information system of the CRC screening programme (ScreenIT). ScreenIT includes 
personal details (like gender, date of birth, place of residence, postal code), FIT results, 
medical details from the pre-colonoscopy intake and colonoscopy results from endoscopy 
centres and pathology diagnoses from the national pathology registry PALGA. The Dutch 
screening programme is described in more detail in a previous publication.13
Measuring socioeconomic status
Area SES, based on the postal code, was used as a measure for SES. The Dutch postal code 
consists of four-digits and two letters, of which the four-digit postal code of the invitees’ place 
of residence was used. Scores per four-digit postal code were provided by The Netherlands 
Institute for Social Research.14 The provided SES scores per postal code are calculated with a 
principal components analysis based on income, employment status and educational level.14 
Socioeconomic data of 2014 were used. The scores based on postal codes were divided into 
quintiles based on the rank of the scores, corrected for the number of individuals (of all ages) 
living in the postal code areas. The population in the quintiles was calculated with data on 
the number of inhabitants per age-group in each postal code in 2014.15 Quintile 1 was the 
least deprived quintile, with the highest scores (high income, high employment rate, high 
educational level), while Quintile 5 was the most deprived, with the lowest scores.
Background incidence
Background incidence of CRC across SES groups prior to the introduction of screening was 
determined as comparator for the yield in FIT participants. All CRC diagnoses from 2008 till 
2012 were obtained from the Dutch Cancer Registry (NKR), with the year of diagnosis, the 
age of the patient at diagnosis and the SES. The SES was determined as described earlier but 
based on SES scores and population numbers in 2010.
Analysis
National screening programme
Data on the invitees of 2014 and 2015 were collected until 31 March 2016. Outcomes were 
1) participation rate of FIT screening, 2) positivity rate of FIT, 3) colonoscopy uptake after 
a positive FIT, 4) positive predictive value (PPV) for advanced neoplasia (AN, advanced 
adenomas and CRC combined) and CRC alone, 5) detection rates per participant and 6) yield 
per invitee of AN and of CRC.
The FIT participation rate was defined as the number of persons returning a stool sample 
divided by the number of persons invited. Positivity rate was defined as the number 
of participants with a test result at or above the cut-off level divided by the number of 
89
SOCIOECONOMIC DIFFERENCES
participants with an assessable stool sample. Cut-off level for a positive test result was 47 
ug Hb/g faeces. Positive tests with a result between 15 and 47 ug Hb/g faeces of individuals 
screened with the lower cut-off level of 15 ug Hb/g faeces were considered as a negative test 
result and all data collected after the positive test, such as colonoscopy uptake and detected 
lesions, were not included. The colonoscopy uptake was defined as the number of persons 
who underwent a colonoscopy divided by the number of persons with a positive FIT. The PPV 
of AN and CRC was calculated as the number of persons with AN or CRC respectively, divided 
by the number of persons who underwent a colonoscopy. An advanced adenoma was 
defined as any adenoma with 1) histology showing ≥25% villous component or 2) high-grade 
dysplasia or 3) size ≥10 mm. The DR was defined as the number of persons with AN and CRC 
detected during colonoscopy divided by the number of screened persons with an assessable 
stool sample (assuming full compliance to colonoscopy). Similarly, the yield per invitee 
was calculated as the number of persons with AN and CRC detected during colonoscopy 
divided by the number of invitees. Proportions were determined by descriptive analyses. 
Logistic regression analysis was performed to estimate odds ratio (OR) of the quintiles on FIT 
participation rate, positivity rate, colonoscopy uptake, PPV for AN and for CRC and detection 
rate per invitee for AN and for CRC, adjusted for age and gender. To determine the DR per 
FIT participant, we performed poststratification (including gender and age) to adjust for the 
differences in colonoscopy uptake across SES quintiles and assumed full compliance.
Background incidence
Age-standardised incidence rates were calculated by direct standardisation to the European 
Standard Population (Eurostat 2013).16 All rates are presented as European age-standardised 
rates (ESR per 100,000), with 95% confidence intervals (CI). The incidence rate ratio (IRR) was 
calculated by dividing the ESR of each SES quintile with the corresponding ESR of Quintile 1 
(the least deprived quintile), 95% CI were determined.
Sensitivity analysis
In the sensitivity analyses we replicated all analyses with SES divided in deciles instead of 
quintiles.




Descriptive national screening programme
In 2014 and 2015, 1,882,916 individuals were invited for first round FIT screening, of whom 
1,866,060 (99.1%) had an area-based SES score. Quintile 3 contained the largest proportion 
of invitees (Table 1). Of the invitees with SES score, 49.3% were male, ranging from 48.1% in 
Quintile 5 to 49.8% in Quintile 2. The invitees of Quintile 5 had a median age of 66.8 years 
compared with 65.9 years in the total population.
Table 1: Descriptive of the number, age and gender distribution of the invitees in each quintile. Quintile 1 least 
deprived, Quintile 5 most deprived.
Quintile
Overall Gender male Age
n % n % Median
1 334,233 17.9 166,013 49.7 65.7
2 381,344 20.4 189,929 49.8 65.8
3 403,907 21.6 199,777 49.5 66.0
4 388,664 20.8 191,341 49.2 66.4
5 357,912 19.2 172,222 48.1 66.8
Total 1,866,060 100.0 919,282 49.3 p <0.001 65.9 p <0.001
Participation and positivity rate
With Quintile 1 as reference, participation to FIT screening was higher in Quintile 2 and 
3 (Quintile 1 73.9%, Quintile 2 and 3: 75.1% (Table 2 and Figure 1), but lower in Quintile 
4 and Quintile 5, with the lowest participation rate in Quintile 5 (67.0%). Multivariable 
analysis showed an OR of 0.73 (95% CI: 0.72-0.74) for Quintile 5 compared with Quintile 1. 
The positivity rate was lowest in Quintile 1 (5.8%) and gradually increased with increasing 
Quintile. The positivity rate of Quintile 5 (7.2%) had an OR of 1.22 (95%CI: 1.20-1.25) 
compared to Quintile 1. Colonoscopy uptake after a positive FIT showed a similar pattern 
as the participation to FIT screening, with the highest uptake in Quintile 2 (82.4%) and 
significantly lower uptake in Quintile 4 and 5 (80.0% and 75.8% respectively) compared to 
Quintile 1 (81.3%) (Quintile 5 versus Quintile 1 OR:0.73, 95%CI: 0.69-0.77).
Diagnostic yield
The PPV for AN was highest in Quintile 3 (58.4%) and lowest in Quintile 5 (56.1%). Multivariable 
analysis showed an OR of 1.06 (95%CI: 1.01-1.12) for Quintile 3 compared with Quintile 1 and 
an OR of 0.98 (95%CI: 0.93-1.03) for Quintile 5 compared with Quintile 1. The PPV for CRC was 
also highest in Quintile 3 (9.6%, compared to Quintile 1 adjusted OR: 1.03, 95%CI: 0.95-1.11) 
and lowest in Quintile 4 (8.5%, compared to Quintile 1 adjusted OR: 0.90, 95%CI: 0.82-0.97; 









































































































































































































































Table 2: The participation to FIT, positivity rate and colonoscopy uptake after a positive FIT in each quintile, 
with the univariate and multivariable odds ratio (OR) and 95% CI.
Quintile n Attendance to FIT OR* 95% CI  
1 246,858 73.9% 1  p <0.001
2 286,527 75.1% 1.07 1.06 - 1.08  
3 303,133 75.1% 1.07 1.06 - 1.08  
4 283,640 73.0% 0.96 0.95 - 0.97  
5 239,945 67.0% 0.73 0.72 - 0.74
Quintile n Positivity rate OR * 95% CI  
1 14,466 5.8% 1  p <0.001
2 17,726 6.2% 1.05 1.03 - 1.08  
3 19,235 6.3% 1.08 1.06 - 1.10  
4 19,037 6.7% 1.15 1.12 - 1.17  
5 17,145 7.1% 1.22 1.20 - 1.25
Quintile n Attendance colonoscopy OR* 95% CI  
1 11,768 81.3% 1  p <0.001
2 14,612 82.4% 1.08 1.02 - 1.14  
3 15,732 81.8% 1.04 0.98 - 1.10  
4 15,234 80.0% 0.93 0.88 - 0.98  
5 12,992 75.8% 0.73 0.69 - 0.77  
* The multivariable OR is corrected for age and gender.
Table 3: The positive predictive value (PPV) of FIT for advanced neoplasia (AN) and colorectal cancer (CRC) in 
each SES quintile, with the univariate and multivariable odds ratio (OR) and 95% CI.
Quintile n PPV AN* OR** 95% CI
1 6,689 56.8% 1   p <0.001
2 8,388 57.4% 1.02 0.97 - 1.07  
3 9,191 58.4% 1.06 1.01 - 1.12  
4 8,872 58.2% 1.06 1.01 - 1.11  
5 7,295 56.1% 0.98 0.93 - 1.03
Quintile n PPV CRC* OR** 95% CI  
1 1,103 9.4% 1  p <0.01
2 1,376 9.4% 1.00 0.92 - 1.09  
3 1,516 9.6% 1.03 0.95 - 1.11  
4 1,301 8.5% 0.90 0.82 - 0.97  
5 1,165 9.0% 0.94 0.86 - 1.02
*An advanced adenoma was defined as any adenoma with histology showing ≥25% villous component or 
high-grade dysplasia or with size ≥10 mm. The PPV was calculated as the number of persons with an advanced 
adenoma or with a CRC (together called advanced neoplasia (AN) divided by the number of persons who 
underwent a colonoscopy after a positive FIT.
**The multivariable OR is corrected for age and gender.
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gradually increased with higher quintile (Quintile 5: 4.01% corrected; OR: 1.20, 95%CI: 1.16-
1.24; Table 4 and Figure 1). The DR for CRC in FIT participants varied between the quintiles 
and was significantly higher in Quintile 5 with 0.52% (OR: 1.17, 95%CI: 1.08-1.27) compared 
to Quintile 1. The yield of AN and of CRC in invitees was similar for Quintile 1 and 5, but both 
Quintiles had significantly lower yield than Quintiles 2 to 4 (Table 4 and Figure 1).
Table 4: The detection rate (DR) per 100 participants uncorrected and corrected for colonoscopy uptake and 
the yield per 100 invitees of advanced neoplasia (AN) and colorectal cancer (CRC) for each quintile, with the 
univariate and multivariable odds ratio (OR) and 95% CI.
 
Quintile 
 PER PARTICIPANT  PER INVITEE  




OR*** 95% CI  DR AN OR*** 95% CI  
1 6,689 2.71% 3.33% 1  p<0.01 2.00% 1  p 0.44
2 8,388 2.93% 3.55% 1.07 1.04 - 1.10  2.20% 1.10 1.06 - 1.13  
3 9,191 3.03% 3.70% 1.12 1.09 - 1.15  2.28% 1.13 1.10 - 1.17  
4 8,872 3.13% 3.91% 1.18 1.15 - 1.21  2.28% 1.15 1.11 - 1.19  
5 7,295 3.04% 4.01% 1.21 1.18 - 1.24 2.04% 1.02 0.99 - 1.06
Quintile n DR CRC* DR CRC** OR*** 95% CI  DR CRC OR*** 95% CI  
1 1,103 0.45% 0.55% 1 <0.01 0.33%  p 0.07
2 1,376 0.48% 0.58% 1.06 0.98 - 1.15  0.36% 1.09 1.00 - 1.18  
3 1,516 0.50% 0.61% 1.11 1.03 - 1.20  0.38% 1.13 1.04 - 1.22  
4 1,301 0.46% 0.57% 1.04 0.96 - 1.13  0.33% 1.00 0.92 - 1.08  
5 1,165 0.49% 0.64% 1.17 1.08 - 1.27 0.33% 0.97 0.89 - 1.05
*An advanced adenoma was defined as any adenoma with histology showing ≥25% villous component or high-
grade dysplasia or with size ≥10 mm. The detection rate was defined as the number of persons with advanced 
adenomas or with CRC (together called advanced neoplasia (AN)) detected during colonoscopy divided by the 
number of screened persons with an assessable stool sample.
**The detection rate was corrected for the differences in colonoscopy uptake compared to Quintile 1.
***The multivariable OR is corrected for age and gender and in the analysis per participant we corrected the 
DR for non-compliance to colonoscopy using post stratification (assuming full compliance).
Table 5: The number of colorectal cancer cases recorded between 2008 and 2012 and the European age-
standardised ratio across the Quintiles of socioeconomic status, and the incidence rate ratio (IRR) of the 
Quintile compared to the most affluent Quintile (Quintile 1)
Quintile Incident cases ESR 95% CI IRR
1 11,123 456 448 - 465
2 12,827 467 459 - 475 1.02
3 13,804 466 458 - 474 1.02
4 14,197 471 463 - 478 1.03




In total, 65,130 incident cases of CRC were recorded from 2008 to 2012. The European 
age-standardised rate was very similar across SES quintiles, varying from 456 per 100,000 
in Quintile 1 to 462 per 100,000 in Quintile 5 and was highest in Quintile 4 with 471 per 
100,000 (IRR of 1.03; Table 5).
Sensitivity analyses
Using deciles of SES rather than quintiles led to similar patterns in participation, detection and 
yield, albeit the difference between SES groups was more pronounced. For instance, participation 
to FIT screening was lowest in Decile 10 with 64.3% compared to 72.6% in Decile 1 (adjusted OR: 
0.69, 95%CI: 0.68-0.70). The detection rate per FIT participant for advanced neoplasia gradually 
increased from 3.2% in Decile 1 to 4.1% in Decile 10 (adjusted OR: 1.28, 95%CI: 1.24-1.33).
DISCUSSION
Our study showed a significantly lower participation to FIT screening and subsequent 
colonoscopy in case of a positive FIT for individuals in the lowest SES group. The participation 
was stable for high and moderate SES but decreased for individuals with a low SES. The 
positivity rate and detection rate of AN gradually and significantly increased with decreasing 
SES, while the PPV of AN and CRC was quite stable across SES groups.
Even though the participation was lower in Quintile 5, the participation rate of 67.0% 
in this Quintile was still higher than the desired 65.0% participation rate recommended 
by the European Union (EU) guidelines for quality assurance.17 In contrast, the uptake of 
colonoscopy after a positive FIT was lower than the accepted 85% by the EU guidelines for 
quality assurance for all quintiles (range 82.4%-75.8%), and was lowest for individuals with 
a low SES. It is known that the uptake of colonoscopy in case of a positive FIT is higher than 
registered in the national screening database because some participants opt to have their 
colonoscopies at centres outside the screening programme. However, we do not expect that 
individuals with lower SES are more likely to perform the colonoscopy outside the screening 
programme than those with higher SES and thus do not expect that the observed SES 
gradient is the result of underreporting.
The SES difference in uptake of colonoscopy can in theory result from a higher prevalence 
of comorbidity among individuals with lower SES, resulting in exclusion for colonoscopy 
before or at intake. However, we did not find a difference in ORs for colonoscopy uptake if we 
corrected for the individuals that were excluded for colonoscopy at intake (data not shown). 
Another explanation for the association between SES and uptake of colonoscopy is the fact 
that colonoscopy after a positive FIT is considered standard medical care and is therefore 
covered by insurance companies. All citizens have an obligatory co-payment for delivered 
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care during a calendar year ranging between €350 and €850. Therefore, individuals might 
omit to undergo the procedure or postpone the procedure if this co-payment maximum 
has not been reached in a given year. This may influence individuals to delay or even forego 
colonoscopy in order to avoid co-payments, particularly in lower SES.
The positivity rate gradually increased with decreasing SES. Because the PPV of FIT was 
stable across the SES range, the increase in positivity rate can only be caused by an increase 
in both true positive (the detection rate) and false positive FIT results. More false positive 
tests in low SES groups compared to high SES imply that FIT specificity is lower in low SES 
groups. A possible explanation for the lower specificity could be more comorbidity or 
anticoagulant use.18-20
The increased detection rate in participants with lower SES can either be caused by a 
higher FIT sensitivity in lower SES for the same reasons as described for specificity or a higher 
CRC incidence in lower SES. We did not find a difference in CRC incidence by SES quintile for 
the time period of 2008-2012 (i.e. before the start of the implementation of the national 
screening program). However, this does not preclude a difference in CRC incidence in those 
that participate to FIT across SES quintiles. If in lower SES groups individuals with symptoms 
are more prone to attend screening than individuals without symptoms (“unhealthy 
screenee bias”), or individuals with an immigrant background are less prone to participate 
than native Dutch individuals who have a higher CRC incidence, background incidence in 
the lower SES participants (in contrast with invitees) could be higher than in those with 
higher SES. Since a previous study observed similar stage distribution of screen-detected 
CRC across SES quintiles, the first explanation seems unlikely.21 However, differences in 
participation between native Dutch and ethnic minorities on the other hand have been 
previously reported.22
Strength of our study is the large sample size and high data completion rate due to the 
fact that data from different sources were automatically collected in the national screening 
database ScreenIT, like data on diagnostic yield of the screening programme. Our study also 
has a limitation; we did not have the personal SES, but based our analysis on the four-digit 
postal code. These aggregated data on SES may provide an inaccurate representation of 
the true individual SES. The use of area SES may diffuse results, therefore the observed 
differences could be more pronounced if linked to personal SES. In theory, there could be a 
mix of socioeconomic classes in the middle quintiles, but less in quintile 5. In that case the 
drop in participation might be due to the lack of diffusion in the lowest SES areas.
In other countries with an organised FOBT-based screening programme the smallest 
socioeconomic difference in participation was 6% (66% for most deprived and 72% for least 
deprived), while the largest difference was 24% (42% versus 66%).5 With 67.0% for Quintile 5 
versus 75.1% for the middle Quintiles, the difference in participation between SES groups in 
the Netherlands is at the lower end of this range. The difference between SES groups is also 
comparable to the differences in the breast cancer screening programme in the Netherlands 
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(participation rate of 79% for the most deprived up to 87% in the least deprived).23 The 
SES differences in yield could also be compared to two other studies. One of those studies 
used gFOBT instead of FIT and showed a higher positivity rate in higher SES (least deprived), 
opposite to our findings and a lower PPV for higher SES while we found a stable PPV.7 A 
smaller study from the Basque country using FIT was more similar to our results, it showed 
a similar PPV among SES groups and a higher detection rate in deprived men (but not in 
women) with an OR of 1.38 (95%CI: 1.23-1.55).12
Screening is often argued to increase already existing health inequalities. Based on our 
data, this is not observed in the Netherlands. Because of the higher yield in lower SES, it 
even has the potential to decrease health inequalities, however, this is currently offset by 
the lower participation in lower SES. It is therefore important to know the reasons behind 
the lower uptake in lower socioeconomic classes. In theory, patient preferences might be 
different and therefore lead to more individuals not undergoing screening due to a well-
informed choice. However, it is more plausible that the lower participation in lower SES 
is not based on well-informed decision-making, since we previously found that across all 
quintiles only 12% of non-participants made an informed choice not to participate.24
It is difficult to find interventions that decrease the socioeconomic gap in CRC screening. 
Several interventions have been found to increase overall uptake, such as the involvement 
of the family doctor. However, most did not reduce the socioeconomic gap or their influence 
on the socioeconomic gap was not assessed. To date, only two interventions have been 
demonstrated to reduce the gap, namely targeting specific groups and sending an enhanced 
reminder letter with a banner that reiterates the screening offer.25,26 Especially involvement 
of the family doctor after a positive screening test would be a plausible candidate for 
decreasing the SES gap in follow-up colonoscopy uptake. However, to recommend this and 
other specific interventions, further research is needed, also on the underlying reason for 
non-participation across the socioeconomic groups and to regional and ethnical differences 
in participation. This research could further clarify how to target groups that are less 
compliant and/or more at risk for AN and ensure well-informed decision-making.
In conclusion, screening has the potential to reduce existing socioeconomic inequalities in 
CRC mortality, because of a higher yield in more deprived participants. However, this higher 
yield is currently offset by the lower participation in this group. Further research is needed 
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Quality assessment is crucial for consistent programme performance of colorectal cancer 
(CRC) screening programmes using faecal immunochemical test for haemoglobin (FIT). 
However, literature on the consistency of FIT performance in laboratory medicine was 
lacking. This study examined the consistency of FIT in testing positive or detecting advanced 
neoplasia (AN) for different specimen collection devices, lot reagents and laboratories.
Methods
All participants with a FIT sample with a cut-off of 47 µg Hb/g faeces in the Dutch CRC 
screening programme in 2014 and 2015 were included in the analyses. Multivariable logistic 
regression analyses were performed to estimate the odds ratios of collection devices, 
reagents and laboratories, on testing positive or detecting AN and positive predictive value 
(PPV).
Results
87,519 (6.4%) of the 1,371,169 participants tested positive. Positivity rates and detection 
rates of AN differed between collection devices and reagents (all p <0.01). In contrast, PPV 
were not found to vary between collection devices, reagents or laboratories (all p >0.05). 
Positivity rates showed a small difference for laboratories (p 0.004), but not for detection 
rates of AN. Size of the population impacted by the deviating positivity rates was small (0.1% 
of the total tested population).
Conclusions
Variations were observed in positivity and detection rates between collection devices and 
reagents, but there was no detected variation in PPV. While the overall population-impact 
of these variations on the screened population is expected to be modest, there is room for 
improvement.
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INTRODUCTION
In recent years many countries have introduced organised screening programmes for 
colorectal cancer (CRC) using the faecal immunochemical test for haemoglobin (FIT).1 Such 
programmes require careful balancing of harms and benefits and adequate quality control.2 
The European Union has therefore developed quality assurance guidelines for CRC screening 
with the aim to enhance the quality and effectiveness of CRC screening.3
In the Netherlands, a national CRC FIT-based screening programme was initiated in 2014. 
Quality assessment of analytical performance of FIT in the Dutch CRC screening programme 
consists of three steps: 1) synthetic controls, 2) commutable faeces based controls, and 3) 
repeated assessment of participant samples with a wide range of FIT results. Recently Fraser 
et al. (2018) have suggested new analytical performance specifications for FIT, because 
this quality assessment in the Dutch CRC screening programme has some limitations.4 
Firstly, both internal and external quality assessment are not used for trueness verification 
purposes as promoted by the 2014 Milan consensus agreement on analytical performance 
specifications.5 Secondly, the currently used criteria for accepting reagent and calibrator lots 
are arbitrary based on expert opinion instead of acceptable impact on predictive value.6 The 
expert opinion was dictated as a minimal requirement for the reagent supplier in the tender 
procedure preceding the implementation of the screening programme and was inherited as 
an acceptance criterion for laboratory professionals in verifying lot-to-lot variability. However 
lot-to-lot variability within the acceptance criterion could still result in substantial variation 
in key screening performance indicators which could not be taken into account when setting 
the criterion. Thirdly, in its current form the analytical FIT performance specifications within 
the screening laboratories, which were defined before the start of the Dutch programme in 
2014, are not based on their impact on clinical endpoints within the Dutch population-based 
CRC screening programme.
We therefore examined consistency of FIT over time on clinical endpoints within a national 
FIT-based CRC screening programme.
METHODS
Screening programme and population
The Dutch national CRC screening programme was initiated in January 2014, with biennial 
FIT screening for men and women aged 55 to 75 years.7 The programme has been gradually 
implemented by birth cohort. Individuals receive an invitation letter and information 
leaflet with one single FIT specimen collection device (Appendix I). After faecal sampling, 
FIT samples were sent by postal mail to an assembly point and randomly assigned to one 
of three central laboratories, where all assessable FITs were analysed. In this study the 
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laboratories were de-identified by labelling them with a unique letter (LabA, LabB, LabC). 
If sample return time exceeded 6 days or the FIT specimen collection device was used after 
the expiration date, individuals with a negative test result were sent a new FIT specimen 
collection device with the request to resample. All participants with a positive test result 
were invited for a pre-colonoscopy intake interview and, if no contraindications, referred 
for colonoscopy. The national screening organisation is responsible for the logistics of the 
programme and ordering of new FIT specimen collection devices and new reagent lots for 
the three laboratories.
Faecal immunochemical test
The FOB-Gold (Sentinel Diagnostics SpA, Milan, Italy), an automated quantitative FIT, 
was used. In this reagent, polyclonal anti-human haemoglobin (Hb) antibodies coated on 
polystyrene beads, bind human haemoglobin thereby triggering an agglutination reaction 
that can be quantified by turbidity. Samples were pre-analytically processed using an Impeco 
track. Turbidity analysis was performed by a track connected JCA-BM6010 Biomajesty clinical 
chemistry analyser (Jeol). The FIT specimen collection devices contain a buffer solution 
(1.7 mL) and a green screw-cap with faecal collector. All specimen collection devices were 
labelled with a unique bar code. Different batches with FIT collection devices, all FOB-Gold 
(Sentinel Diagnostics SpA) were labelled with a three letter code; these are the first three 
letters of the unique bar code on the FIT specimen collection device (AAA, AAC, AAD, AAE). 
During the pilot phase at the end of 2013, preceding the start of the national programme, 
specimen collection device AAB was used. This data was not included in the study. The FIT 
manufacturer claims Hb stability in the FIT specimen collection device for 14 days at 2-8 °C 
or 7 days at 15-30 °C. A sample taken from the FIT specimen collection device is mixed with 
latex reagent. An immunological latex reagent is used for the determination of haemoglobin, 
added and mixed with the buffer solution in the FIT specimen collection device. Different 
reagent lots were also labelled with a unique lot number (1-6). The cut-off for a positive test 
result was initially set at 15 µg Hb/g faeces. As the programme performed differently than 
the predefined programme indicators, the cut-off was increased to 47 µg Hb/g faeces in July 
2014.7
Quality control in the Dutch programme
Pre-analytical aspects and analytical performance of the FIT analysis are described in the 
FITTER checklist (Appendix II). Daily controls in the participating laboratories, supervised by 
the Dutch Foundation for Quality Assessment in Medical Laboratories (SKML) consist of three 
groups of controls: 1) Synthetic controls provided by the IVD manufacturer, 2) Commutable 
faeces based controls with addition of known amounts of human haemoglobin provided by 
EQAS organiser SKML, 3) The percentage of patients above and below certain predefined 
values in the participating laboratories. Laboratories determine analytical performance by 
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judging their own control performance on a daily basis and by judging the comparison of 
the three laboratories on weekly basis supported by SKML. SKML also provides commutable 
faeces based external quality assessment with known amounts of haemoglobin that are 
blinded to the laboratories. These samples are provided in 6 rounds of 15 samples each with 
values across the measurement range. Laboratories measure external quality assessment 
on a weekly basis and receive reports every two months. Prior to reagent acceptance for 
measurement by the participants, all reagent and calibrator lot combinations are compared 
to the previous reagent and calibrator of the same product using internal control of Sentinel, 
that of SKML, and 40 participants’ samples. Acceptance criteria state that all results must 
be within ±7.5% of the overall-all-lot mean. This approach aims to prevent a worst-case 
difference between lot differences of larger than 15%. During the pilot phase at the end of 
2013, preceding the start of the national programme, only one reagent lot was not accepted 
because it did not meet these criteria. The results in this study were only measured with 
accepted reagent lots.
Data collection
This study included all participants invited in 2014 and 2015. For the purpose of these 
analyses, only data of participants with an assessable faecal sample were analysed. Data 
were obtained from the national CRC screening database (ScreenIT). Individuals who 
objected to exchange of data were not included in the analyses. ScreenIT includes date 
of invitation, date of faecal sampling, date of analysis, concentration µg Hb/g faeces and 
colonoscopy and pathology reports. Data were collected until April 24, 2017. Data on reagent 
and time to expiry date of collection devices were collected through the regional screening 
organisations. Data on the ambient temperature were collected from the Royal Netherlands 
Meteorological Institute (KNMI).
Measures and definitions
The outcomes of interest were FIT positivity rate, detection rate of advanced neoplasia (AN), 
and PPV. ANs are considered relevant findings within the Dutch CRC screening programme 
and consist of CRCs and advanced adenomas (AAs). An AA is defined as any adenoma with 
histology showing >=25% villous component or adenoma with high-grade dysplasia or with 
size >=10 mm. FIT positivity rate was calculated as the number of individuals with a test 
result at or above the cut-off divided by number of participants with an assessable FIT. For 
the purpose of these analyses, all FITs were only considered positive at a cut-off of 47 µg 
Hb/g faeces, regardless of the 15 or 47 µg Hb/g cut-off applied within the national screening 
programme. The same applies to colonoscopy results; these outcomes were also only 
included in the analyses if the FIT result was above a cut-off of 47 µg Hb/g faeces. Detection 
rate was considered as the number of individuals with AN detected during colonoscopy 
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divided by the number of screened individuals. PPV was defined as the number of individuals 
with AN among individuals with a positive FIT who underwent a diagnostic colonoscopy.
Outcome variables were FIT specimen collection devices, reagent lots, laboratories, sex, 
age, ambient temperature, sample return time and time to expiry date of the test. Age 
was determined at the self-sampling date. Ambient temperature was assessed at the date 
of analysis of the faeces sample minus one day, based on the assumption that the faecal 
sample was outdoors during the transportation phase. As a reference place for the average 
ambient temperature we used a geographically central location in the Netherlands (De Bilt). 
Sample return time was defined as the interval in weekdays between self-sampling date and 
analysis date. Negative values of sample return time were coded as missing, as these were 
data entry errors. As only data of samples with a sample return time ≤6 days with a positive 
test result were analysed and not those with a negative test result, for the purpose of this 
analysis individuals with values >6 days (positive and negative) were removed. The time to 
expiry date of the test was the interval between the date of analysis and the expiry date 
indicated on the FIT specimen collection device. Individuals with negative values were coded 
as missing and samples exceeding the expiry date were removed from the analysis.
Statistical analysis
Descriptive analysis were conducted to determine means and proportions of baseline 
characteristics. The Pearson chi-square test was used for the comparison of dichotomous 
or categorical variables and the t-test was used for the comparison of continuous variables. 
Multivariable logistic regression analyses were performed to estimate the odds ratios (OR) 
for FIT specimen collection device, reagent lots and laboratories, for a positive test result, 
detection of AN and PPV. Outcomes were adjusted for sex, age, ambient temperature, 
sample return time, and time to expiry date of test. Continuous variables were modelled 
with splines, using 3 knots, except for sample return time. This variable had one spike 
(majority having same value of 1 day), which was therefore added as a categorical variable. 
Overall significance was tested with ANOVA.
Two uncertainty analyses were performed. The first analysis assessed whether the results 
of the multivariable logistic regression analyses changed when adding a combined variable 
of FIT specimen collection device and reagent lots in the multivariable logistic regression 
model. The second analysis was carried out to assess whether results changed when the 
multivariable logistic regression analyses were stratified by age. Because the programme 
was gradually implemented by year of birth, age was highly correlated with collection 
devices and reagent. The age groups 63 and 67 years were chosen for evaluation of the age 
effect as these age groups comprised the largest number of individuals in each subgroup 
of categorical variables. All statistical tests were two-tailed and P <0.05 was considered 
statistically significant. Statistical analyses were performed with the R statistical package 
version 3.2.3.
107
CONSISTENCY OF FIT PERFORMANCE
RESULTS
Study population characteristics
A total of 1,372,020 first-round participants had an assessable FIT. In 851 (0.1%) individuals 
the sample return time exceeded 6 days. They were excluded from the analysis, leaving 
1,371,169 participants for analyses. Of these 663,884 (48.4%) were men. The majority of 
participants, 1,313,052 (96.3%) returned their faecal sample within two days after sampling. 
Of all participants with an assessable FIT, 87,519 (6.4%) tested positive, 71,931 (82.2%) of 
these individuals underwent colonoscopy. Results of colonoscopy and/or pathology were 
available for 71,753 (99.8%) individuals. Of those, 6,636 (9.2%) were diagnosed with CRC 
and 34,803 (48.5%) with AA, with a PPV for AN of 57.8%. All baseline characteristics of 
participants differed between FIT positives and FIT negatives, except time to expiry of the 
test (Table 1).
Multivariable logistic analyses
Multivariable logistic regression analysis showed that participants tested with FIT specimen 
collection device AAE are less likely to test positive than collection device AAA (OR:0.82, 
95%CI: 0.73-0.92; Table 2). There were also differences in the probability of testing positive 
between individuals analysed with different reagent lots (OR ranging from 1.11 to 1.31, p 
<0.001; Table 2). Individuals that had their FIT analysed in laboratory B and laboratory C 
tested positive more often (p 0.004; Table 2), however the effect size was very small (LabB 
OR:1.03, 95%CI: 1.01-1.05; LabC OR:1.02, 95%CI: 1.01-1.04).
The detection rate of AN showed a similar pattern as the positivity rate with respect to 
FIT specimen collection device and reagents lots (device p <0.001; reagent lots p 0.004; 
Table 3). Detection rate of AN was especially lower for participants tested with device AAE 
(OR:0.77, 95%CI: 0.65-0.91) and higher for participants tested with reagent lot 6 (OR:1.23, 
95%CI: 1.07-1.41). No difference was observed between the three laboratories in having a 
diagnosis with AN (p 0.37).
PPV for AN did not significantly differ for any of the variables of interest (device p 0.70, 
reagent lot p 0.96, laboratory p 0.23; Table 4).
Uncertainty Analyses
When adding a combined variable of batch FIT specimen collection devices and reagent 
lot into the multivariable logistic regression analysis for testing positive, an association 
between this combined variable and testing positive remained. Remarkable was that a batch 
in combination with the latest added reagent lot (highest number) resulted more often in a 
positive FIT test result: AAA3, AAC5 and AAD6 (Appendix III). Largest deviating positivity rates 
were observed in the combination AAA3 (OR:1.31, 95%CI: 1.02-1.69) and AAC5 (OR:1.51, 
95%CI: 1.05-2.18); however the population tested with these two combinations was very 
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Table 1: Baseline characteristics of participants with an assessable faeces sample
FIT negatives FIT positives* Total p value
Total (n, %) 1.283.650 (93.6) 87.519 (6.4) 1.371.169 (100) <0.001
Sex (n, %)
Men 611,125 (92.1) 52,759 (7.9) 663,884 (100) <0.001
Women 672,525 (95.1) 34,760 (4.9) 707,285 (100)
Age (mean, sd)
Year 66.9 (4.3) 67.7 (4.6) 67.0 (4.4) <0.001
Device (n, %)
AAA 304,754 (93.3) 22,018 (6.7) 326,772 (100) <0.001
AAC 308,413 (93.8) 20,292 (6.2) 328,705 (100)
AAD 575,421 (93.7) 38,811 (6.3) 614,232 (100)
AAE 95,062 (93.7) 6,398 (6.3) 101,460 (100)
Reagent lot (n, %)
1 249,787 (93.3) 17,937 (6.7) 267,724 (100) <0.001
2 232,445 (93.7) 15,557 (6.3) 248,002 (100)
3 235,090 (93.7) 15,770 (6.3) 250,860 (100)
4 233,284 (93.9) 15,224 (6.1) 248,508 (100)
5 158,091 (93.8) 10,523 (6.2) 168,614 (100)
6 174,953 (93.3) 12,508 (6.7) 187,461 (100)
Laboratory (n, %)
LabA 414,232 (93.5) 28,651 (6.5) 442,883 (100) <0.001
LabB 423,476 (93.5) 29,300 (6.5) 452,776 (100)
LabC 445,942 (93.8) 29,568 (6.2) 475,510 (100)
Ambient temperature (mean, sd)
degrees Celsius 10.8 (5.3) 10.7 (5.3) 10.8 (5.3) 0.02
Sample return time (n, %)
1 day 1,042,322 (94.1) 65,167 (5.9) 1,107,489 (100) <0.001
2 days 192,919 (93.8) 12,644 (6.2) 205,563 (100)
3 days 30,823 (93.7) 2,077 (6.3) 32,900 (100)
4 days 10,202 (93.6) 700 (6.4) 10,902 (100)
5 days 3,852 (93.7) 258 (6.3) 4,110 (100)
6 days 2,776 (93.8) 182 (6.2) 2,958 (100)
Time to expiry of device (mean, sd)
Days 293.4 (83.0) 293.3 (84.1) 293.4 (83.0) 0.69
Abbreviations: FIT (faecal immunochemical test for haemoglobin).
*FITs were considered positive at a cut-off of 47 µg Hb/g faeces.
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small (0.1%). Additionally, the combination of AAD6 and AAA1 resulted in deviating positivity 
rates, however the effect size was smaller (OR:1.14, 95%CI: 1.08-1.20 and OR:0.92, 95%CI: 
0.88-0.95, respectively). Although these combinations showed smaller ORs, they affected 
a larger group of individuals (24.8%). The remaining combinations were not significantly 
different.
Stratifying the multivariable models for two age groups for testing positive resulted in 
similar effects sizes as the full model, although some differences were no longer statistically 
significant because of the longer sample size.
Table 2: FIT* test results by specimen collection device, reagent, laboratory and multivariable logistic 
analysis**
Positivity rate (95% CI) OR (95% CI) p value
Device
AAA 6.7 (6.7-6.8) REF <0.001
AAC 6.2 (6.1-6.3) 0.98 (0.94-1.03)
AAD 6.3 (6.3-6.4) 0.94 (0.87-1.02)
AAE 6.3 (6.2-6.5) 0.82 (0.73-0.92)
Reagent lot
1 6.7 (6.6-6.8) REF
2 6.3 (6.2-6.4) 1.11 (1.06-1.16) <0.001
3 6.3 (6.2-6.4) 1.14 (1.08-1.21)
4 6.1 (6.0-6.2) 1.14 (1.06-1.22)
5 6.2 (6.1-6.4) 1.13 (1.04-1.24)
6 6.7 (6.6-6.8) 1.31 (1.19-1.44)
Laboratory
LabA 6.5 (6.4-6.5) REF 0.004
LabB 6.5 (6.4-6.5) 1.03 (1.01-1.05)
LabC 6.2 (6.2-6.3) 1.02 (1.01-1.04)
Abbreviations: FIT (faecal immunochemical test for haemoglobin), OR (Odds ratio), CI (confidence interval).
*FITs were considered positive at a cut-off of 47 µg Hb/g faeces.





In a well-organised FIT-based screening programme with strong focus on quality assurance, 
FIT positivity rates varied by FIT specimen collection devices, reagent lot, and laboratories 
as well as detection of AN for FIT specimen collection devices and reagent lot. These effects 
remained after multivariable correction for sex, age, ambient temperature, sample return 
time and time to expiry of collection device. The PPV for AN were not found to differ between 
FIT specimen collection devices, reagent lots and laboratories. The small difference between 
the three laboratories responsible for the analyses in the national Dutch CRC screening 
programme is considered clinically irrelevant.
The observed differences in this study were surprising and unexpected, as we currently 
have a thorough quality assessment programme in the Netherlands. With every reagent lot 
change quality assessments are in place and quality assessments are regularly carried out 
in the laboratories. On the other hand, the results are not that surprising, considering the 
Table 3: Detection rates of advanced neoplasia* by specimen collection device, reagent, laboratory and 
multivariable logistic analysis **
Number of 
participants
Number of individuals with 
advanced neoplasia  
(detection rate (95% CI)) OR (95% CI) p value
Device
AAA 326,772 10,624 (3.3 (3.2-3.3)) REF <0.001
AAC 328,705 9,529 (2.9 (2.8-3.0)) 0.96 (0.90-1.02)
AAD 614,232 18,500 (3.0 (3.0-3.1)) 0.92 (0.82-1.02)
AAE 101,460 2,786 (2.7 (2.6-2.8)) 0.77 (0.65-0.91)
Reagent lot
1 267,724 8,644 (3.2 (3.2-3.3)) REF 0.004
2 248,002 7,392 (3.0 (2.9-3.0)) 1.07 (1.01-1.14)
3 250,860 7,403 (3.0 (2.9-3.0)) 1.10 (1.01-1.19)
4 248,508 7,310 (2.9 (2.9-3.0)) 1.10 (1.00-1.22)
5 168,614 5,074 (3.0 (2.9-3.1)) 1.11 (0.98-1.25)
6 187,461 5,616 (3.0 (2.9-3.1)) 1.23 (1.07-1.41)
Laboratory
LabA 442,883 13,530 (3.1 (3.0-3.1)) REF 0.37
LabB 452,776 13,801 (3.0 (3.0-3.1)) 0.99 (0.97-1.02)
LabC 475,510 14,108 (3.0 (2.9-3.0)) 0.98 (0.96-1.01)
Abbreviations: OR (Odds ratio), CI (confidence interval).
*Advanced neoplasia was defined as CRCs and advanced adenomas (AA). AA is defined as any adenoma with 
histology showing ≥25% villous component or high-grade dysplasia or adenoma with size ≥ 10 mm.
** Multivariable OR were corrected for sex, age, ambient temperature, sample return time and time to expiry 
of collection device
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many uncontrolled factors that can influence the quality of FIT specimen collection devices 
and reagent: variations in composition of the tube material, buffer, brush, stick, antibodies 
and so on. Remarkable was that the largest observed differences were predominantly 
observed in FIT specimen collection devices that were analysed with a newer reagent lot, as 
shown in the uncertainty analysis. These differences were seen in individuals that were sent 
a FIT during a certain reagent, but who waited a considerable time before returning their FIT 
during which a new reagent lot was introduced. This difference may be the result of selection 
bias, if individuals that wait longer to return their FIT are a selected group of individuals 
with more CRC or AA but also more comorbidities. An alternative explanation might be that 
the manufacturer calibrates a new reagent lot on the buffer of new specimen collection 
devices, and not on the old devices. Fortunately, the clinical impact of the difference in 
Table 4: PPV for advanced neoplasia* at colonoscopy (PPV) by specimen collection device, reagent, laboratory 




Number of individuals with 
colonoscopy
(participation rate (95% CI))
Number of individuals 
with advanced neoplasia 
(PPV (95% CI))*** OR (95% CI)
p value
Device
AAA 22,018 17,959 (81.6 (81.0-82.1) 10,624 (59.4 (58.6-60.1)) REF 0.70
AAC 20,292 16,658 (82.1 (81.6-82.6)) 9,529 (57.3 (56.5-58.0)) 0.99 (0.89-1.09)
AAD 38,811 32,132 (82.8 (82.4-83.2)) 18,500 (57.7 (57.2-58.3)) 0.97 (0.82-1.14)
AAE 6,398 5,182 (81.0 (80.0-81.9)) 2,786 (53.9 (52.5-55.2)) 0.90 (0.69-1.16)
Reagent lot
1 17,937 14,648 (81.7 (81.1-82.2)) 8,644 (59.2 (58.4-60.0)) REF 0.96
2 15,557 12,754 (82.0 (81.4-82.6)) 7,392 (58.0 (57.2-58.9)) 0.97 (0.89-1.06)
3 15,770 12,997 (82.4 (81.8-83.0)) 7,403 (57.1 (56.2-57.9)) 0.96 (0.85-1.09)
4 15,224 12,702 (83.7 (83.1-84.2)) 7,310 (57.5 (56.7-58.4)) 0.95 (0.81-1.11)
5 10,523 8,688 (82.7 (82.0-83.4)) 5,074 (58.4 (57.4-59.4)) 0.97 (0.80-1.17)
6 12,508 10,065 (80.7 (80.0-81.4)) 5,616 (55.8 (54.8-56.8)) 0.95 (0.77-1.17)
Laboratory
LabA 28,651 23,607 (82.4 (81.9-82.8)) 13,530 (57.5 (56.8-58.1)) REF 0.23
LabB 29,300 24,028 (82.0 (81.6-82.4)) 13,801 (57.6 (56.9-58.2)) 1.00 (0.96-1.04)
LabC 29,568 24,296 (82.2 (81.7-82.6)) 14,108 (58.2 (57.6-58.8)) 1.03 (0.99-1.07)
Abbreviations: OR (Odds ratio), CI (confidence interval), PPV (Positive Predictive Value), FIT (faecal 
immunochemical test for haemoglobin).
*Advanced neoplasia was defined as CRCs and advanced adenomas (AA). AA is defined as any adenoma with 
histology showing ≥25% villous component or high-grade dysplasia or adenoma with size ≥ 10 mm.
** Multivariable ORs were corrected for sex, age, ambient temperature, sample return time and time to 
expiry of collection device.
***In total, 71,931 (82.2%) individuals underwent colonoscopy. Results of colonoscopy and/or pathology 
were missing for 178 (0.2%) individuals. Those individuals were not included in the calculation of the PPV.
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positivity rate on population level is very small, as only 0.1% of the population tested had 
these significantly higher odds ratios of 1.3 or higher.
To our knowledge, no previous studies have examined the performance of the FIT test, 
using different FIT specimen collection devices, reagent lots and laboratories. Our findings 
for the confounding factors were consistent with literature (data not shown).8,9 Therefore we 
expect that the findings of our study are not unique for FOB-Gold or the Netherlands, but 
are generally applicable for FIT-based screening programmes throughout the world. Other 
studies have shown instability of the positivity rate of FIT-based screening programmes, which 
even resulted in temporary suspension of some programmes.10,11 The variation reported 
here is not of the same magnitude and requires other measures such as the development 
of a regular monitoring system. This emphasises an important caveat when publishing 
data on FIT screening, as continuous improvements to FIT systems by manufacturers affect 
the relevance of the results over time. Although results cannot directly be used by other 
programmes, these results highlight the importance of careful and continuous monitoring 
of the FIT results.
A key strength of the present study is that it is the first to report on consistency in 
performance of FIT at population level. Another important strength is the large population-
based design, which made it possible to examine the performance of FIT and analytical 
performance on a large scale. There are also some noteworthy limitations. First, there might 
be a correlation between specimen collection devices and reagent, as both were gradually 
introduced consecutively. However, we tested this correlation with the sensitivity analysis 
by looking at a combined variable, and obtained similar results to the main analysis. A 
correlation is also possible between specimen collection device, reagent and season, but 
we tried to diminish the impact by correcting for ambient temperature and using data of 
two screening years. Another limitation is the use of positivity rate as performance indicator 
instead of distribution of faecal haemoglobin concentration.12 However, in this study we 
focused on the real programme performance, which was reflected by the positivity rate. The 
largest shortcoming is intrinsic to the concept of screening; we could not assess the negative 
predictive value, as individuals with negative FIT results were not assessed by endoscopy.
Although we hypothesised the cause of the observed difference to be related to a 
specific group of individuals or combination of reagent and buffer, we also found odds 
ratios significantly different from 1 for a different and larger group of individuals: 15% 
higher odds for the combination of device AAD and reagent lot 6 and 8% lower odds for 
the first combination used, device AAA with reagent lot 1. These effect sizes are much 
smaller and therefore the clinical impact will be less important. They do, however, affect 
a considerably larger number of individuals (almost 25% of the tested population). These 
results therefore emphasise the importance of the need for standardisation of quality 
control of FIT performance. Currently no standard exists for acceptable range of variation on 
the outcomes of a FIT-based CRC screening programme. Although SKML EQA samples have 
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target values assigned by weighed in addition of human haemoglobin and therefore could 
be used for trueness verification, this is not the current practice due to debate on the value 
assignment as a lack of international standardisation of the method for value assignment in 
FIT testing and agreement of performance specifications. Although manufacturers assess 
the quality of the FIT, they use small sample sizes and data is not publicly available. Again, 
this highlights the necessity of standardising quality assessment. To define this standard, 
the International Federation of Clinical Chemistry and Laboratory Medicine has set up a 
Faecal Immunochemical Testing working group (WG-FIT).13 Additionally, more information is 
needed on the long-term impact of this observed variation of FIT. Therefore we are currently 
performing a decision analysis to define a range in which variation is acceptable without 
affecting long-term effect of screening (by means of mortality reduction and life years 
gained). Furthermore, evaluation of the effect of analytical performance on clinical outcomes 
is planned following the approach of the European Federation of Clinical Chemistry and 
Laboratory Medicine.13 In addition to standardising quality assessment, a three-step plan 
must be set up: 1) controls in the laboratory itself, 2) regular monitoring of FIT performance, 
and 3) evaluation of FIT performance at population level. All steps are currently followed in 
the Netherlands, but the lack of international standardisation of methods, value assignment 
and acceptance criteria hamper correlating analytical performance and screening efficiency. 
Another possible approach to reduce the observed differences could be synchronisation of 
specimen collection device and reagent lot changeover, however this is logistically difficult 
to implement in the national screening programme.
Conclusions
Test positivity of FIT and detection rates of AN differed between FIT specimen collection 
devices and reagent lots, however no variation in PPV was observed. Clinically the programme 
is performing well, but there is room for improvement. Acceptable ranges of variation are 
lacking. These results can be used as input for the international initiative for standardising 
FIT quality assessment and for improving a regular monitoring system to reduce the impact 
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APPENDIx II





Name of specimen collection device and sup-
plier (address)
Name collection device: FOB-Gold
Supplier: FOB-Gold, Sentinel Diagnostics, Via 
Robert Koch, 2-20152 Milan, Italy
Description of specimen collection device (vial 
with probe/stick, card, other)
Round tube with collection stick immerged in 
a preservative solution
Description of specimens used if an in vivo 
study (single or pooled feces, artificial matrix 
with added blood, etc)
Single human faeces sample
Details of faecal collection method (sampling 
technique and number of samples)
Ribbed section of the sampling stick is dipped 
in 4 different parts of the stool
Who collected the specimens from the samples 
(patient, technician, etc)
Participant
Number of faecal specimens used in the study 
(single, pooled, individual patient feces)
Single sample of individual patient feces
Mean mass of faeces collecteda 10 mg
Volume of buffer into which specimen is taken 
by probe, applicator stick, or carda
1.7 mL
Time and storage conditions of faecal specimen 
from “passing” to sampling, including time and 
temperature (median and range)
Analysis took place at same day of arrival (<24 
h) of the FIT in the laboratory and the FIT was 
kept by ambient air temperature
Time and storage of collection devices from 
specimen collection to analysis, including time 
and temperature (median and range). A concise 
description of process from collection to analy-
sis is recommended.
Participants were asked to post the faeces 
samples within 24 h after collection and keep 
the sample in the refrigerator. The date of 
sample collection is noted. FIT was transport-
ed and analysed by ambient air temperature.
Analysis Name of analyzer, model, supplier (address), 
number of systems if more than 1 used.
Bio Majesty JCA-BM6010/C, serial number CA 
1401000690069. Supplier: Sysmex Nederland 
BV Ecustraat 11 4879NP Etten Leur
Number of times each sample was analysed. Single or twice. If first analysis resulted in “no 
results” analysis was repeated.
Analytical working rangea and whether samples 
outside this range were diluted (factor) and re-
assayed.
0.4–797.2 ng/mL. Client samples outside this 
linearity range were not diluted.
Source of calibrator(s) (supplier with address), 
number of calibrator(s), how concentrations 
were assigneda and details of calibration pro-
cess including frequency.
Calibrator supplier: Sentinel Diagnostics, Via 
Robert Koch, 2-20152 Milan, Italy
Calibrator levels: 6
Standard calibration is performed with every 
reagent and calibrator lot number change.
CHAPTER 7
120
Table 1: FOB-Gold Standard for Faecal Immunochemical Tests for Hemoglobin (FITTER) Checklist21,22 (continued)
Topic Item Documentation
Analytical imprecision,a ideally with number of 
samples analysed, concentrations, and mean, 
SD and CV.
Before the go-live a CLSI EP5A2 protocol was 
performed on all 3 Sentinel controls (low, mid, 
high) to verify the imprecision specifications 
conform tender requirements of the Dutch 
colorectal cancer screening programme.
CLSI EP5A2 results:
Sentinel low: 50 ng/mL
Lot number control: 30004/A0546
SD with-in (calculated) = 4.04
SD with-in (claim) = 5.00 (10% of 50 ng/mL)
(User variance/claim variance) degrees of 
freedom = 26.13
Critical χ2 value = 55.76
Claim accepted? Yes
SD total (calculated) = 5.12
SD total (claim) = 7.50 (15% of 50 ng/mL)
(User variance/claim variance) df = 25.63
Critical χ2 value = 73.03
Claim accepted? Yes
Sentinel mid: 71 ng/mL
Lot number control: 30004/A0551
SD with-in (calculated) = 3.69
SD with-in (claim) = 7.10 (10% of 71 ng/mL)
(User variance/claim variance) df = 10.82
Critical χ2 value = 55.76
Claim accepted? Yes
SD total (calculated) = 5.49
SD total (claim) = 10.60 (15% of 71 ng/mL)
(User variance/claim variance) df = 11.98
Critical χ2 value = 61.66
Claim accepted? Yes
Sentinel high: 312 ng/mL
Lot number control: 30004/A0552
SD with-in (calculated) = 4.81
SD with-in (claim) = 31.20 (10% of 312 ng/mL)
(User variance/claim variance) df = 0.95
Critical χ2 value = 55.76
Claim accepted? Yes
SD total (calculated) = 7.41
SD total (claim) = 46.80 (15% of 312 ng/mL)
(User variance/claim variance) df = 1.08
Critical χ2 value = 59.30
Claim accepted? Yes
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Source (address) or description of internal qual-
ity control materials, number of controls, as-
signed target concentrations and ranges, how 
target concentrations were assigned, rules used 
for acceptance and rejection of analytical runs.
3 rounds of control before running daily analy-
ses were done and 3 rounds after, conform 
Sentinel’s quality rules. If 2 of 3 controls are 
within the range, analytical runs are accepted.
Apart from the Sentinel controls, a mid-daily 
run of control conform SKML (SKML CFB, Mer-
cator 1, Toernooiveld 214, NL-6525 EC, Nijme-
gen, The Netherlands) is performed, every 
other day a high run or low run:
SKML low: 212 ng/mL →5.05%
SKML high: 510 ng/mL →3.10%
If the control is not right, controls are being 
repeated, if not right after multiple control 
rounds, the clinical chemist is consulted.
Participation in external quality assessment 
schemes: (name and address of scheme), fre-
quency of challenges, performance attained.
Participation in external quality assessments 
of SKML (foundation of quality control of 
medical laboratory diagnostics) following a 
fixed schedule. Assessment results are moni-
tored by the national functionary FIT
Accreditation held by the analytical facility (ad-
dress).
Accreditation by CCKL, Mariaplaats 21-D, 3511 
LK Utrecht
The number, training and expertise of the per-
sons performing the analyses and recording the 
results
7 trained technician’s
Result handling Mode of collection of data; manual recording or 
via automatic download to IT system, single or 
double reading
Results are automatically uploaded to Scree-
nIT, after authorisation by the laboratory ana-
lyst the results are uploaded to the screening 
IT system ScreenIT.
Units used, with conversions to μg Hb/g faeces 
if ng Hb/mL used.
In analyzing and reporting results ng Hb/mL 
was used. For reporting in publications this is 
converted to μg Hb/g faeces.
Cutoff concentration(s) if used and explanation 
of how assigned locally or by manufacturer
Positive: ≥275 ng Hb/mL (47 µg Hb/g faeces). 
This was locally assigned by researchers and 
approved by the Ministry of Health.
Were the analysts blinded (masked) to the re-





APPENDIx III: UNCERTAINTY ANALYSES
Uncertainty Analysis I
Table 1: Multivariable logistic analysis of persons with positive FIT* test result by combined batch-reagent lot 
and laboratory
Device and reagent lot Population tested FIT positives
n (%)
OR 
(95% CI) p value
AAD3 113,283 7,085 (6.3) REF <0.001
AAA1 253,600 17,022 (6.7) 0.92 (0.88-0.95)
AAA2 72,158 4,915 (6.8) 1.05 (0.99-1.12)
AAA3 1,014 81 (8.0) 1.31 (1.02-1.69)
AAC1 14,124 915 (6.5) 0.99 (0.91-1.06)
AAC2 175,844 10,642 (6.1) 0.98 (0.94-1.03)
AAC3 136,563 8,604 (6.3) 1.02 (0.96-1.07)
AAC4 1,738 95 (5.5) 0.95 (0.76-1.18)
AAC5 436 36 (8.3) 1.51 (1.05-2.18)
AAD4 246,770 15,129 (6.1) 0.98 (0.94-1.02)
AAD5 168,162 10,486 (6.2) 0.97 (0.92-1.02)
AAD6 86,017 6,111 (7.1) 1.14 (1.08-1.20)
AAE56 101,460 6,398 (6.3) 1.00 (0.96-1.04)
Laboratory
LabA 442,883 28,651 (6.5) REF 0.004
LabB 452,776 29,300 (6.5) 1.03 (1.01-1.05)
LabC 475,510 29,568 (6.2) 1.02 (1.01-1.04)
Abbreviations: FIT (faecal immunochemical test for haemoglobin).
* FITs were considered positive at a cut-off concentration of 47 µg Hb/g faeces.
**Multivariable OR were corrected for sex, ambient temperature, sample return time and time to expiry of 
collection devices.
123
CONSISTENCY OF FIT PERFORMANCE
Uncertainty analysis II
Table 2: Multivariable logistic analysis of persons with positive FIT* test result by specimen collection device, 
reagent lot and laboratory by two age groups
Device
Age 63 Age 67
OR (95% CI) p value OR (95% CI) p value
AAA REF 0.23 REF 0.004
AAC 0.92 (0.77-1.10) 0.86 (0.76-0.97)
AAD 0.89 (0.68-1.16) 0.74 (0.60-0.92)
AAE 0.74 (0.48-1.14) 0.55 (0.39-0.78)
Reagent lot
1 REF 0.005 REF <0.001
2 1.08 (0.95-1.23) 1.19 (1.09-1.29)
3 1.13 (0.95-1.33) 1.33 (1.17-1.52)
4 1.21 (0.98-1.50) 1.39 (1.15-1.67)
5 1.13 (0.86-1.47) 1.46 (1.16-1.83)
6 1.38 (1.01-1.88) 1.79 (1.39-2.29)
Laboratory
LabA REF 0.69 REF 0.38
LabB 0.98 (0.94-1.03) 1.03 (0.98-1.07)
LabC 0.99 (0.95-1.04) 1.03 (0.98-1.07)
Abbreviations: FIT (faecal immunochemical test for haemoglobin).* FITs were considered positive at a cut-off 
concentration of 47 µg Hb/g faeces.
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This study compared adherence to four faecal immunochemical testing (FIT) based 
screening programmes for colorectal cancer (CRC) in Flanders, France, Basque country and 
the Netherlands to identify factors to further optimise FIT programmes.
Methods
Background information and data on performance indicators were collected and compared 
for the four CRC screening programmes.
Results
Invitation method, reminders, funding, FIT cut-off and follow-up after positive FIT differed 
between the four programmes. In France only an invitation letter is send by mail, while the 
sample kit needs to be collected at general practitioner (GP). In the other programmes, an 
invitation letter including the sample kit is send by mail. Participation rates varied substantially 
with method of invitation, with the highest participation rates in the Netherlands (73.0%) 
and Basque country (72.4%), followed by Flanders (54.5%) and France (28.6%). Basque 
country (92.8%) and France (88.4%), the two programmes with most active involvement 
of GPs in referral for colonoscopy, showed the highest participation rate with colonoscopy.
Conclusions
Large differences in screening participation were observed between programmes in line 
with the invitation method used. This finding suggests that changes to the design of the 
programme, such as including the sample kit with the invitation or active involvement of 




Many countries or regions have implemented colorectal cancer (CRC) screening by faecal 
occult blood testing (FOBT), in particular by means of faecal immunochemical testing (FIT).1 
FOBT as screening method is also recommended by the European Union.2 The effectiveness of 
population-based screening programmes is not only driven by the sensitivity of the screening 
method, but also depends on the availability of resources, healthcare infrastructure and 
population preferences in each country. Population preferences will especially be reflected 
in participation rate.
To determine the most optimal screening method for the population, pilot studies were 
performed in the Basque country, Flanders and the Netherlands before the initiation of the 
regional or national screening programme. In the Basque Country a pilot study was carried 
out in 2009 and high participation rate with FIT screening of 64.3% was demonstrated.3 
In Flanders, a pilot study was performed to compare two invitation strategies: FIT directly 
send by mail or invitation to collect the FIT at the general practitioner (GP). Participation by 
mail was 52.3% versus 24.6% through the GP.4 In the Dutch pilot studies different screening 
methods were compared. These studies showed that FIT screening resulted in the highest 
CRC detection per invitee compared to other screening methods like guaiac FOBT (gFOBT), 
colonoscopy and sigmoidoscopy screening.5-7
After choosing the best screening method, the organisational structure of the programme 
is crucial for optimal screening performance. Many different aspects how to organise the 
programme have been studied like pre-invitation letter, reminders, and FIT mailing.4,8,9 
However, almost all of these studies have been carried out in trials and not in real-life 
settings. In running programmes many more aspects are involved, for example organisation 
of healthcare systems and healthcare insurance. Besides, these organisational aspects have 
never been compared across programmes, but only in one specific group of individuals. It is 
unknown of all these different organisational aspects will work out the same for individuals 
residing in different countries. A national population-based CRC screening programme was 
initiated in 2002 in France using gFOBT, which was changed to FIT in April 2015. FIT screening 
was introduced in 2009 in the Basque country (Spain), in 2013 in Flanders (Belgium), and 
in 2014 in the Netherlands. As these programmes are geographically close and connected, 
all situated in Europe, and have recently been implemented similar outcomes with respect 
to CRC screening may have been expected. This study was able to evaluate similarities and 
differences between the organised population-based CRC screening programmes using FIT 
in France, Basque country (Spain), Flanders (Belgium), and the Netherlands and assesses 




Organisational structure of CRC screening programmes
Information was collected on year of initiation, target population, eligible population, 
screening interval, methods of invitation to FIT screening and to colonoscopy following a 
positive FIT, funding and executive organisation of the screening programmes. The target 
population was defined for each population-based CRC screening programme according to 
programme specific policies. The eligible population is the target population excluding those 
that are not eligible for screening based on exclusion criteria. Eligible population were all 
individuals that should have been invited in 2016. This number can deviate from the total 
target population, because of biennial screening or phased implementation of the national 
screening programme.
Performance indicators of CRC screening programmes
Data on performance indicators were extracted from each of the national or regional 
screening databases. Data from France were extracted from the database of French Public 
Health Agency (Santé Publique France) and Organized screening structure of the Big East 
region and the Pyrénées. Data from Flanders were extracted from the screening database, 
the Belgian Cancer Registry and reimbursement data from the Health insurance companies. 
All data from the Basque country were extracted from programme database (PCCR) which 
is linked with medical records, population and hospital cancer registries. All data from 
the Netherlands were extracted from the national database for screening programmes 
(ScreenIT). In France, data on the invitees starting in April 2015 to December 2016 were 
collected until June 2017, in the Basque country data on the invitees of 2016 were collected 
until December 2017, in Flanders and the Netherlands data on the invitees of 2016 were 
collected until 30 June 2017.
Data were collected on main performance indicators: participation rate, positivity rate 
of the FIT, participation rate to colonoscopy following positive FIT, detection rate of CRC or 
advanced neoplasia (AN) per participant, and diagnostic yield. Definitions of the indicators 
are in accordance with recommended definitions for performance indicators by the European 
Union CRC screening guidelines.11
1. Participation rate was calculated as the number of persons sending back the FIT sample 
divided by the number of persons receiving an invitation letter. For Flanders and France 
persons were only considered as participant if they returned the FIT sample within 
12 months after the invitation. In the Basque Country persons were only considered 
participant if they returned an assessable FIT sample within six months after the 
invitation. In the Netherlands individuals were considered participant until the date of 
the invitation of subsequent screening round.
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2. Positivity rate was calculated as the number of persons with a FIT result at or above the 
cut-off level divided by the number of persons with an assessable stool sample.
3. Participation rate colonoscopy was calculated as the number of persons undergoing a 
colonoscopy divided by the number of persons with a positive FIT result.
4. Detection rate was defined as the number of persons with AN detected during 
colonoscopy per participant. AN was considered as relevant abnormality within a CRC 
screening programme. AN was defined as CRC or any adenoma with histology showing 
>=25% villous component or high-grade dysplasia or adenoma with size >= 10 mm. In 
Flanders, only adenoma with any villous component and/or high grade dysplasia was 
counted as advanced adenoma, because no data were available on adenoma size or the 
amount of villous components. In the Basque country, in addition to histology, dysplasia 
and size, having ≥3 adenomas was also considered as advanced adenoma.
5. Diagnostic yield of the programme was defined as the number of persons with AN 
detected during colonoscopy divided by all individuals that received an invitation. In 
Flanders, data of colonoscopy yield is not linked to the date of invitees of the programme. 
The denominator can contain individuals invited in previous year.
Analysis
First, organisational structure of the four programmes were compared using thematic 
analysis to identify similarities or differences. Second, outcomes of the performance 
indicators for each of the four programmes were compared. To rule out that the observed 
difference is related to cultural differences between populations rather than organisational 
differences, the programme of Basque country in Spain was compared with the Basque 
country in France. These are two regions that are very close with respect to geographical 
location and cultural background. The different subgroups were compared using chi-squared 
test and p value <0.05 was considered statistically significant. Chi-square test was performed 
using R version 3.5.0.
RESULTS
Organisation of the programmes
The age range of the target population differed, with France and the Basque country having 
the lowest starting age of 50 years and the Basque country having the lowest stopping age 
of 69 years (Table 1). All four countries used a two years screening interval. Exclusion criteria 
prior to invitation differed between the four programmes, with very limited exclusion 
criteria in the Netherlands compared to the other three programmes: persons were only 
excluded based on a positive FIT in previous screening round (Table 1). France, Flanders and 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































performed colonoscopy before invitation. France and Flanders also excluded individuals 
with a recently performed FIT. Additionally, the Basque country excluded individuals with 
severe or terminal illness.
Methods of invitation differed between the four programmes. The eligible population 
in France received an invitation letter to collect the FIT sample kit at the GP. In Flanders 
individuals received an invitation including the FIT sample kit. In the Basque country and 
the Netherlands a pre-invitation letter was send prior to invitation followed by an invitation 
letter including the FIT sample kit. All four screening programmes used a reminder letter, but 
all at different time points ranging from 30 days (Basque country) until 6 months (France). 
France sent two reminder letters. All four programmes used another cut-off for a positive FIT 
for referral to colonoscopy: Flanders used the lowest cut-off of 15 µg Hb/g faeces, followed 
by the Basque country with 20 µg Hb/g faeces and France with 30 µg Hb/g faeces. The 
highest cut-off was used in the Netherlands with 47 µg Hb/g faeces (Table 1).
Performance indicators
A total of 18.9 million individuals were invited to participate in FIT screening among the 
four CRC screening programmes. Highest participation rate was observed in the Netherlands 
(73.0%), followed by the Spanish Basque country (72.4%), Flanders (54.5%) and France 
(28.6%, p <0.001). As a consequence of the different FIT cut-offs used, positivity rate differed 
between the four programmes, from 4.7% in France to 6.7% in Flanders (p <0.001). Highest 
participation rate for the colonoscopy following a positive FIT result was observed in the 
Basque country (92.8%), France (88.4%), Flanders (81.9%) and the Netherlands (82.8%) (p 
<0.001). Detection rate for AN per participant was highest in the Netherlands (2.3%) and 
lowest in Flanders (1.0%). Diagnostic yield for AN per invitee was highest in the Netherlands 
(1.6%) and lowest in Flanders (0.6%, p <0.001).
French versus Spanish Basque country
Despite cultural similarities, differences in screening performance indicators were observed 
between the French and the Spanish parts of the Basque country (Table 3). The participation 
rate in the Spanish part, with 72.4% was 2.5 times as high as the French part of the Basque 
country, with 24.6% (p <0.001; Table 3). Participation rate to colonoscopy was of the same 
magnitude in both regions: 92.8% in the Spanish part and 87.4% in the French part (p 0.37).
DISCUSSION
Large differences in screening participation were observed between programmes in line 
with invitation method used, such as a pre-invitation letter and including the FIT sample kit 
with the invitation. The high participation to colonoscopy in France might indicate that well 
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informed and motivated people that collect the FIT sample kit at the GP, are more likely to 
undergo a colonoscopy.
For the large difference in FIT participation we have several explanations. First, sending 
the FIT home is more effective than collecting it at the GP. Almost all studies were irrevocably 
showing a huge increase in participation when including the FIT sample kit with the 
invitation.8,12-14 However, one Italian study showed only a modest increase in participation, 
but this study was performed in previously screened individuals (used to other screening 
Table 2: Performance indicators for France, Flanders, the Netherlands and Basque country
 France Flanders Netherlands Basque country p value
Calendar year 2015-2016 2016 2016 2016
Age (year) 50-74 56-74 59-76 50-69
Target population  19,043,771 1,447,434† Unknown 273,084









Number of participants 4,779,845 311,453 1,063,651 166,110 <0.001
Participation rate FIT 28.6% 54.5%‡ 73.0% 72.4% 
Men 27.8% 53.1% 71.1% 70.0%
Women 30.8% 56.0% 74.8% 74.6%
Screen round Any round First and second First and second First to Fourth 
Cut-off level (Hb/g faeces) 30 µg 15 µg 47 µg 20 µg
Positivity rate 4.7% 6.7% 5.4% 5.2% <0.001
Participation rate colonoscopy 88.4%* 81.9% 82.8% 92.8% <0.001
Detection rate
AN 1.5%* 1.0% 2.3% 1.9% <0.001
CRC 0.31%* 0.28% 0.35% 0.20% <0.001
Diagnostic yield programme      
AN 0.4%* 0.6% 1.6% 1.4% <0.001
CRC 0.09%* 0.15% 0.25% 0.15% <0.001
† Eligible population in Flanders is the total amount of 56-74 years old for two year minus those excluded for 
invitation. Eligible population for 2016 only could not be provided.
‡ Coverage by examination, also including opportunistic screening by FIT or colonoscopy, resulted in 65.5% of 
the target population to be screened.
* In France the participation rate of colonoscopy and number of colorectal cancers and advanced neoplasia 
was based on data from April 2015 until December 2015.
Abbreviations: AN (Advanced Neoplasia); N.A. (Not available).
Advanced neoplasia was defined as CRC or any adenoma with histology showing >=25% villous component or 
high-grade dysplasia or adenoma with size >= 10 mm. In Basque country also ≥3 adenomas were considered 
AN. In Flanders, adenoma with a villous component and/or high grade dysplasia was counted as advanced 
adenoma. There were no data available on the size or the amount of villous components in an adenoma. 




strategy).16 One French study showed low uptake rates with direct mailing of the FOBT.16 
This inconsistency may be due to the test modality, gFOBT instead of FIT, resulting in lower 
participation rates.17 Second explanation for a higher FIT participation may be the advanced 
notification letter as illustrated by the higher participation rate in the Basque country and 
the Netherlands. However, this will only explain a small proportion of the total difference, 
as studies have shown that sending a pre-invitation letter results in a three percentage 
point increase.9,10 Only one study from Australia showed a higher increase, nine percentage 
point.18 Both direct mailing as well as the pre-invitation letter are in line with a recent 
systematic review.19 However, one large difference is noteworthy. The review reported that 
GP involvement improved participation. We showed the opposite in this study; a country 
with no involvement of GPs like the Netherlands, participation rates were very high, while 
in a country with active involvement of the GPs like in France, participation rates were 
substantially lower. We hypotheses that GP endorsement can have a positive impact on 
participation, as long this requires no effort of the participant. This is in line with findings 
of the CRC screening programme in England, showing an increase in participation if the 
invitation letter was added with a GP endorsement banner. Our analysis of the two Basque 
regions in France and Spain showed that very similar cultures can have very different rates 
in screening participation, and that culture may not be the driving factor of performance 
Table 3: Outcomes performance indicators Basque region




Number of participants 11,293 166,110
Participation rate FIT 24.6% 72.4% <0.001 
Cut-off level (Hb/g faeces) 30 µg 20 µg
Positivity rate 4.6% 5.2% 0.07
Participation rate follow-up colonoscopy 87.4% 92.8% 0.37
Detection rate
AN 1.4% 1.9% <0.001
CRC 0.27% 0.20%
Diagnostic yield    
AN 0.4% 1.4% <0.001
CRC 0.07% 0.15%
Abbreviations: AN (Advanced Neoplasia)
Advanced neoplasia was defined as CRC or any adenoma with histology showing >=25% villous component or 
high-grade dysplasia or adenoma with size >= 10 mm. In Basque country also ≥3 adenomas were considered 




differences between programmes. However, we cannot rule out cultural differences 
completely. We know from literature that cultural difference in screening attitude is also 
observed in the participation rates of other cancer screening programmes, for example 
participation to breast cancer screening. In 2016, this was also lower in Flanders (51.9%) than 
in the Netherlands (77.6%) and the Basque country (80.1%), with France having the lowest 
participation rate (50.7%).21-23 Remarkably, the participation rate for breast cancer screening 
in France is similar to Flanders, while there is a much larger difference in participation rate 
for CRC screening. Gender cannot explain this difference, as both men and women showing 
a similar pattern in participation. Thus, this again reflects the negative impact of using a 
different invitation method in France for CRC screening.
Participation rate to follow-up colonoscopy was considerable high in all four screening 
programmes. However, the rate was below the recommend level of 85% in the Netherlands 
and Flanders. We hypothesize that higher participation to follow-up colonoscopy can be 
the result of the active involvement of GPs during the screening process. In France and the 
Basque country GPs play an active role in 1) defining the eligible population by excluding 
those with severe comorbidity from invitation, 2) selecting the population eligible for FIT 
screening at pick-up of the screening test or 3) following individual up after negative FIT. 
Consequently, those participating in FIT screening are all healthy enough to undergo follow-
up colonoscopy. Other way around it also explains the lower participation to colonoscopy in 
the Netherlands, as there is no exclusion of individuals based on co-morbidities or medical 
history. Additionally, in France probably only the most motivated individuals collect the FIT 
sample kit at their GP practice and they may be more motivated to go for colonoscopy in 
case of a positive FIT. Only involving GPs for referral to colonoscopy, without involvement in 
selecting those eligible for FIT screening, will be less effective.8 Reimbursement differences 
of the colonoscopy do not seem to explain participation differences. Although in the Basque 
country the colonoscopy is free of charge, the participation in France was only slightly lower, 
while French individuals may have significant expenses.
Positivity rate differed for all the four programmes. This is due to three important reasons: 
cut-off of the FIT, target age group and screening round (first or subsequent round).24 The 
same explanations hold for the difference in detection rates and diagnostic yield of the 
programme. We could not restrict our analysis for the same age ranges, as the Netherlands 
is still in the implementation phase and not all age groups of the target population have 
been invited yet. Therefore, the outcomes of the positivity rate and detection rates should 
be addressed as exploratory, and further research is needed to explain the differences 
between these rates.
Our study has three strengths. It is the first that gives detailed information on organisational 
structure of four programmes provided by representatives of each country. These details are 
in general unknown, as key elements of CRC screening programmes are only described in 
its own country language: Flemish, French, Spanish/Basque, and Dutch. These details can 
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be used by other countries/regions considering CRC screening and are valuable for policy 
makers. Also, our study showed very recent outcomes of four large population-based 
programmes, all using the same test modality (FIT). Lastly, our study compared screening 
programmes of neighboring countries with cultural similarities and differences, and can thus 
address the impact of cultural and organisational aspects in the uptake of CRC screening.
The study has also some limitations. First, comparing quality indicators was challenging 
due to different definitions and differences in cut-off and number of screening rounds. 
Unfortunately, we could not restrict the comparison to first screen round data only as not all 
programmes had such detailed information. Second, data collection may be of a concern, for 
example France does not have a central data collection of quality indicators and diagnostic 
yield.
The findings of the study suggest that the organisational structure impacts the participation 
rate to FIT and follow-up colonoscopy, like sending out the FIT, pre-invitation letter, 
involvement of the GP in the whole screening process. These results can be used to optimise 
each of the four screening programmes or can be used as an example for other organised 
FIT-based CRC screening programmes. Possibilities for optimisation can be diverse for every 
programme as health care systems, funding of the colonoscopy and available resources 
differ. Interventions for optimisation will cost money and these results can therefore be 
used to explore the additional benefit and additional costs for each of the programmes. 
France already started optimising their screening programme, but maybe not in the good 
way. Indeed it has been decided to mail the FIT with the first reminder but only to those who 
had already been participating in previous round, whereas the study by Giorgi-Rossi and 
colleagues suggests that they may not be the best target.15
Although sending the FIT by mail and actively approaching FIT positives for the colonoscopy 
seems to be most effective, this can be considered as infringement of free will.25 High 
participation should not be the goal of screening programmes, but the level of informed 
choice. However, there is no indication that high participation in the Netherlands for example, 
results in a lower level of informed choice.26,27 Besides these ethical considerations, there is 
also a remaining difference in participation that cannot be explained by the organisational 
structure and is difficult to unravel. It seems to be a difference in attitude towards screening 
in general between the different regions or countries. It is unclear how this arises and can 
be solved.
In conclusion, this study shows that including the FIT with the invitation results in higher 
FIT participations rates. Actively involvement of the GP will result in higher participation rates 
to colonoscopy follow-up, but only if no effort of participants is required. Adjustments to the 
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The general aim of this thesis was to evaluate the performance of the national colorectal 
cancer (CRC) screening programme with biennial faecal immunochemical testing (FIT) in the 
Netherlands during the implementation phase. In this chapter, I first will discuss the most 
important findings of this thesis. Secondly, I will discuss the methodological considerations 
of the studies described in this thesis. Finally, I will elaborate on future perspectives and 
draw final conclusions.
9.1 MOST IMPORTANT FINDINGS OF THE DUTCH COLORECTAL CANCER 
SCREENING PROGRAMME DURING THE IMPLEMENTATION PHASE
From 2014 until 2017, 5.3 million individuals were invited to participate. A total of 3.9 million 
individuals returned their FIT. The FIT was positive for 223,043 individuals. A total of 180,398 
individuals underwent a colonoscopy. During colonoscopy, 14,084 CRCs and 76,022 AA were 
diagnosed. Based on these promising results during the implementation phase, it is expected 
that on the long-term CRC-related mortality will decrease, which is observable by 2029. 
Below the most important performance indicators of the Dutch CRC screening programme 
will be discussed separately, combining results of different chapters of this thesis. 
Participation rate FIT
In Chapter 2 we observed a very high participation rate (71.3%) in the first year of the 
national CRC screening programme. In the study described in Chapter 4 we evaluated 
participation in the second screening round and estimated a consistent participation of 93% 
among the individuals that previously participated. The high FIT participation rate is still one 
of the highest across the world, as was also confirmed in Chapter 8.1 Such high participation 
rate to primary screening test offered by the Dutch government is also observed in the two 
other large cancer screening programmes; 78.8% for breast cancer and 64.6% for cervical 
cancer.2,3 High participation rate is a relevant finding, as high participation will eventually 
result in high CRC detection rates per invitee.4-6 In the pilot study a stable FIT participation 
between 60-62% was observed over four screening rounds.7 If the results of the pilot study 
reflect what will take place in the national screening programme, the participation rate will 
remain high in coming years.
Despite the high participation in screening in the Netherlands, still almost 30% of the 
population does not participate in the CRC screening programme. The question is how 
much effort should be put in reaching out to nonparticipants. Striving for 100% uptake of 
the primary screening test should in my opinion not be the goal. It is of great importance 
that all individuals participating in screening do make an informed choice. The goal should 
be to increase the number of individuals making an informed choice to participate in 
screening. We know from previous studies among the Dutch population, that reasons for 
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nonparticipation are often related to lack of knowledge about CRC.8,9 Therefore, reaching 
out to nonparticipants is beneficial and should be undertaken. Up to now, it is unknown how 
to approach this in the Netherlands.
FIT positivity
In chapter 2, we described that weekly monitoring revealed that FIT positivity rate in 
the Dutch CRC screening programme was higher than anticipated, with an age-adjusted 
positivity rate of 10.7% at the cut-off of 15 µg Hb/g faeces. Consequently, a higher number of 
individuals were referred for colonoscopy. This higher positivity rate together with the lower 
than anticipated PPV for CRC and AA, resulted in the urgency to adjust the CRC screening 
programme. The outcomes of the programme were evaluated with a decision analysis tool, 
aiming to identify the best option to optimise the screening programme. Three options were 
evaluated: increase cut-off, postpone screening in selected age groups and forego screening 
in older age groups. This analysis showed that increasing the cut-off level not only resulted 
in lowest decrease in CRC deaths prevented, but also resulted in a balance between harms 
and benefits of screening in accordance with that aimed for at start of the programme.10 
The age-adjusted positivity rate of 6.7% at the higher FIT cut-off was now in line with the 
expected positivity rate of 6.4%.
The higher than anticipated positivity rate and subsequent adjustment of the FIT cut-off 
was widely debated. How could it possible that after extensive preparations, the national 
CRC screening programme differed so considerably from expectations? The debate was 
mostly on similarity of different FIT brands. The FIT brand selected through public tender was 
FOB-Gold (Sentinel, Italy), which differed from the brand OC Sensor (Eiken, Japan) that was 
used in the pilot studies. Because equal performance of the two FIT brands was uncertain, 
accuracy of the two FIT brands were compared.11 Main finding of this study was that faecal 
Hb concentrations and FIT positivity differed, but similar detection of CRC or AA at a pre-set 
positivity rate was observed. It is of note that, although FIT positivity rate differed, OC-
Sensor had higher positivity rates at lower FIT cut-offs. Therefore, using FOB-Gold instead of 
OC-Sensor is not the explanation for the higher positivity rate at the start of the programme. 
Another more likely explanation is that the manufacturers of the stool tests have improved 
the test itself. Several programmes had shown that the FIT had a worse performance at 
higher ambient temperature.12,13 In a response to this unfavourable outcome, we assumed 
that the buffer of the test has been improved resulting in better preservation of faecal Hb. 
Other recent studies also using new generation FITs showed no impact on clinical outcome 
at higher ambient temperatures and delayed sample return time, indicating improved FIT 




Participation to follow-up colonoscopy
The high FIT participation rate in the current Dutch programme did not apply to participation 
to follow-up colonoscopy. The observed participation to the colonoscopy follow-up after a 
positive FIT of 77.8% in the Netherlands is below the recommended acceptable level of 85%, 
which is a major concern.16 In Chapter 8 we observed a higher participation rate to follow-up 
colonoscopy in surrounding countries. One explanation for the low participation may be that 
not all colonoscopy results were integrated in ScreenIT (6-8% of all FIT positives), because 
some individuals may have had a colonoscopy in centres outside the screening programme. 
Still, effort should be undertaken to increase this low participation rate, because individuals 
without appropriate follow-up after a positive FIT were seven times more likely to die from 
CRC than individuals with appropriate follow-up.17 Higher participation rates could possibly 
be reached by active involvement of the general practitioner (GP), as described in chapter 
8. Especially the involvement of GPs is subject of continuous debate in the Netherlands. At 
the start, GPs received the result of individuals with a positive FIT if participants entered GP 
details in the reply form. Since 2017, a reply form is no longer included and consequently 
GP contact information is often not provided anymore. This situation makes involvement 
of GPs to increase colonoscopy follow-up difficult. Currently, options to automatically 
obtain individuals GPs details from existing databases are explored. If legally and technically 
possible, the FIT result can automatically be sent to the GP which may have a positive impact 
on the number of individuals with a complete follow-up after positive FIT.
Involvement of the GP would only lead to an increase in colonoscopy participation, if 
individual’s motives for nonparticipation are unjustified. In 2017 a qualitative study using 
interviews among Dutch invitees was carried out. This qualitative study showed a wide 
variety of motives for nonparticipation: low risk perception for CRC, alternative explanation 
for blood loss, not realising consequence of positive FIT, resentment against colonoscopy, 
aversions to organisational structure, or unwilling to visit a hospital (Bertels et al. submitted). 
The authors concluded that based on these outcomes increasing individual’s risk-perception 
for CRC might be the most effective to increase colonoscopy participation rate, but needs to 
be further studied. Potentially, GPs can play an important role in explaining risks of CRC to 
their own patients. Besides individuals’ motive, co-morbidities may often be the reason for 
nonparticipation. However, individuals are not excluded prior to invitation based on their 
medical history.
Colorectal cancer and advanced adenoma detection
As discussed above, in Chapter 2 we described that the screening programme was optimised 
by increasing the FIT cut-off. This was predominantly decided because of a lower than 
anticipated PPV. As described in Chapter 1, the Health Council preferred a FIT cut-off of 15 
µg Hb/g faeces over 10 µg Hb/g faeces, aiming for a more optimal balance between true 
and false positives. The PPV as observed in the first half year of 2014 of 42.1% was below 
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this desired PPV of 51.6%. As a result of the increased FIT cut-off, the PPV for CRC and AA 
increased to a more desirable level of 49.1%. However, the detection rate decreased for CRC 
(5.8‰ to 4.4‰) and AA (30.8‰ to 20.6‰), indicating that CRCs will be missed in the first 
screening round. We hypothesised in Chapter 2 that missed CRCs or AAs in the first screening 
round, may be detected in the second screening round. In Chapter 4 we therefore evaluated 
the impact of the increased FIT cut-off on outcomes of the second screening round. We 
concluded that using a higher FIT cut-off has limited impact on the CRC and AA detection 
because a substantial part of the missed lesions will be detected in subsequent screening 
round. However, after two screening rounds the cumulative yield of CRC and AA is still lower 
for those tested with the higher cut-off in the first year compared to those tested with the 
lower cut-off in the first year. It is expected that this difference will become insignificant 
after more screening rounds. The limited impact of the increased cut-off is also confirmed 
in Chapter 5 indicating a small difference in sensitivity between the two FIT cut-offs. Based 
on both the outcomes of the second screening round and number of interval CRCs, we can 
cautiously conclude that indeed programme performance has been optimised by increasing 
the FIT cut-off. Currently, there is no urgent need to change the FIT cut-off. However, it is 
important to obtain additional information on stage distribution in subsequent rounds, to 
ensure that CRCs detected in the second round still have a favourable stage distribution at 
both FIT cut-offs.
In Chapter 4 we also showed that individuals with a faecal Hb concentration between 
15-47 µg Hb/g faeces (below FIT cut-off) were 23.2 more likely to have a CRC or AA detected 
in the consecutive screening round than individuals with no detectable faecal Hb. This makes 
the previous faecal Hb concentration an important risk factor, which could potentially be 
used for personalised screening as will be discussed in more detail in the next section.
Stage distribution
In Chapter 3, stage distribution of CRCs were compared, showing a more favourable stage 
distribution (stage I and II) in screen-detected CRCs (66.7%) than in symptom-detected CRCs 
(39.8%). These findings are in line with expectations, aiming for early detection of cancers 
thereby improving survival. The results are a promising sign that CRC screening may decrease 
CRC-related morbidity and eventually mortality rates. Nevertheless, stage distribution 
of screen-detected CRCs in subsequent screening rounds should be monitored closely to 
make sure that majority of screen-detected CRCs will still be detected in an early stage. The 
more favourable stage distribution had also a direct impact on the treatment. Since the 
introduction of screening in the Netherlands a shift in treatment options was observed for 
individuals with CRCs detected through screening (Figure 1).18 Screen-detected CRC patients 
on average received less invasive and curative treatment compared to symptom-detected 
CRC patients. This result is satisfying and is an indication that CRC-related morbidity will 




In Chapter 3 we showed that screen-detected CRCs were more often located in the left 
hemi colon compared to those CRCs detected without screening. Results of previous studies 
showed conflicting results.19,20 Results from Chapter 5 however confirm our hypothesis of 
a lower FIT sensitivity for right-sided cancers, as many more interval cancers were located 
right-sided. First explanation might be that FIT is less sensitive for right-sided cancers due 
to degradation of Hb during colon transit.21 Another explanation might be that FIT is less 
sensitive for sessile serrated lesions and this type of polyps are more often detected in 
the right colon. If these precancerous stages are missed with FIT screening, an increase 
in proportion of right-sided cancers will appear in the long-term.22,23 However, this latter 
Figure 1: Treatment options of screen-detected versus non screen-detected (a) colon cancers or (b) rectal 
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hypothesis can only explain a part of the finding, as approximately 20-30% of the CRCs 
are thought to derive of the serrated neoplasia pathway. Probably it is a combination of 
hypotheses, longer transit and lower sensitivity for serrated lesions which makes FIT less 
suitable for right-sided lesions.
Interval cancers
In Chapter 5 we evaluated the interval CRC incidence rate and FIT sensitivity after the first 
screening round and the impact of the adjustment of FIT cut-off. We observed a low cumulative 
incidence of interval CRCs because of the high sensitivity of FIT for CRC. We also concluded 
that there is an optimum in FIT cut-off at which it is not beneficial (i.e. lowering referrals for 
colonoscopy with restricted resources) to further increase the FIT cut-off. The main reason for 
this is that above 80 µg Hb/g faeces there is a large decrease in FIT sensitivity for CRC, while 
decrease in positivity rate (i.e. number of referrals) is mild. This mild decrease in positivity rate 
at higher cut-offs was also observed in the FIT pilot study in England.24 The current FIT cut-off 
in the Dutch CRC screening programme is far below 80 µg Hb/g faeces. This again confirms 
that the increase to 47 µg Hb/g faeces was a prudent decision to optimise the screening 
programme. The outcomes of the study in Chapter 5 however may be informative to design 
a more tailored screening strategy. Using the information of previous FIT result, individuals 
at highest risk for interval CRC can be identified. Recent analysis of our research group has 
shown that individuals with an Hb concentration just below the cut-off of 47 µg Hb/g faeces 
were 16 times more likely to have an interval CRC. Consequently, tailored screening intervals 
could be designed to increase the benefits of screening while reducing the harms.
Socioeconomic differences
In Chapter 6 we evaluated differences in FIT screening by social economic status (SES). We used 
area SES and compared the performance indicators participation rate, positivity rate, PPV and 
detection rate for CRC and AA between different SES quantiles. We concluded that CRC and AA 
yield per invitee does not differ by SES in the Dutch CRC screening programme. FIT screening 
even has the potential to reduce health inequalities in CRC mortality, because of a higher yield 
in participants with the lowest SES. However, this is currently offset by the lower participation 
in this group. A recent review confirms this variation in participation across SES in organised 
programmes worldwide.25 Targeting individuals with the lowest SES could be beneficial, as 
highest health gains can be achieved in this group. However, similar to participation in general, 
individuals’ motive for nonparticipation is unknown. Therefore, it is not clear what the best 
method is to inform and motivate individuals with the lowest SES to participate in screening. 
In England extensive research has been conducted to assess the impact of different evidence-
based interventions on participation among individuals with the lowest SES. All different types 
of written materials enclosed with the invitation had no impact on the participation rate; 
GIST (Goals, Ideas, Step-projects, and Tasks)-based leaflet, narrative leaflet or GP endorsed 
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invitation.26 The only method that showed a small increase in participation rate for individuals 
with the lowest SES was an enhanced reminder letter.26 Not only an association with SES was 
observed, but the overall participation increased with an enhanced reminder letter.
Consistency of FIT performance
In the study in Chapter 7 we estimated consistency of FIT performance over time on positivity 
and detection rates of CRC and AA within a national FIT-based CRC screening programme. 
Variation was observed for FIT positivity rate and detection rates of CRC and AA between FIT 
specimen collection devices (batches) and reagent lots, but no difference in PPV was identified. 
Based on these outcomes we concluded that clinically the programme is performing well, 
but there is room for improvement of the current quality assessment of the FIT within the 
Netherlands. Currently, no acceptable ranges of variation in positivity rate or Hb concentration 
exist. As a consequence of the observed variation, a discussion was started among parties 
involved in the Dutch CRC screening programme. Surprisingly, the discussion was not on the 
result itself, but more on the current set-up of the Dutch quality assurance system for FIT 
screening. It was realised that there were no acceptable range for observed variation and how 
to deal with observed variation. A discussion was initiated on important quality aspect of the 
performance of the FIT test including acceptable range of variation and value assignment. Daily 
controls in the participating laboratories are currently supervised by the Dutch Foundation for 
Quality Assessment in Medical Laboratories (SKML). They are carrying out three groups of 
controls, as described in detail in Chapter 7. However, international standardisation of quality 
assessment is lacking. Consequently, a national working group ‘Quality assurance FIT’ was 
set-up. The aim of this working group is to improve quality assessment of FIT screening in the 
Netherlands, combining the expertise of different stakeholders.
9.2 LIMITATIONS / METHODOLOGICAL CONSIDERATIONS
The most important event during the implementation phase of the Dutch CRC screening 
programme was the adjustment of FIT cut-off in the first year. As a consequence, we were 
able to compare important performance indicators by two cut-offs. A limitation of using data 
from the implementation phase of the Dutch CRC screening programme is that the screening 
programme was implemented by birth cohort. The conclusions in this thesis could therefore 
only be based on selected age groups and not on all age groups (55-75 years old) within the 
target population. Moreover, for the comparison of different rates of performance indicators 
by two FIT cut-offs, age-adjusted rates had to be calculated using direct standardisation. 
Because of large differences in the sample size per age group, wide confidence intervals (CI) 
were observed. Based on these wide CI, we concluded, for example for FIT sensitivity, that 
there was no significant difference between the different FIT cut-offs. However, the wide CI 
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indicates the uncertainty of the age-adjusted rates. Therefore we subsequently carried a 
logistic regression analysis, which showed a significant difference between the two cut-offs. 
Another limitation is that we started with older age groups; therefore the conclusions of this 
thesis are predominantly based on older age groups. In 2019, all age groups will have been 
invited at least once. More certainty about the performance indicators of the Dutch CRC 
screening programme should be obtained in the coming years, when all age groups have 
been invited, to ensure the programme is still performing in line with the expectations.
Another limitation is the completeness of the national information system (ScreenIT). 
ScreenIT is an excellent system which automates a large part of the screening process, from 
selection of eligible individuals of screening to obtaining result of endoscopy. However, in 
the first place it has been developed to structure the logistics of the screening process. 
As a result, obtaining data for scientific purpose has been a challenge. For example, for 
each individual polyp detected, pathology results cannot be linked directly to endoscopy 
results yet. This means that we know for a specific individual from the endoscopy report 
that there were four polyps detected and removed and one of them was large (> 10 mm). 
From the pathology report, we know that three of the polyps were adenomas and one was 
hyperplastic. We cannot distinguish whether the large polyp from the endoscopy was the 
adenoma or hyperplastic. In such situations we assumed the large polyp to be adenomatous, 
which is reasonable in most cases, but may have led to a small overestimation of AA. Another 
problem is that, especially as a result of long waiting periods in the first year, individuals may 
have had a colonoscopy scheduled outside of the screening programme. The results of these 
colonoscopies were not entered in ScreenIT. We estimated with data of national pathology 
database PALGA that 6-8% of the individuals with a positive FIT in 2014 had a colonoscopy 
outside the programme. It is expected that this percentage will be lower now the programme 
is fully implemented and waiting periods have been reduced and more colonoscopy centres 
joined the screening programme.
The last limitation is the difference in data collection and definition of performance 
indicators between the four CRC screening programmes described in Chapter 8. In France 
there is no national centralised information system collecting data on quality indicators and 
diagnostic yield. In Flanders a different definition of AA was used, because no data on size of 
the polyps was available. These limitations made it difficult to compare the CRC and AA yield 
of the four CRC screening programmes. This emphasises the importance of standardisation 
of important performance indicators for international comparison purposes.
9.3 FUTURE PERSPECTIVES
At the end of the implementation phase we may conclude that the Dutch CRC screening 
programme has reached a steady state and is performing in line with expectations. The main 
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goal should be to maintain this stable CRC programme with optimal programme performance. 
Nevertheless, there is always potential to further optimise a screening programme. The 
current programme could be expanded by inviting more age groups, a new test could be 
chosen or risk-factors could be used to invite those individuals’ with highest CRC risk.
Expansion of the current screening programme
The Dutch CRC screening programme could be expanded in three ways: by lowering the 
starting age, lowering the FIT cut-off or adjusting the screening interval. Recently, the 
American Cancer Society changed their recommendations for CRC screening to start at a 
lower age (45 years old). The reason for this change is the observed increase in CRC incidence 
in young adults.26 A similar increase has been observed in Europe.28 Lowering the starting age 
will also be more in line with the European recommendation, that advices CRC screening in 
men and women aged 50-74.29 However, it is unclear yet what the impact is of the increased 
incidence in young adults on the effectiveness of the Dutch CRC screening programme.
Rationale for lowering the FIT cut-off comes from a previous decision analysis. This 
analysis showed that increasing the FIT cut-off was the most effective option with limited 
colonoscopy resources compared to postpone screening in certain age groups.10 The same 
could apply the other way around; lowering the FIT cut-off is the most effective option if the 
current programme can be expanded. The decision about whether lowering the FIT cut-off, 
widening the age range or shortening of the interval should be considered for expansion of 
the programme can be informed by model decision analyses. The outcomes of the studies 
included in this thesis can be used to inform several important decision model parameters.
New test modality
FIT has a high sensitivity for CRC, as also described in this thesis, but FIT has a lower sensitivity 
for AA (31%).30 New test modalities are developed aiming for a higher sensitivity for CRC 
and AA. Stool DNA testing and video endoscopy seem to be promising new test modalities. 
They are not considered cost-effective yet, because their high costs do not outweigh the 
small additional benefit.31 A new development is the use of protein biomarkers for the 
detection of CRC or AA, instead of or supplement to Hb protein. An early clinical phase 
of biomarker development study showed that new stool-based protein biomarkers have a 
higher discriminatory power than Hb protein alone.30 A combination of 4 proteins resulted 
in a sensitivity for CRC of 80% similar to FIT and for AA of 45%, substantially higher than FIT. 
Potentially, these proteins could easily be implemented in a national FIT-based screening 
programme. Other promising new test modalities are FIT combined with blood markers for 
CRC or AA detection. A recent review concluded that most studies have not been able to 
prove improved FIT characteristics.32 However, DNA hyper methylation markers seem most 
suitable, specifically methylated Septin 9 DNA plasma assay (mSEPT9). This could be potentially 
a good alternative for CRC screening. However, it can only be cost-effective compared to 
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FIT-based screening if participation with FIT will drop below 70%.33 The current participation 
rate in the Netherlands is still above 70%, therefore with the current test characteristics 
of mSEPT9 it is not a better option than FIT. When considering a new screening test it is 
important to realise that the new test should be relatively cheap to be a good candidate to 
introduce on population level. Decision analysis showed that costs of a new biomarker test 
should not exceed 7-fold the costs of FIT.34 Another important aspect considering a new and 
more sensitive test for CRC is the associated specificity. If the new test has a lower specificity, 
this also should be taken into account when this test will be introduced on a population 
level. Lower specificity will lead to an increase in number of individuals with a false-positive 
result, resulting in more individuals undergoing an unnecessary colonoscopy.
Personalised screening strategy
Contemplating on the outcomes of the performance indicators described in this thesis, it 
seems that differential FIT cut-off by gender or previous screening result might lead to a more 
(cost-) effective screening programme. Decision analyses can be performed comparing such 
strategies to identify the optimal screening strategy for the current situation with uniform 
screening.10 Other possible new strategies might be applying different FIT cut-offs for the 
first and subsequent screening rounds or allocating different intervals based on previous Hb 
concentration. 
The first option for a more personalised screening strategy is to screen men and women 
differently. Men have higher CRC and AA detection rates and higher FIT sensitivity for CRC 
than women.35 A tailored screening strategy could focus on similar sensitivity for both men 
and women by lowering the cut-off for women. The other way around is also an option, 
aiming for similar PPV for both men and women by lowering the cut-off for men.36 However, 
long-term effectiveness of screening in terms of life years gained, estimated with decision 
modelling, it shows similar effectiveness for men and women. This is mainly the result of 
the fact that women will have a longer life expectancy than men. This is in line with previous 
results of our research group, showing that a different screening strategy for men and 
women is not cost-effective.37 Note, this decision analysis assumed unlimited colonoscopy 
capacity. If programmes have limited colonoscopy resources, applying different screening 
strategies for men and women may be cost-effective, but this need to be further studied.
Faecal Hb concentration in previous screening round is another risk factor for the 
development of CRC and AA that also can be used for personalised screening. Individuals 
with a faecal Hb concentration below the cut-off (between 15 and 47 µg Hb/g faeces) are 
at higher risk for the detection of CRC or AA during consecutive screening rounds than 
individuals without any faecal Hb detected.38-41 The biological hypothesis behind this finding 
is that adenomas will progressively bleed when developing to carcinoma, and therefore even 
low concentrations of Hb may be an indication of the presence of adenoma.42 Therefore, 
individuals with high Hb concentration in the previous screening round may benefit from 
153
GENERAL DISCUSSION
shorter screening intervals. Contrary, individuals without detectable Hb in the previous 
screening round may benefit from extended screening intervals. Personalised screening 
based on faecal Hb concentration has two advantages over other known risk factors like 
smoking, obesity, food intake or family history. The estimated hazard ratios for individuals 
with small amount of faecal Hb concentration compared to those with no detectable faecal 
Hb concentration are considerably higher than those reported for e.g. lifestyle or family 
history.41 Another advantage of using faecal Hb concentration of the previous screening round 
is its availability. This information is already being registered in the national information 
system (ScreenIT). Therefore, additional questionnaires on obtaining information on lifestyle 
and family history, which could jeopardise screening participation, are not needed.
Ideally, all potential risk factors like gender, age and Hb concentration of the previous 
screening round will be combined in one prediction model. All these separate risk factors 
contribute to individual’s risk of having a CRC or AA. All risk factors should be combined to 
determine a person’s individual risk. A Flemish study showed that men aged 74 with Hb 
concentration of >200 µg Hb/g faeces were 58 times more likely to be diagnosed with a CRC 
than women aged 56 with Hb concentration of 15 µg Hb/g faeces.43 It is unknown to what 
extent the complexity of personalised strategies will impact the adherence to screening. 
For genetic testing it is known that knowing your gene-based risk profile will increase the 
willingness to participate in screening with 43%.44 It is unknown whether this increase in 
adherence would also hold for an approach using relatively simple risk factors like gender, 
age and faecal Hb concentration. It will be totally different from genetic testing and might 
not lead to the same increase. The overall participation in the Netherlands is already high, 
so we will be more concerned if personalised screening will negatively impact the high 
participation.
9.4 FINAL CONCLUSIONS AND RECOMMENDATIONS
From the results of the studies that are presented in this thesis, the following conclusions 
can be drawn:
- Piloting, planning and implementing of the Dutch CRC screening programme may serve 
as a best practice for many screening initiatives currently being organised worldwide.
- The FIT participation rate in the first screening round in the Netherlands (71.8%) was one 
of the highest across the world and remained stable in the second screening round.
- Participation in follow-up colonoscopy (77.8%) was short of the minimally acceptable 
level of 85% and lower than surrounding countries in Western-Europe.
- Adjustments of the cut-off from 15 to 47 µg Hb/ g faeces halfway through the first year of 
the programme was necessary to ensure that the programme met the intended balance 
of harms and benefits of CRC screening.
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- Using a higher FIT cut-off (47 µg Hb/ g) had limited impact on the cumulative CRC and AA 
detection because a substantial part of the missed lesions was detected in the second 
screening round.
- There is a strong correlation between faecal Hb concentration and detection of CRC and 
AA in subsequent screening. Individuals with a faecal Hb concentration just below the 
current cut-off (15-47 µg Hb/g faeces) were 23 times more likely to have CRC or AA 
detected at subsequent screening than those without detectable faecal Hb.
- Screen-detected CRCs have more often a favourable stage distribution (stage I and II) 
(67%) than symptom-detected CRCs (40%). Screen-detected CRCs were more often 
located in the left colon and rectum (73%) than symptom-detected CRCs (65%).
- FIT showed a high sensitivity for CRC (85.5%) with an associated low cumulative incidence 
of interval CRCs.
- FIT screening could potentially have a higher yield in participants with the lowest SES, 
but this higher yield is currently offset by the lower participation in this group.
- The overall population-impact of the variations in FIT positivity and detection rates 
between specimen collection devices and reagent lots is expected to be modest, but 
there is room for improvement of quality assessment. Currently, acceptable ranges of 
variation are lacking.
Based on these conclusions, we formulated the following recommendations:
- Coming years CRC-related mortality rates need to be closely monitored to ensure that 
CRC-related mortality is indeed decreasing as a consequence of the introduction of CRC 
screening in the Netherlands.
- Given the low participation to follow-up colonoscopy (77.8%), future research should be 
undertaken to identify reasons for nonparticipation and options to increase colonoscopy 
participation rate to the recommend level of 85%.
- The observed variation in FIT performance between batches and lot reagents described 
in this thesis can be used as input for the international initiative for standardising FIT 
quality assessment and for improving a regular monitoring system to reduce the impact 
of test variation on detection of CRC and AA.
- Outcomes during the implementation phase are mainly based on older age groups. Close 
monitoring of participation rate, positivity rate and detection of CRC and AA is needed to 
obtain estimates for all age groups of the target population.
- Personalised screening based on previous faecal Hb concentration is an important 
next step to explore for further optimisation of the Dutch CRC screening programme. 
Future studies are needed that evaluate the effectiveness of applying different screening 
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Worldwide, the incidence of colorectal cancer (CRC) is increasing due to ageing of the 
population, change in dietary habits and rise in risk factors like smoking, obesity, and lack 
of physical activity. It is expected that without interference the number of CRC cases in the 
Netherlands will increase from 13,000 to 17,000 persons per year by 2020. 
Worldwide, many countries have implemented a CRC screening programme, with the 
aim to reduce the high incidence and mortality rates of CRC. Choosing the best screening 
strategy for the population is a complex process. When deciding on which test to use, several 
aspects should be taken into account: test sensitivity and specificity, participation, harms, 
resource capacity and costs. The Netherlands may well serve as an excellent example for 
how all these aspects of screening were weighed into the decision for the most optimal CRC 
screening method for the Dutch population. In the Netherlands, an extensive preparatory 
process has taken place before the implementation of the national population-based CRC 
screening programme.
In 2006, pilot studies were initiated to study the potential of a national CRC screening 
programme in the Netherlands. The aim of these Dutch pilot studies was to evaluate the most 
important aspects (i.e. participation, diagnostic yield and cost-effectiveness) of the most 
relevant screening methods: guaiac Faecal Occult Blood Test gFOBT), Faecal Immunochemical 
Test (FIT; with FIT cut-offs ranging from 10-40 µg Hb/g faeces), sigmoidoscopy, colonoscopy 
and computed tomographic colonography (CTC). FIT screening showed the highest 
participation rate up to 60-62% in the first round, compared to 47-50% for gFOBT, 32% for 
sigmoidoscopy, 34% for CTC and 22% for colonoscopy. FIT also showed the highest diagnostic 
yield, with the highest detection of CRC per 1,000 invitees over two screening rounds. Based 
on these outcomes, subsequent modelling and the advice of the Dutch Health council it was 
decided to implement FIT screening, with a cut-off of 15 µg Hb/g faeces for a positive result. 
This cut-off was predominantly preferred because of a more favourable balance between 
true-positives and false-positives (higher positive predictive value) than a cut-off of 10 µg 
Hb/g faeces. It would also result in a lower colonoscopy demand. 
The Dutch CRC screening programme was gradually implemented by age group from 2014 
onwards, with biennial for men and women aged 55 to 75 years. While the design of a CRC 
screening programme may be evidence-based and well-planned, this does not guarantee 
that the performance on a national level will be in line with the expectations. Therefore, 
monitoring a screening programme is essential, especially during the implementation phase.
To ensure that these expectations are met on a national level, monitoring and evaluation 
of the national screening programme in real setting and/or national level is important. The 
general aim of this thesis is therefore to evaluate performance of the Dutch colorectal cancer 
screening programme during the implementation phase. We evaluated the participation to 
FIT, FIT positivity, participation to follow-up colonoscopy, CRC and advanced adenoma (AA) 
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detection in the first screening round (Chapter 2) and second screening round (Chapter 
4), the stage- and location distribution of screen-detected cancers (Chapter 3), and the 
incidence interval cancers (Chapter 5). For all these performance indicators, the impact of 
the adjusted cut-off in the first half year was evaluated. The most important performance 
indicators were also compared between different surrounding countries that implemented 
FIT screening (Chapter 8). 
Participation FIT 
High participation rate is a relevant finding, as high participation is an important indicator for 
a successful screening program. We observed high participation rate (71.3%) in the first year 
of the national CRC screening programme. This rate is one of the highest in the world and 
remained high in the second screening round (75.9%), driven by a consistent participation of 
93% among the individuals that previously participated. Moreover, 21% of non-participants 
in the first round sent in a FIT in the second screening round. 
FIT positivity 
Real-time monitoring allowed for instant adjustment of the programme when the outcomes 
substantially differed from what was expected. Higher positivity rate (10.6% versus expected 
6.4%) together with the lower than anticipated PPV for CRC and AA (42.1% versus expected 
51.6%) in the first half year of implementation, resulted in the decision to increase the cut-
off for a positive FIT from 15 to 47 µg Hb/g faeces. This adjustment resulted in a programme 
that more closely met the expectations, with a positivity rate of 6.7% and PPV for CRC and 
AA of 49.1%. The better balance of harms and benefits of the screening programme was also 
more in accordance with the recommendation of the Dutch Health Council before the start 
of the programme. As expected, the positivity rate dropped in the second screening round to 
3.3% for those previously tested with the low cut-off and to 4.3% for those previously tested 
with the higher cut-off. 
Participation to follow-up colonoscopy 
The high FIT participation rate in the current Dutch programme did not apply to participation 
to follow-up colonoscopy. The observed participation to the colonoscopy follow-up after a 
positive FIT of 77.8% in the Netherlands is below the minimally acceptable recommended 
level of 85% and lower than surrounding countries (92.8% in the Basque country, 88.4% in 
France and 82.8% in Flanders). The rate in the Netherlands is most likely an underestimation, 
as some individuals (6-8%) may have had a colonoscopy in centres outside the screening 
programme. These colonoscopy results were not integrated in the national screening 
information system ScreenIT.  Effort should be undertaken to increase this relatively low 
participation rate, because individuals without appropriate follow-up after a positive FIT are 
seven times more likely to die from CRC than individuals with appropriate follow-up. 
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Colorectal cancer and advanced adenoma detection 
The PPV as observed in the first half year of 2014 of 42.1% was below the desired PPV of 
51.6%. As a result of the increased FIT cut-off, the PPV for CRC and AA increased to a more 
desirable level of 49.1%. However, the detection rate decreased for CRC (5.8‰ to 4.4‰) and 
AA (30.8‰ to 20.6‰), indicating that CRCs will be missed in the first screening round. Based 
on the results of the second screening round we concluded that using a higher FIT cut-off 
has limited impact on the CRC and AA detection overall, because as a substantial part of 
the missed lesions will indeed be detected in subsequent screening rounds. However, after 
two screening rounds the cumulative yield of CRC and AA is lower for those tested with the 
higher cut-off in the first year compared to those tested with the lower cut-off in the first 
year. We also showed that individuals with a negative FIT in the first round, but with a faecal 
Hb concentration between 15-47 µg Hb/g faeces (just below FIT cut-off)  had 23 times the 
odds of having CRC or AA detected in the consecutive screening round than individuals with 
no detectable faecal Hb. 
Stage distribution and location 
Screen-detected CRCs showed a more favourable stage distribution (stage I and II, 66.7%) 
than symptom-detected CRCs (stage I and II, 39.8%). These findings are very encouraging 
and it is a promising sign that screening may decrease CRC-related morbidity and eventually 
mortality rates. We also showed that screen-detected CRCs were more often located in the 
left hemicolon than symptom-detected CRCs (45.9% versus 31.4%). Combining this with 
the outcomes of interval CRCs we conclude that FIT has a lower sensitivity for right-sided 
cancers, as many more interval cancers were located right-sided. The first explanation for 
this finding might be that FIT is less sensitive for right-sided cancers due to degradation of 
Hb during colon transit. Another explanation might be that FIT is less sensitive for sessile 
serrated polyps and this type of polyps is more often detected in the right colon.  
Interval cancers 
We observed a low two-year cumulative incidence of interval CRCs after negative FIT 
(11.2 per 10,000 individuals) because of the high sensitivity of FIT for CRC (85.5%). The 
age-adjusted cumulative incidence of interval CRCs of 9.5 per 10,000 individuals at the low 
cut-off was significantly lower than the 13.8 per 10,000 individuals at the higher cut-off. 
Age-adjusted FIT sensitivities for CRC were statistically different with 90.5% at the low cut-off 
and 82.9% at the higher cut-off. FIT sensitivity for CRC was higher for men (87.4%) than for 
women (82.6%).
Socioeconomic differences 
Screening performance indicators were also compared by socioeconomic status (SES), with 
Quintile 1 being the least deprived and Quintile 5 the most deprived. The analyses showed 
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that performance indicators vary by SES. Participation to FIT screening was significantly lower 
for individuals in the lowest SES quintile (67.0%) compared to the other four quintiles (73.0% 
to 75.1%). A similar pattern was observed for colonoscopy participation after a positive FIT: 
75.8% for individuals in the lowest SES quintile and 80.0-82.4% for individuals in the other 
quintiles. On the other hand, the detection rate per FIT participant for advanced neoplasia 
gradually increased from 3.3% in Quintile 1 to 4.0% in Quintile 5. The lower participation 
but higher yield per participant resulted in a similar yield per invitee for the lowest (2.04%) 
and the highest SES quintile (2.00%). These results show that screening has the potential to 
reduce health inequalities in CRC mortality, because of a higher detection in more deprived 
participants. However, this is currently offset by the lower participation in this group. 
Consistency of FIT performance 
We observed small variation in FIT positivity rate and detection rates of CRC and AA between 
FIT specimen collection devices (batches) and reagent lots. In contrast, PPV was not found 
to vary between collection devices, reagents or laboratories. The size of the population that 
was impacted by these deviating rates was small (0.1% of the total tested population). Based 
on these outcomes we concluded that clinically the Dutch CRC screening programme is 
performing well, but there is room for improvement. Currently, no recommendation on the 
variation in positivity rate or Hb concentration exists. Effort is undertaken in the Netherlands 
to improve the quality assessment of the FIT within the screening programme.
Conclusions and recommendations  
From the results of the studies that are presented in this thesis, the following conclusions 
can be drawn:
- Piloting, planning and implementing of the Dutch CRC screening programme may serve 
as a best practice for many screening initiatives currently being organised worldwide. 
- The FIT participation rate in the first screening round in the Netherlands (71.8%) was one 
of the highest in the world and remained stable in the second screening round. 
- Participation in follow-up colonoscopy (77.8%) was below the minimally acceptable level 
of 85% and lower than surrounding countries in Western-Europe.
- Adjustments of the cut-off from 15 to 47 µg Hb/ g faeces halfway through the first year of 
the programme was necessary to ensure that the programme met the intended balance 
of harms and benefits of CRC screening.
- Using a higher FIT cut-off (47 µg Hb/ g) had a limited impact on the cumulative CRC and 
AA detection because a substantial part of the missed lesions was detected in the second 
screening round. 
- There is a strong correlation between faecal Hb concentration and detection of CRC and 
AA in subsequent screening. Individuals with a faecal Hb concentration just below the 
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current cut-off (15-47 µg Hb/g faeces) were 23 times more likely to have CRC or AA 
detected at subsequent screening than those without detectable faecal Hb.
- Screen-detected CRCs more often have a favourable stage distribution (stage I and II) 
(67%) than symptom-detected CRCs (40%). Screen-detected CRCs were more often 
located in the left colon and rectum (73%) than symptom-detected CRCs (65%). 
- FIT showed a high sensitivity for CRC (85.5%) with an associated low cumulative incidence 
of interval CRCs. 
- FIT screening could potentially have a higher yield in participants with the lowest SES, 
but this higher yield is currently offset by the lower participation in this group. 
- The overall population-impact of the variations in FIT positivity and detection rates 
between specimen collection devices and reagent lots is expected to be modest, but 
there is room for improvement of quality assessment. Currently, acceptable ranges of 
variation are lacking.
Based on these conclusions, we formulated the following recommendations:
- In the coming years, CRC-related mortality rates need to be closely monitored to ensure 
that CRC-related mortality is indeed decreasing as a consequence of the introduction of 
CRC screening in the Netherlands.
- Given the low participation to follow-up colonoscopy (77.8%), future research should be 
undertaken to identify reasons for nonparticipation and options to increase colonoscopy 
participation rate to the recommend level of 85%. 
- The observed variation in FIT performance between batches and lot reagents described 
in this thesis can be used as input for the international initiative for standardising FIT 
quality assessment and for improving a regular monitoring system to reduce the impact 
of test variation on detection of CRC and AA.
- Outcomes during the implementation phase are mainly based on older age groups. Close 
monitoring of participation rate, positivity rate and detection of CRC and AA is needed to 
obtain estimates for all age groups of the target population. 
- Personalised screening based on previous faecal Hb concentration is an important 
next step to explore for further optimisation of the Dutch CRC screening programme. 
Future studies are needed that evaluate the effectiveness of applying different screening 





Wereldwijd neemt de incidentie van darmkanker toe als gevolg van de vergrijzing van de 
bevolking, verandering van eetgewoontes en ongezonde leefstijl zoals roken, obesitas 
en onvoldoende beweging. De verwachting is dat zonder interventie het aantal nieuwe 
diagnoses van darmkanker in Nederland zal stijgen van 13.000 nu naar 17.000 gevallen per 
jaar in 2020.
Verschillende landen hebben in de afgelopen jaren een bevolkingsonderzoek naar 
darmkanker geïmplementeerd, met als doel de incidentie en sterfte ten gevolge van 
darmkanker te verminderen. De keuze voor de beste strategie om te screenen is complex. 
Verschillende aspecten moeten overwogen worden; sensitiviteit, specificiteit, deelname, 
nadelen (bijvoorbeeld complicaties), capaciteit en kosten. Nederland is een goed voorbeeld 
van een land waarbij deze verschillende aspecten zijn afgewogen voordat er een beslissing 
is genomen over de meest optimale opzet voor het Nederlandse bevolkingsonderzoek 
darmkanker. 
In 2006 zijn er proefbevolkingsonderzoeken gestart om de mogelijkheden voor invoering 
van een landelijk bevolkingsonderzoek in kaart te brengen. De belangrijkste uitkomsten zoals 
deelname, detectiecijfer darmkanker en advanced adenomen (AA) en kosten-effectiviteit 
zijn vergeleken voor verschillende screeningtesten: de ontlastingstesten guaiac faeces occult 
bloed test (gFOBT) en faeces immunochemische test op occult bloed (FIT), sigmoїdoscopie, 
coloscopie, en CT-colonografie. Met een deelnamepercentage van 60-62% was deelname 
het hoogst voor genodigden met FIT, gevolgd door 47-50% voor gFOBT, 32% voor 
sigmoїdoscopie, 34% voor CT-colonografie en 22% voor coloscopie. Per 1.000 genodigden 
werden met de FIT ook deze meeste darmkankers gevonden. Op basis van deze uitkomsten, 
samen met de uitkomsten van kosten-effectiviteitanalyse en advies van de gezondheidsraad, 
is besloten om FIT met een afkapwaarde van 15 µg Hb/g ontlasting in te voeren voor het 
landelijke bevolkingsonderzoek. Deze beslissing was met name gebaseerd op het streven 
naar een goede balans tussen de voordelen (terecht-positieven, darmkanker detectie) en 
nadelen (fout-positieven, onnodige coloscopie) van het bevolkingsonderzoek. 
Het bevolkingsonderzoek darmkanker werd van 2014-2018 per geboortecohort gefaseerd 
ingevoerd. De uiteindelijke doelgroep van het bevolkingsonderzoek darmkanker bestaat uit 
mannen en vrouwen van 55 tot en met 75 jaar, die elke twee jaar uitgenodigd worden voor 
screening d.m.v. de (FIT). Monitoren van een bevolkingsonderzoek is belangrijk, met name 
gedurende de invoeringsfase van een nieuw programma. De opzet van het programma kan 
goed onderzocht en gepland zijn, maar het is onbekend of de prestatie van het programma 
op landelijke niveau overeen zal komen met de verwachting. 
Na jaren van voorbereiding, waren de verwachtingen van het landelijke 
bevolkingsonderzoek hoog. Het doel van dit proefschrift is daarom om de prestatie van 
het landelijke bevolkingsonderzoek te evalueren gedurende de implementatie fase. De 
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belangrijkste prestatie indicatoren, zoals deelnamecijfer, verwijscijfer, deelnamecijfer 
coloscopie en detectiecijfer darmkanker en AA, werden geëvalueerd voor eerste ronde 
genodigden (hoofdstuk 2) en tweede ronde genodigden (hoofdstuk 4). Daarnaast hebben 
we de stadiumverdeling van screen-gedetecteerde darmkankers (hoofdstuk 3) en het aantal 
interval kankers na negatieve FIT (hoofdstuk 5) geanalyseerd. Voor bovenstaande uitkomsten 
hebben we ook de impact van het verhogen van de afkapwaarde halverwege het eerste jaar 
berekend. Als laatste hebben we de uitkomsten van het Nederlandse programma vergeleken 
met programma’s in omliggende landen: Baskenland (Spanje), Frankrijk en Vlaanderen 
(België) (hoofdstuk 8). 
Deelnamecijfer
In het eerste jaar van het Nederlandse bevolkingsonderzoek darmkanker was de deelname 
hoog; 71.3%. Daarmee heeft Nederland de hoogste opkomst wereldwijd. De uitkomsten 
van de tweede uitnodigingsronde lieten zien dat de deelname met 75.9% hoog blijft in 
vervolgrondes; 93% van de deelnemers in de eerste ronde neemt opnieuw deel en 21% van 
de niet-deelnemers in de eerste ronde neemt nu wel deel. 
FIT verwijscijfer 
Het wekelijks monitoren van de uitkomsten van het bevolkingsonderzoek liet zien dat 
het programma niet presteerde in lijn met onze verwachting waardoor een aanpassing 
noodzakelijk was. In het eerste half jaar van het bevolkingsonderzoek was er namelijk een 
hoger dan verwacht verwijscijfer (10,6% versus de verwachtte 6,4%) met een lager dan 
verwacht positief voorspellende waarde voor darmkanker en AA (42,1% versus de verwachtte 
51,6%). Dit heeft er toe geleid dat de afkapwaarde voor een positieve test verhoogd is van 
15 naar 47 µg Hb/g ontlasting, met als resultaat een lager verwijscijfer (6,7%) en hogere 
positief voorspellende waarde (49,1%). Hiermee voldoet de prestatie van het programma 
meer aan de verwachting, met een betere balans tussen de voordelen en nadelen van het 
bevolkingsonderzoek darmkanker. Zoals verwacht daalde het verwijscijfer in de tweede 
uitnodigingsronde ten opzichte van de eerste ronde naar 3,3% voor personen die eerder 
getest waren met de lage afkapwaarde en 4,3% voor personen die eerder getest waren met 
de hoge afkapwaarde.
Deelname aan coloscopie 
Deelnemers met een positieve FIT uitslag worden uitgenodigd voor een vervolgcoloscopie. 
Deelname aan deze coloscopie is met 77,8% lager dan de in Europa geadviseerde 85% en is 
ook lager in vergelijking met omliggende landen (deelname van 92,8% in Baskenland, 88,4% 
in Frankrijk en 82,8 in Vlaanderen). Het deelnamecijfer in Nederland is hoogstwaarschijnlijk 
een onderschatting omdat 6-8% van de deelnemers buiten het georganiseerde programma 
een coloscopie ondergaat. De bevindingen bij deze coloscopieën komen niet in de 
169
SAMENVATTING
landelijke screeningdatabase ScreenIT. Desalniettemin is het belangrijk dat er actie wordt 
ondernomen om dit lage deelnamecijfer te verhogen. Personen met een positieve FIT zonder 
vervolgcoloscopie hebben namelijk zeven maal meer kans om te overlijden aan darmkanker 
dan personen die wel zijn gekomen. Grotere betrokkenheid van huisartsen, die het belang 
van het vervolgonderzoek kunnen toelichten, zou eventueel tot een stijging in de deelname 
aan coloscopie kunnen leiden. 
Detectiecijfer van darmkanker en advanced adenomen 
Zoals reeds hierboven vermeld, was de positief voorspellende waarde in het eerste half jaar 
lager dan gewenst: 42,1% versus 51,6%. Een direct effect van het verhogen van de afkapwaarde 
was een hogere positief voorspellende waarde voor darmkanker en AA, namelijk 49,1%. 
De verhoging van de afkapwaarde had ook een negatief gevolg. Het detectiecijfer voor 
darmkanker daalde van 5,8‰ naar 4,4‰ en voor AA daalde het van 30.8‰ naar 20.6‰. 
Dit wijst er op dat er in de eerste ronde kankers zijn gemist. In hoofdstuk 4 concluderen 
we echter dat de verhoging van de afkapwaarde bij herhaalde deelname minimale impact 
heeft op het aantal gevonden darmkankers en AA. Een groot deel van de gemiste laesies 
wordt namelijk in de tweede uitnodigingsronde gevonden. Ondanks dat het meerendeel 
van de gemiste laesies in de volgende ronde wordt gevonden, was de cumulatieve opbrengst 
van darmkanker en AA over twee uitnodigingsrondes hoger voor personen die in de eerste 
ronde met een lage afkapwaarde waren getest. We toonden ook aan dat personen met een 
negatieve FIT in de eerste ronde, maar met een hemoglobine level net onder de huidige 
afkapwaarde (FIT uitslag tussen 15 en 47 µg Hb/g ontlasting),  23 keer meer kans hebben 
op het ontdekken een darmkanker of AA in de vervolgronde in vergelijking met personen 
zonder bloed in de ontlasting. 
Stadiumverdeling en locatie 
Screen-gedetecteerde darmkankers hebben een gunstigere stadiumverdeling (stadium I en II, 
66,7%) in vergelijking met symptoom-gedetecteerde darmkankers (39,8%). Deze resultaten 
zijn veelbelovend en lijken erop te duiden dat het bevolkingsonderzoek darmkanker zal 
leiden tot een afname in darmkanker gerelateerde ziekte en sterfte. We constateerden 
ook dat screen-gedetecteerde kankers vaker linkszijdig worden gevonden ten opzichte van 
symptoom-gedetecteerde damkankers. Op basis van deze resultaten kunnen we concluderen 
dat FIT een lagere sensitiviteit heeft voor rechtszijdige kankers, wat bevestigd werd door de 
uitkomsten van de interval kankers. Een mogelijke verklaring hiervoor is dat de FIT minder 
gevoelig is voor rechtszijdige kankers als gevolg van degradatie van het hemoglobine tijdens 
passage door de darm. Een andere verklaring is dat FIT minder gevoelig is voor sessile 
serrated poliepen en dit type poliep zit voornamelijk rechtszijdig in de darm.
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Interval kankers 
We toonden in hoofdstuk 5 aan dat de FIT een hoge sensitiviteit (85,5%) heeft voor 
darmkanker, met als gevolg een lage cumulatieve incidentie van interval kankers (11,2 per 
10.000 personen). Cumulatieve incidentie van interval kankers was verschillend voor de 
twee afkapwaardes: personen getest met 47 µg Hb/g ontlasting hadden een iets hogere 
cumulatieve incidentie (13,8 per 10.000 personen) dan personen getest met 15 µg Hb/g 
ontlasting (9,5 per 10.000 personen). De FIT met een afkapwaarde van 15 µg Hb/g ontlasting 
heeft een sensitiviteit voor darmkanker van 90,5%. De sensitiviteit was lager bij een FIT 
afkapwaarde van 47 µg Hb/g (82,9%). FIT heeft een hogere sensitiviteit in mannen (87,4%) 
dan in vrouwen (82,6%) 
Sociaal economische verschillen 
We hebben ook de prestatie indicatoren vergeleken voor personen met een verschillende 
sociaal economische status (SES), opgedeeld in vijf groepen. Deelname aan FIT was lager 
voor personen met de laagste SES (67,0%) in vergelijking met de andere vier SES groepen 
(73,0-75,1%). Een soortgelijk patroon was te zien voor deelname aan de coloscopie, met de 
laagste deelname voor personen met de laagste SES (75,8%) in vergelijking met de andere 
vier SES groepen (80,0-82,4%). Personen met de laagste SES hadden vaker een positieve 
FIT en ook het detectiecijfer van darmkanker en AA per deelnemer was hoger bij personen 
in een lagere SES groep (hoogste SES 3,3% en laagste SES 4,0%). Als gevolg van een lagere 
deelname aan de coloscopie maar een hoger detectiecijfer van darmkanker en AA in de 
lagere SES, waren er geen verschillen tussen de vijf SES groepen in het detectiecijfers 
voor darmkanker en AA per genodigden. FIT screening heeft de mogelijkheid om de 
gezondheidsongelijkheid ten gevolge van darmkanker sterfte te verminderen, door het 
hogere detectiecijfer van darmkanker en AA. Echter wordt dit nu gehinderd door een lagere 
deelname aan FIT screening door personen met de laagste SES status. 
Consistentie FIT prestatie 
We lieten kleine verschillen zien voor het verwijscijfer en het detectiecijfer van darmkanker 
en AA als personen werden getest met FIT buizen afkomstig uit verschillende leveringen of 
met verschillend reagens lots. Er werd hierin geen verschil waargenomen voor de positief 
voorspellende waarde voor darmkanker en AA. Deze verschillen hebben echter betrekking 
op een zeer kleine groep personen (0,1% van de totale groep). We concluderen daarom dat 
het programma klinisch goed presteert, maar dat er op analytisch gebied nog ruimte is voor 
verbetering. Op dit moment zijn er geen afspraken gemaakt over welke variatie in prestatie 
van FIT acceptabel is. Daarom is er een landelijke werkgroep opgericht, die zich bezig houdt 
met de kwaliteits monitoring van de FIT en de analyse daarvan. 
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Op basis van de resultaten gepresenteerd in dit proefschrift, kunnen de volgende conclusies 
worden getrokken:
- De implementatie van het Nederlandse bevolkingsonderzoek darmkanker dient als een 
goed voorbeeld voor veel andere programma’s  wereldwijd.
- De verhoging van de afkapwaarde halverwege het eerste jaar was noodzakelijk om weer 
een goede balans te vinden tussen de voordelen en nadelen van deelname aan het 
Nederlandse bevolkingsonderzoek darmkanker.
- Het deelnamecijfer aan FIT screening in Nederland is één van de hoogste wereldwijd en 
blijft hoog in vervolgrondes.
- Deelname aan de vervolgcoloscopie in Nederland is lager dan de geadviseerde 85% en 
ook lager dan omliggende landen.
- De hogere afkapwaarde heeft minimale impact op het detectiecijfer van darmkanker en 
AA, omdat een groot deel van de laesies in de vervolgronde wordt gedetecteerd.
- Er is een sterkte associatie tussen de hemoglobine concentratie in de ontlasting en het 
detectiecijfer van darmkanker of AA in een vervolgronde.  
- Screen-gedetecteerde darmkankers hebben een gunstigere stadiumverdeling en worden 
vaker linkszijdig gevonden dan symptoom-gedetecteerde darmkankers.
- FIT heeft een hoge sensitiviteit voor darmkanker met een lage cumulatieve incidentie 
voor interval kankers.  
- FIT detectiecijfer voor darmkanker en AA per genodigde zou hoger kunnen zijn voor 
personen met een lagere SES, maar wordt tenietgedaan door een lager deelnamecijfer. 
- De impact van de variatie in verwijscijfer en detectiecijfer tussen verschillende leveringen 
van buizen en reagentia lots is klein, maar er is ruimte voor verbetering. 
Op basis van deze conclusies kunnen de volgende aanbevelingen worden gedaan:
- De evaluatie van de prestatie-indicatoren zijn veelbelovend en het lijkt erop dat als 
gevolg van FIT screening de darmkanker gerelateerde ziekte en sterfte zal afnemen. 
Komende jaren zal de darmkanker gerelateerde stefte gemonitord moeten worden om 
vast te stellen of dit inderdaad het geval is. 
- Vanwege de lage deelname aan de vervolgcoloscopie, zal er meer onderzoek gedaan 
moeten worden naar de reden van niet deelname en naar opties om deze deelname te 
verhogen. 
- De geobseerveerde variatie tussen leveringen van buizen en reagentia lots kan gebruikt 
worden om internationaal standaarden vast te stellen voor kwaliteitscontrole van de FIT. 
Daarnaast kan het gebruikt worden om kort-cyclische monitoring op te zetten. 
- Het bevolkingsonderzoek kan verder geoptimaliseerd worden door personen uit te 
nodigen op basis van het risico op darmkanker of AA door gebruik te maken van de 
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Professor Meijer, professor de Rijke en professor van Hal, hartelijk dank voor het beoordelen 
van mijn proefschrift en de bereidheid om plaats te nemen in de kleine commissie. 
Professor Timmermans and Professor de Beaufort dank voor het zitting nemen in de 
promotiecommissie. 
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LECO teamleden: Manon Spaander, Evelien Dekker, Ernst Kuipers, Iris Nagtegaal, Hanneke 
van Vuuren, Hans Bonfrer, Chris Ramakers, Katharina Biermann, Loes Velthuysen, Folkert 
van Kemenade, Maarten Thomeer, Harriët van Veldhuizen en Marjolein van Ballegooijen. 
Nu mijn promotie ten einde loopt besef ik me wat een voorrecht het is om als eerste op de 
data van het landelijke bevolkingsonderzoek darmkanker te promoveren. Velen van jullie 
hadden jaren voorbereiding achter de rug en ik was de geluksvogel om mijn naam op de 
papers te mogen zetten. Ondanks al jullie drukke agenda’s ontving ik altijd snel uitgebreide 
en gedetailleerde feedback. Jullie hebben de papers naar een hoger niveau getild, ik had het 
niet zonder jullie gekund. Dank!
Dear co-authors: Marc Bardou, Isabel Portillo, Sarah Hoeck, Isabel de Brabander, Philippe 
Perrin, Catherine Dubois, Marloes Elferink, Valerie Lemmens and Marc Thelen. It was a 
pleasure to work with all of you; it gave me a broader perspective on colorectal cancer 
screening, inside and outside the Netherlands. 
Lydia, Sten, Monique, Iris en alle andere RIVM betrokkenen, het was fijn samenwerken, 
bedankt! Het opleveren van de landelijke monitor en notities in combinatie met promoveren 
was ideaal. Jullie zijn de ultieme stok achter de deur. Jullie betrokkenheid, enthousiasme en 
bereikbaarheid zorgde voor een efficiënte samenwerking. 
FSB en in het bijzonder Else-Mariëtte, in de eerste jaren van mijn promotie zag ik jullie 
wekelijks. Uren hebben we samen gezeten om de monitor en indicatoren goed in ScreenIT 
te krijgen. Else, jouw precisie heeft ervoor gezorgd dat alles goed verwerkt is. Bedankt voor 
het aanleveren van alle benodigde data voor onze landelijke monitor en evaluaties.  
Arry, dank voor al jouw hulp wanneer er iets geregeld moest worden, vooral voor mijn 
verdediging. Jij loopt altijd een paar stappen voor ons uit. 
Lieve kamergenootjes, in vier jaar tijd ben ik twee keer een verdieping naar boven verhuisd. 
Van een zespersoonskamer, naar een achtpersoonskamer, naar flexwerken. Het grote 
voordeel hiervan is dat ik veel collega’s beter heb leren kennen. Daardoor kon ik altijd 
iemand vinden die mij kon helpen als ik ergens tegenaan liep of als ik zin in koffie had. 
Flexwerken is zo slecht nog niet. 
Mijn GI-collega’s: Frank, Miriam, Sonja, Steffie, Reinier, Maaike, Andrea, Amir, Dayna, Elleke, 
Carlijn, Arthur, Caroline, Lucie en Brechtje. It was great to be part of the biggest and smartest 
research group of MGZ. We’re the best! Now I am working from home, I realise how important 
and relevant colleagues are. Thank you for all your help, support, and ‘gezelligheid’.
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DANKWOORD
Lieve Elleke and Dayna, our weekly gossip hour is amazing. It’s great to share our experience 
about our long-distance relation with MGZ. Elleke, bedankt dat je de eerste versies van mijn 
introductie en discussie hebt gelezen, waardoor ik enorm. 
Lieve Arthur, mijn kleine broertje. Het was een feest om met jou samen te werken, samen 
als de data-‘sukkels’.  Je bent een relaxed persoon en vindt alles mooi. Ik heb je nog nooit 
chagrijnig gezien, zelfs niet na het krijgen van negatieve feedback. Bedankt voor alle keren 
dat je dingen van mij hebt overgenomen, omdat ik weer eens zwanger was of ging verhuizen 
naar de andere kant van de wereld. Ik kijk uit naar jouw verdediging!  
Lieve Carlijn, wat fijn dat jij bij MGZ kwam werken. Naast een gezellige, enthousiaste en 
slimme collega ben je vooral ook een lieve vriendin geworden. Naast lekker klagen over 
PhD-gerelateerde zaken, was het heerlijk om samen te trainen voor de triatlon, shoppen en 
zelfs chillen in Singapore. Het is meer dan verdiend dat jij vandaag naast mij staat te shinen! 
Lieve vriendjes en vriendinnetjes, ik ga jullie niet bij naam noemen omdat ik bang ben dat ik 
iemand vergeet J. Maar jullie geven mijn leven kleur en zijn allemaal op jullie eigen manier 
belangrijk voor mij. Uit het oog is hopelijk niet uit het hart!
Lieve Janneke en Rosa, voor jullie een speciaal dankwoord. Jullie zijn die vriendinnen met 
wie ik hard kan lachen, maar die ook ongemakkelijke vragen stellen. Jullie maken mij tot 
een mooier mens, bedankt! Jans, jij bent vandaag de vertegenwoordiging van de kippetjes. 
Lieve (schoon)familie: Oma Grietje, Sanne, Corstiaan, Tiemen, Jos, Liesbeth, Rogier, Marieke, 
Ilse, Niels, Jurre, Femke, en alle kleine neefjes en nichtjes. Ik ben blij met jullie allemaal. Lieve 
Liesbeth, bedankt voor alle uren oppassen, het was heerlijk werken als de mannetjes thuis 
met oma waren. Lieve Femke, bedankt voor het ontwerpen van de cover. 
Lieve broer, zus en zusje. Ik voel me gelukkig omdat ik jullie zusje ben. Het is een fijne, 
gezellige en drukke bende met elkaar (die tijdens mijn promotie is uitgebreid met 7 kinderen 
J). Ik ben trots op jullie alle drie! Lieve Roeland, jij zorgde voor mijn afstudeerplek bij de 
MDL, wat indirect heeft geleid tot deze promotie plek. Door jouw voorbeeld wist ik dat 
promoveren vooral heel leuk is. Mooi om te zien hoe jij je werk als MDL-arts, je rol als man 
en vader en je uren wielrennen weet te combineren. Lieve Mirjam, onze hoogtepunten 
tijdens mijn promotie waren overduidelijk: twee keer tegelijk zwanger en een baby krijgen, 
fantastisch! Door jou was (en is) het helemaal niet zwaar om moeder te worden (en zijn). Je 
bent loyaal en hardwerkend, al jaren de beste fysio van Rijndam. Lieve Judith, je blijft altijd 
mijn kleine zusje, al ben je dat al lang niet meer. Zeker niet nu je ook moeder bent van mijn 
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kleinste neefje. Heerlijk om te zien hoe gepassioneerd je bent bij de dermatologie en hoe je 
daar van geniet. Ik hoop dat je papers ook eindigen in een mooi proefschrift! 
Lieve pap en mam, bedankt voor jullie nooit aflatende aandacht en liefde. Jullie hebben mij 
laten zien dat ik geliefd ben om wie ik ben, niet om wat ik doe. Jullie waren denk ik net zo 
trots op mijn zwemdiploma als op mijn promotie. Jullie zijn een voorbeeld voor me, ik hoop 
dat ik net zo goed voor mijn eigen kinderen zal zorgen. 
Lieve Jens en Faas, mijn twee kleine boeven. Jullie waren de mooiste hoogtepunten van mijn 
promotietraject. Ik heb altijd zin om te gaan werken, maar sinds jullie er zijn is thuiskomen 
een feest! Jullie werken ook relativerend, sinds jullie komst ben ik nooit meer gestrest. Ik ben 
dankbaar dat ik jullie moeder mag zijn, ik hou oneindig veel van jullie. 
Lieve Harmen, de afgelopen jaren waren er meer life events dan publicaties; promoveren 
leek eigenlijk bijzaak. Van ons huurappartementje naar ons eigen (klus)huis in het pittoreske 
Overschie, geboorte Baby 1, geboorte Baby 2, en de emigratie naar Singapore. Het was een 
goede tijd, we zijn rijk gezegend. Ik hou van je! Dat er nog veel mooie herinneringen bij 
mogen komen.
Lieve God, wetenschappelijk niet te verklaren, maar voor mij dagelijkse realiteit. Leven met 
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